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Understanding the Speciation of Ruthenium Arene Complexes as Precursors to 
Unnatural Enzyme Cofactors 
 
George Samuel Biggs 
 
Ruthenium arene complexes have been extensively explored as metallo-pharmaceuticals and 
as small molecule catalysts. Exploring the overlap between these areas, this thesis describes a 
body of work aimed at quantitatively understanding the biological speciation and catalytic 
behaviour of ruthenium arene complexes when exposed to the many potential Lewis basic 
ligands provided by protein scaffolds.  
Combining nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), X-ray 
crystallography and other biophysical characterisation techniques, the speciation of ruthenium 
arene bipyridine complexes with small molecule amino acids, short peptides and whole 
proteins has been monitored. A 19F NMR spectroscopic method was developed to quantitively 
trace the preferred amino acid binding partners of ruthenium complexes coordinated to 
fluorinated ligands. Liquid chromatography mass spectrometry (LC-MS) was used to explore 
the ligand exchange behaviour between ruthenium complexes and protein scaffolds, 
particularly variants of the small proteins ubiquitin and cytochrome b562. Additionally tandem 
MS/MS experiments were used to determine the  final protein binding sites of non-fluorinated 
ruthenium fragments coordinated to proteins.  
The resulting deep understanding of how ruthenium arene complexes coordinate to specific 
proteins was used to develop artificial metalloenzymes (ArMs) with direct protein-metal 
coordination. The catalytic capabilities of these hybrid systems was then explored. ArMs are 
synthetic biocatalysts that result from either the combination of an artificial metallo-cofactor 
being introduced into a protein scaffold or a natural metalloprotein being evolved to perform 
catalytic reactivity.  
Taking inspiration from naturally occurring metalloproteins, this research showed that it was 
possible to form ArMs via a ligand exchange process between a ruthenium arene precursor 
complex and a protein scaffold, resulting in the precursor complex being activated towards 
catalysis. Direct protein – metal coordination enables the protein to impart both an electronic 
and steric contribution to catalysis and attenuate reactivity at the metal centre in ways that have 
not been previously studied. The four helical bundle protein cytochrome b562 was selected as 
 vi 
the protein scaffold for ArM development due to its dynamic structure and nascent haem 
binding site, which in the absence of haem provides a hydrophobic pocket capable of 
accommodating a ruthenium cofactor and catalytic substrate. Cytochrome b562 – ruthenium 
hybrids (with direct coordination) were identified that have catalytic transfer hydrogenation 
activity greater than a known dimeric catalyst. This demonstrates an exciting starting point to 
explore the evolutionary potential of these ArMs through directed evolution, hopefully 




































‘If it was not for chemistry, I’d probably be a lawyer, 
and I am glad that’s not the case.’ 
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1.1.  Metals in Synthetic and Biological Catalysis 
The production and functionalisation of a large range of fine chemicals, biomolecules and 
materials is underpinned by catalytic chemistry, with the resulting products being crucial for 
health, quality of life and the global economy. Catalysis can be broadly split into three main 
areas, which are all used in everyday industrial processes: (a) heterogeneous, solid catalysis, 
(b) homogeneous, small molecule catalysis and (c) enzymatic catalysis (including 
metalloenzymes).1,2 
Unlike heterogeneous catalysis, which occurs at the interface between two phases, 
homogeneous catalysis is molecular in nature and occurs at a single site, resulting in greater 
selectivity, milder reaction conditions and greater molecular efficiency than heterogeneous 
alternatives. The disadvantages of homogeneous catalysts are that they are often shorter lived 
and less robust their heterogeneous counterparts and their separation from products is 
challenging. Transition metal catalysts consist of a metal ion or ions, with a number of ligands 
coordinated, forming a primary coordination sphere. Different ligands can control the 
reactivity, chemo and stereoselectivity of the catalysis, and there is an extensive body of 
research aiming to optimise ligands for catalytic transformations.3 Such ligand optimisation is 
a difficult process, as the chemical possibilities for metal-ligand combination are vast. 
Like homogeneous catalysis, enzymatic catalysis in biological systems also involves molecular 
species. Biological catalysts contain a combination of the 20 amino acid building blocks which 
fold into a 3D structure with one (or more) active site(s), which localise, bind and organise 
substrates ready for catalytic transformation. Many enzymes have transition metal ions at their 
active site and these metal ions play a crucial role in catalysis: this family of enzymes are called 
metalloenzymes. Scientists have long been fascinated by how proteinaceous ligands tune the 
properties of metal ions for function, and with technological advances, metalloenzymes can 
not only be studied but research has been driven towards designing and engineering 
metalloenzymes for the synthesis of fine chemicals. This research is focussed towards the goal 
that petroleum based, energy intensive and inefficient chemical synthesis can be replaced by 
enzymes to fulfil societal needs with enhanced efficiency.4 
 2 
The most abundant transition metals found in metalloenzymes are Mn, Fe, Co, Cu, Zn and Mo, 
and biology has evolved remarkable methods of being able to accumulate, transport, store and 
use these six metals for catalysis. Metal ions that are required for an enzyme’s activity as a 
catalyst are called cofactors. These cofactors increase the rate of the chemical reaction and are 
essential to enzymatic catalysis. Metal cofactors can be found in proteins encapsulated by 
ligands supplied by the protein (for example zinc in carbonic anhydrase), or with non-protein 
ligands coordinated (for example a porphyrin ring coordinated to iron in the case of the haem 
cofactor). 
Biology has evolved to predominantly incorporate and use 3d metals over 4d metals for 
catalysis, apart from molybdenum, which will be discussed later. A number of reasons can be 
used to explain this preference, but most obvious is that in prebiotic chemistry the 3d metals 
were more naturally abundant and available for incorporation than the 4d metals (Table 1.1).5 
Therefore, when exploring the usefulness of 3d metals for catalytic transformations and 
structure, cells developed machinery that enabled them to selectively accumulate specific 
metals based on their electronic properties and size. Through evolution, biology has ensured 
that organisms will accumulate and use 3d metals and largely ignore 4d and 5d metals. 
Biological systems will decide whether to accumulate a metal based on a combination of 
abundance and usefulness, 4d and 5d metals are simply not abundant enough to be fit for 
purpose. In the presence of toxic 4d and 5d metals, biology has evolved systems to export or 
pacify them (e.g. lead and cadmium). 
An interesting evolutionary question to consider is whether, if the later 4d and 5d transition 
metals had been as naturally abundant as 3d metals when life began, would biology have used 
these elements for metalloenzymes instead or as well? 
Table 1.1: Abundance of a selection of transition metal elements in the Earth’s crust given in 
mg/Kg. 
Cr Fe Co Ni Cu Zn 
1.02 x 102 5.63 x 104 2.5 x 101 8.4 x 101 6.0 x 101 7.0 x 101 
Mo Ru Rh Pd Ag Cd 
1.2 x 100 1.0 x 10-3 1.0 x 10-3 1.5 x 10-2 7.5 x 10-2 1.5 x 10-1 
1.1.1. 3d vs 4d Metals; When Biology is Given a Choice 
The group 6 metals molybdenum and chromium are the exception to the trend of biological 
systems accumulating 3d over 4d transition metals. Molybdenum is essential for life, whereas 
 3 
chromium has no significant biological role. Although chromium is more Earth abundant, the 
favourable properties of molybdenum led to it being selected for by biology. One useful 
property of molybdenum is that it is redox active under physiological conditions and can access 
+IV, +V and +VI oxidation states with relative ease enabling both one- and two-electron redox 
reactivity to occur.6  
A key factor to consider when analysing the biological usefulness of 3d and 4d metals is their 
ligand exchange rates, which inform how kinetically active the metal is Figure 1.1.7 
Understanding the exchange kinetics of inorganic complexes was pioneered by Henry Taube 
in the 1950s.8 The strength of metal-ligand coordination bonds and steric effects greatly 
influence the kinetic stability of a complex; if the coordination bonds are strong than the 
complex will be slower to exchange ligands. Another key factor in ligand exchange rates of 
transition metal complexes are the changes in ligand field stabilisation energy (LFSE) moving 
from the reactant species to the transition state.  
To generalise, ligand exchange rates are generally faster for M2+ ions than for M3+ ions as there 
is a stronger electrostatic attraction between the positively charged metal and the ligand 
electrons. Additionally, the 4d and 5d transition metals are much more kinetically inert than 3d 
metals due to a better orbital overlap between the diffuse 4d and 5d orbitals and the ligand 
orbitals, leading to stronger metal-ligand bonds. This is not however, the case when comparing 
chromium and molybdenum, as chromium, in its most stable +III oxidation state, forms strong 
bonds to ligands and has very slow ligand exchange rates, as shown in Figure 1.1.   
Figure 1.1: Schematic representation of relative kinetics for the aquation of a variety of metal 
ions. Figure developed from reference (7).  
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Biology has evolved unique methods of manipulating the fast ligand exchange rates of certain 
first row transition metal ions used in catalysis. The metal-ligand exchange rates of Fe2+ are 
greatly reduced when bound to multidentate chelating ligands, e.g. porphyrins. However, in 
iron porphyrins the axial ligands, which are not part of the chelate ring, maintain kinetic lability 
enabling ligand exchange and catalysis to occur. Haem, or iron protoporphyrin IX is a metal-
containing cofactor found ubiquitously in nature. 
1.1.2. Biological Chemistry of Iron 
Iron is the most important transition metal to all life and performs a diverse number of catalytic 
roles. Iron uptake, distribution and storage is tightly regulated in cells as too much free iron 
leads to oxidative damage to proteins, lipids and nucleic acids, whereas insufficient iron 
impedes the function of many iron-utilising proteins. In aqueous chemistry at pH 7.0 the redox 
potential restricts iron to the +III oxidation state, which precipitates as insoluble Fe(OH)3; 
[Fe3+] cannot exceed 10-18 M, which explains the low concentration (0.05 ppb) of iron in sea 
water. Nature has found ways of overcoming this chemical limitation with iron; there is an 
evolutionary pressure to survive, therefore the element can be extracted to remarkable extents 
which is highlighted by a maximum concentration of iron in marine organisms of 86,000 ppb.9  
The ability of iron to gain and lose electrons, shuttling between Fe2+ and Fe3+ is crucial to its 
widespread participation in a variety of biochemical reactions. The redox potential of iron can 
be modulated via the binding of different ligands and the careful manipulation of different 
ligands can tune the different reactivity of iron. Iron has catalytic roles in three main forms in 
biology; (i) as haem Figure 1.2 (left), (ii) as iron-sulphur prosthetic groups, Figure 1.2 
(middle) and (iii) as iron-oxo clusters Figure 1.2 (right).10 
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Figure 1.2: (left): The structure of haem, iron protoporphyrin IX, a cyclic tetrapyrrole with an 
iron centre. (middle): A non-planar [Fe3S4] cluster (right): A carboxylate-bridged diiron unit 
in oxidised R2 protein of ribonucleotide reductase.  
1.1.3. A Chemist’s Comparison of Iron and Ruthenium 
Iron has an atomic number of 26 with four stable isotopes and a ground state configuration of 
[Ar] 3d64s2. In the previous section the most stable oxidation states have been identified as +II 
and +III, with Fe(IV) existing as a highly reactive and oxidising species. For Fe(II) and Fe(III) 
the balance between high spin and low spin complexes is at its most delicate, as complexes 
with weak field ligands (e.g. H2O and Cl) are high spin, whereas strong field ligands (e.g. CN- 
and CO) are low spin. Iron has been used in many industrial processes, most famously in the 
Haber-Bosch process as a heterogeneous catalyst for the fixation of hydrogen and nitrogen to 
produce ammonia. Furthermore, as discussed in the previous section, molecular iron catalysts, 
both biomimetic haem and non-haem complexes are being explored as they offer a sustainable 
catalytic source.  
Below iron in the periodic table is ruthenium, an element first discovered by Karl Ernst Claus 
in 1844. Ruthenium has an atomic number of 44, with seven major isotopes, and a ground state 
electronic configuration of [Kr]4d75s1. The most stable oxidation states of ruthenium are +II, 
+III and +IV, and ruthenium has an extensive coordination chemistry in multiple oxidation 
states. In solution the most common oxidation state is +III, however, with different ligands 
attached the +II, and +IV can easily be preferred. Ru(VIII), the group oxidation state, can also 
be achieved in the tetrahedral compound RuO4, whereas for iron, the ionisation energy required 





























1.2.  What Happens when Biology Interacts with 4d and 5d Transition 
Metals? 
There is a common misconception that heavy, non-essential 4d and 5d metals are more toxic 
than the metals used by biology. The term ‘toxic heavy metals’ should be avoided without 
careful assessment. In fact, the concentration of the essential metals, e.g. Fe is very tightly 
regulated and if found in excess these metals can be just as toxic as their heavier counterparts 
in biology. There are many different factors to consider when assessing the toxicity of metals 
as the biological properties differ greatly between the atoms and the coordinated compounds 
of that element. Of particular importance are the solubility, oxidation state and bioavailability 
of the elements in question, for example, Ni(II) and Zn(II) chlorides demonstrate moderate 
toxicity, whereas the oxide compounds are non-toxic.11 Therefore, when referring to a metal’s 
toxicity careful consideration of the specific compound is needed, as is the test used to measure 
the toxicity (e.g. an IC50 value).12 
Dispelling the myth that all heavy metal compounds are toxic, the effects of introducing 4d and 
5d metals into biological systems have been widely studied. Many organometallic compounds 
of 4d and 5d metals are ignored by cells in low concentrations. The term bio-orthogonal 
chemistry refers to a chemical reaction that neither interacts nor interferes with biological 
systems, therefore many 4d and 5d organometallic complexes can be referred to as bio-
orthogonal.  
1.2.1. Metals in Medicine, What has been Learnt?  
Although the previous section states that not all 4d and 5d organometallic compounds are toxic, 
there are many 4d and 5d organometallic compounds that show high toxicity to certain cells, 
even at very low concentration. Metal complexes for medicinal chemistry applications have 
been extensively studied due to their ease of functionality and ability to bring about cell death. 
In particular, this field has been dominated by the development of platinum based compounds, 
which began when Barnett Rosenberg discovered that cisplatin (cis-
diamminedichloroplatinum(II)) inhibited growth of E.coli cells.13 These platinum-based 
compounds have found particular application in the treatment of a variety of different cancers. 
Cancer is a disease where certain cells begin to replicate uncontrollably; these cells invade and 
destroy healthy tissues and organs. Some metal complexes, often called metallodrugs e.g. 
cisplatin, bind to DNA and accumulate in rapidly dividing cells, leading to cell cycle arrest and 
stopping a cancerous tumour from forming.  
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In order to develop an effective anti-cancer metallodrug there are some key challenges: (i) first 
the drug must be transported to the cancerous region, (ii) then, preferentially, the drug 
specifically targets the cancerous cells and is transported into the cellular matrix, (iii) finally 
the drug binds to a specific cellular target that induces the phenotypic response of apoptosis. 
Although cisplatin is a very simple coordination compound, it triggers an apoptotic response 
by binding to DNA and inhibiting replication. Certain cancerous cell lines are particularly 
vulnerable to cisplatin (testicular, bladder and ovarian) as they do not have the cellular 
machinery capable of repairing the DNA damage caused by cisplatin. However, cisplatin is not 
a selective drug, when injected into the blood stream it is distributed all over the body and kills 
healthy cells as well as cancerous cells leading to aggressive side effects.14   
Alternative metal complexes are being explored as potential drugs, particularly 4d and 5d 
organometallic complexes, incorporating Ru, Au, Os, Re etc.. There is extensive research, 
particularly in the field of antibody drug conjugates, looking to target toxic payloads (e.g. metal 
drugs) specifically to cancerous cells, which would reduce any side effects associated with 
non-selectivity. Of particular interest in the work contained in this thesis was to understand the 
speciation of ruthenium complexes once they enter a cell, in order to try and identify specific 
cellular targets. 
Several ruthenium-based drugs have entered clinical trials, however, no lead compounds have 
made it to use in a clinical setting. One clear stumbling block to advancement in the field of 
ruthenium metallodrugs is the lack of understanding of the cellular speciation of these 
complexes. If the link between cellular binding site and apoptotic response can be made, this 
will stimulate a more rational design to metallodrugs. Section 1.3 outlines the advances that 
have been made in the field of ruthenium metallo-pharmaceuticals, with particular focus on 
understanding the cellular speciation.  
1.3. Ruthenium Complexes Interacting with Biology for Medicinal 
Application 
1.3.1. Organoruthenium Anti-Cancer Chemistry 
The development of ruthenium anti-cancer complexes is closely related to the worldwide 
clinical use of cisplatin and other platinum therapies. Interest has grown in ruthenium 
complexes due to their apparent difference in mechanism of action to platinum complexes; 
many complexes are perceived to have reduced side effects and been shown to be active against 
cisplatin-resistant cell lines.   
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In recent years, this group’s research has been focused on developing a fundamental 
understanding of how ruthenium complexes coordinate to proteins of therapeutic relevance.15 
Previous work in the group has enhanced our understanding of the speciation of ruthenium 
complexes in biological mixtures. This section gives a brief history of ruthenium complexes as 
anticancer drugs and the major limitations and advances that need to be made for them to be 
used in a clinical setting.   
Metal Based Drugs vs Organic Drugs 
Small, organic drugs traditionally work by forming specific intermolecular interactions with a 
biological target thereby altering its activity. Intermolecular forces in combination can, 
however, be matched, and often bettered in energy by one metal-ligand coordination bond, 
which can range in energy between 50-350 kJ mol-1. For example, the well-known anti-cancer 
drug methotrexate makes a number of intermolecular contacts with the target protein DHFR 
(dihydrofolate reductase) that contribute to an enthalpy of binding of 55.6 kJ mol-1.16 This is 
matched by the enthalpy of substitution of a single ruthenium-thioether bond, 57.3 kJ mol-1, 
measured through calorimetric analysis by Taube et al..17 Furthermore, small molecule drugs 
have carbon skeletons, which generally restrict the geometries of compounds to linear, trigonal 
and tetrahedral. Metal ions on the other hand can access coordination numbers between two 
and ten, allowing for greater structural diversity, which may be beneficial for drug design.18 
Finally the variable oxidation states of transition metal ions has been utilised for the 
development of redox-activatable drug candidates that are activated in the reducing 
environments of cancer cells.19 
What Features of Ruthenium Make it an Attractive Element to Use? 
Ruthenium compounds have shown excellent activity against cancer cell lines and ruthenium 
is a promising metal for medicinal use for the following reasons: 
1. Ruthenium complexes are proposed to act through biochemical mechanisms that are 
different to the DNA cross-linking mechanism of platinum complexes, therefore they 
show activity against cisplatin resistant tumours.20 
2. Ruthenium complexes bind to Lewis basic residues, which are plentiful in cells, to form 
strong metal-ligand coordination bonds.21 
3. The large enthalpy of the metal ligand bonds means ruthenium complexes have 
relatively slow ligand exchange rates which means that once a complex is bound to its 
target its dissociation rate will be low and it will stay bound for the lifetime of the cell. 
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Importantly, ruthenium exchange rates are not too slow so that no ligand exchange is 
possible as often seen for 3rd row transition metal complexes.  
4. The reactivity and physical properties of a given ruthenium complex can be tuned for 
purpose through incorporation of carefully designed ligands, For example, certain 
ligands can make complexes more air and water stable.7,22  
5. Ruthenium complexes are bio-orthogonal, meaning they are active inside a biological 
environment, but are not highly regulated or interfere with native biochemical 
processes. 
6. In terms of practicality, ruthenium is also an attractive metal to use due to its 
affordability (in comparison to platinum) and its good air and moisture stability.  
Two ruthenium(III) complexes have been evaluated in clinical trials, NAMI-A and 
KP1019/NKP-1339, Figure 1.3. NAMI-A shows excellent selectivity against solid metastatic 
tumours, however, this compound did not make it past phase I clinical trials as at a high dose 
the patients developed blisters on hands, fingers and toes.23 KP1019, and its sodium salt NKP-
1339, showed very promising activity and limited adverse side effects throughout phase I 
clinical trials, however, it was concluded a that deeper understanding of the interactions of 
KP1019/NKP-1339 within a cell was required before clinical use.24 One ruthenium(II) complex 
has also entered clinical trials, TLD1433, which contains large aromatic ligands and acts as a 
photosensitizer in photodynamic therapy, however this complex is not designed to form 
coordination bonds to biological molecules.25 
Figure 1.3: The two ruthenium anticancer complexes which have reached clinical trials, 
NAMI-A (left) and KP1019 (right). The counter ions have been removed for clarity, however, 















It has been proposed that both of these Ru(III) complexes are activated by reduction in a 
biological environment to a Ru(II) species, and the redox properties play an important role in 
the drugs’ phenotypic effect.26 Ru(II) species, especially those with an h6-arene ligand, have 
also been explored as potential metallodrugs. The metal in these complexes is stabilised in this 
lower oxidation by the arene’s bonding modes to the metal: (i) A bonding s and p-type 
interaction from the filled ligand p-orbitals to empty metal d-orbitals and (ii) a p-back-bonding 
interaction between the filled dxz and dyz orbitals, and the empty p-antibonding orbitals. The 
ability to synthetically tune the ligands around the metal centre has led to a large number of 
Ru(II) compounds being screened to find the most efficacious drug, Figure 1.4.27–29 
In comparison with Ru(III) complexes, the Ru(II)(h6-arene) bioactive scaffold appears to lead 
to increased control over the biomolecular targets of ruthenium complexes. RAPTA-type 
complexes, [Ru(arene)(PTA)X2] (PTA = 1,3,5-triaza-7-phosphaadamantane) preferentially 
bind to proteins30,31 whereas smaller RAED-type complexes with the general formula 
[Ru(arene)(en)Cl] (en = 1,2-ethylenediamine) preferentially bind to DNA; this binding can be 
enhanced through extended p-systems.32,33 Searching for cellular protein targets has been 
performed using an integrated proteomics-based target-response profiling approach, where 
proteins are incubated with cellular lysate and metallodrug-protein adducts are separated in 
pull down assays. This has identified a preference for a Ru(arene) pyridinecarbothioamide 
complex to target selectively the scaffold protein plectin which regulates keratin and tubulin 
networks.34 These methods are, however, time consuming, and the link between plectin binding 
and phenotypic response needs further research. Although some cellular targets have been 
identified, most Ru(II) arene complexes are still highly promiscuous and there is little insight 
into their complete cellular speciation. 
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Figure 1.4: Chemical structures of a selection of Ru(II) arene compounds with anti-
proliferative properties. 
1.3.2. In vivo Ruthenium Catalysis with Therapeutic Applications 
Many research groups have also postulated that organometallic catalysts at low concentrations 
in cellular environments can bring about an apoptotic response, either through directly 
perturbing the cellular redox potential or through the uncaging of an inactive prodrug in a 
catalytic cycle. These methods apply the well understood catalytic reactivity of platinum group 
metals to the field of medicinal chemistry, and potentially allow for very low concentrations of 
metal to be administered.  
Firstly, Sadler et al. reported on the use of a Noyori-type ruthenium hydride transfer catalyst 
that when co-administered with a hydride source e.g. formate, could reduce NAD+ to NADH, 
and interfere with redox processes within the cell that is hoped to lead to cell death.35 This 
methodology, although intriguing, has some clear limitations, most obviously, that the redox 
state of a cell is so highly regulated that large amounts of formate are required and significant 
catalysis would be necessary for effect to be observed.  
Secondly, metal-catalysed uncaging reactions have drawn recent interest to activate a prodrug 
at a desired therapeutic area.36,37 This has shown particular promise in the field of antibody-
drug conjugates (ADCs), where an antibody is connected to a drug via a bio-orthogonally 























is administered to cleave the linker and release the drug payload. Ruthenium complexes have 
been used for this purpose as shown by Meggers et al. who reported a ruthenium piano-stool 
complex that deprotected the organic drug doxorubicin in HeLa cells resulting in apoptosis.38 
1.3.3. Factors Limiting Advances in Ruthenium Medicinal Chemistry 
To move this field forward to be able to effectively design drugs it is necessary to determine 
how metal adducts are getting to cancerous cells and which metal adducts, generated inside a 
cell, lead to the observed therapeutic response. It is highly possible that the cellular cytotoxicity 
of ruthenium complexes is a result of binding to multiple cellular targets, however, through 
understanding the site preferences and the mechanisms of action of the metal, it might be 
possible to selectively target weak points in a cancerous cell.32 
Understanding the biomolecular targets and cellular speciation of ruthenium complexes in a 
cellular environment remains a difficult task, but through the use of modern analytical 
techniques and a more systematic approach than has been used to date, significant progress can 
be made. The dynamic nature of the cellular concentrations and accessibility of biomolecules 
combined with the characteristically slow ligand exchange rates associated with Ru(II) arene 
complexes, makes understanding the relationship between speciation of the metal complexes 
and cellular response problematic. A direct read out of what the ruthenium compounds are 
bound to in biological environments remains challenging and has so far been restricted to 
methods which do not report the dynamic speciation in solution, such as mass spectrometry39–
41 and X-ray spectroscopic methods.42–44 This research looks to address this issue, and develop 
new methods to track the speciation of ruthenium organometallic compounds.  
1.4.  Catalysis Involving the Group 8 Metals Iron and Ruthenium 
1.4.1. Biological Catalysis Using Haem Enzymes 
In order for a protein to harness the catalytic potential of haem, the protein must be able 
recognise and accommodate haem. Referring to Figure 1.2 (left), the haem cofactor contains 
a large conjugated p-system, a metal ion and ionic functional groups; a protein must be able to 
accommodate all three of these functionalities. Proteins do this through non-specific p-stacking 
of the porphyrin, hydrophobic interactions with the propanoate groups and coordinating axial 
ligands to the metal, usually methionine, histidine or sometimes cysteine. There are two axial 
positions available for coordination to haem; some haem proteins, particularly those involved 
in electron transfer supply two ligands, and other haem proteins supply only one, enabling 
small molecules (e.g. CO and O2) to coordinate to the metal centre. 
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A large group of haem proteins called monooxygenases and dioxygenases are required in 
biological systems for the oxidation of very resistant, inert molecules (e.g. simple aliphatics). 
These proteins manipulate dioxygen as an axial ligand, and form very reactive oxidising 
species. The cytochromes P450 family of enzymes are monooxygenases which generally 
catalyse the hydroxylation of inert R-H organics to R-OH. In cytochromes P450 the general 
mechanism is as follows (i) binding of the organic substrate RH to the Fe(III) enzyme; (ii) 
reduction of iron to high-spin Fe(II); (iii) O2 binding to give a low-spin Fe(II) species or a 
superoxide bound low spin Fe(III) species; (iv) reduction of the Fe(II)-O2 unit to give a short 
lived peroxo group which is rapidly protonated releasing one water molecule and leaving a 
reactive Fe(IV) oxo species with a radical delocalised over the porphyrin; (v) attack of the 
Fe(IV) oxo species on RH to give ROH.  
Chemists have long tried to design synthetic metal complexes which mimic the roles of iron in 
biology. The purpose was initially to establish how natural systems have evolved their catalytic 
activity, and to search for inspiration into how to develop new synthetic catalysts. In the 
pioneering work of Collman et al. in the 1970s, a synthetic [Fe(picket-fence porphyrin)] 
complex was developed which mimicked dioxygen coordination to the respiratory proteins 
haemoglobin (Hb) and myoglobin (Mb).45,46 This model helped confirm that dioxygen 
coordination to iron in Hb and Mb, occurs in an angular end-on fashion as postulated by 
Pauling,47 and there is a formal change in oxidation state from Fe(II) to Fe(III) resulting in a 
reduction in Fe ionic radius bringing the Fe atom into the haem plane. These Fe picket-fence 
porphyrin complexes still inspire the development of new synthetic catalysts. Dey and co-
workers report the use of a synthetic cytochrome P450 mimic, which is capable of the catalytic 
hydroxylation of C-H bonds to alcohols and epoxidation of alkenes using molecular O2 in 
water.48  
1.4.2. Synthetic Catalysis Using Molecular Ruthenium Complexes  
The different accessible oxidation states of ruthenium mean that organometallic compounds of 
the metal have been studied extensively in homogeneous small molecule catalysis. This section 
will focus upon some key chemical transformations catalysed by organometallic ruthenium 
complexes.  
Olefin Metathesis 
The 2005 Nobel Prize in Chemistry was awarded to Grubbs, Shrock and Chauvin for the 
development of the metathesis method in organic synthesis.49 Olefin metathesis involves the 
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redistribution of alkene fragments via the breaking and reforming of C=C double bonds, 
Scheme 1.1. It is applied in the synthesis of a number of high value chemicals, including 
pharmaceuticals, and is used widely in polymerisation processes, via ROMP (ring opening 
metathesis polymerisation). Although a number of different transition metals have been tested 
as metathesis catalysts (titanium, molybdenum and tungsten), the most stable and functional 
group tolerant catalysts are ruthenium based. In the early 2000s, ruthenium complexes with N-
heterocyclic carbene ligands were proven to be excellent metathesis catalysts, exhibiting 
greater metathesis activity, solvent and thermal stability than previous ruthenium phosphane 
complexes.50  
There are no known natural metalloenzymes capable of metathesis activity. It could be argued 
that biology has found alternative methods of forming C-C bonds, and that substrates involved 
in metathesis (specifically terminal alkenes) were never part of metabolism. However, the lack 
of biologically-catalysed metathesis reactions could also be partially understood by looking at 
the requirement for highly electron donating ligands on the ruthenium to stabilise the Ru(II) 
and Ru(IV) oxidation states present in the reaction mechanism. None of the natural, un-
modified 20 amino acid ligands have comparable electronic donating properties to an N-
heterocyclic carbene or a phosphane. 
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Scheme 1.1: Mechanism for olefin metathesis catalysed by Grubbs 2nd generation ruthenium 
catalyst.  
Transfer Hydrogenation 
The 2001 Nobel Prize in Chemistry was part awarded to Knowles and Noyori for the 
development of hydrogenation reactions. In particular, Noyori and co-workers pioneered 
ruthenium catalysed asymmetric transfer hydrogenation. Asymmetric transfer hydrogenation 
(ATH) is the transfer of hydrogen atom to a molecule from a source other than gaseous H2, 
usually isopropanol (IPA), with excellent stereochemical control. Ru(II)(h6-arene) complexes 
bearing a substituted ethylenediamine ligand with two chiral centres, are effective asymmetric 
catalysts of ketones and imines to alcohols and amines respectively, Scheme 1.2.51 Biological 
systems perform a number of hydride transfers and hydrogenations. One family of proteins that 
































Scheme 1.2: Asymmetric transfer hydrogenation of a ketone to an alcohol, and an imine to an 
amine catalysed by Noyori’s ruthenium catalyst. 
Ruthenium Catalysed Reactions 
There are many catalytic transformations catalysed by ruthenium complexes, including C-H 
functionalisation,52 oxidation reactions53 and cycloadditions,54 summarised by Scheme 1.3. All 
these reactions show the versatility of small-molecule ruthenium catalysts. Fundamental to this 
reactivity is the metal’s ability to access a range of different oxidation states and coordinate 





















Scheme 1.3: (a) Ruthenium catalysed C-H functionalisation. (b) Ruthenium catalysed 
oxidation. (c) Ruthenium catalysed azide alkyne cycloaddition.  
1.4.3. A New Approach to Catalysis – Combining Transition Metals and Enzymes 
The coordination chemistry of many transition metal complexes has been explored with 
biological molecules, specifically proteins, to explore the catalytic potential of these protein-
metal hybrids. This work has developed into a thriving area of research where these protein-
metal hybrids, capable of catalysis are called artificial metalloenzymes (ArMs).   
1.5. Artificial Metalloenzymes 
Artificial metalloenzymes are synthetic biocatalysts that result from either the combination of 
an artificial metallocofactor being introduced into a protein scaffold or a natural metalloprotein 
with an unnatural/evolved protein scaffold. These protein-metal hybrids combine the catalytic 
features of natural enzymes and versatile reactivity toolbox of transition metal catalysts. As 
discussed, enzymes have excellent catalytic properties, they combine rapid reaction kinetics, 
high turnover numbers, substrate selectivity and product stereo-control all in relatively mild 

























Transition metal catalysts are capable of catalysing a wide range of chemical transformations. 
These metal complexes have ligands which can be tuned for a specific reaction and many of 
these transformations have well understood catalytic mechanisms. Combining the 
advantageous features of enzymes and transition metal catalysts into ArMs has emerged as a 
powerful tool in synthetic biology showing promising results in the sustainable production of 
commodity chemicals and new-to-nature metabolites.55 Replacing synthetic catalysts, acting 
on petrochemical feedstocks in non-aqueous solvents, with biocatalytic systems working in 
water with simple carbon neutral feedstocks is clearly highly desirable. But why engineer new 
enzymes, particularly using expensive and relatively scarce transition metals, when the ability 
to find new catalysts amongst gene products from all corners of the biological world has 
developed at staggering pace?56–58 As a consequence of the latter, any target chemical can 
conceivably be obtained by recombining pre-existing metabolic pathways.59  
One clear feature is orthogonality – the objective of introducing functionality into a cell that 
has no counterpart in the natural world, could provide reactivity that biology cannot currently 
catalyse – alkene metathesis for example. As there is a limit to the number of additional 
transformations a viable cell will perform, these orthogonal reactions may allow access to much 
shorter, and therefore more efficient, pathways. If not for a synthetic purpose, one could also 
imagine orthogonal catalytic chemistry providing a diagnostic or reporter output without 
interference from the host endogenous processes. For it to be truly orthogonal, it is difficult to 
imagine evolving a new enzyme based around metals already abundant in nature and already 
used as catalysts in biology. The transition metals used by nature are very carefully controlled 
by acquisition and regulatory networks that ensure catalytic metal ions are not free to operate 
outside the endogenous metabolism. Therefore, there is significant advantage in trying to 
introduce metals that biology currently has no evolved means of metabolising.  
A key factor in the potential of ArMs is that the protein scaffold is genetically encoded, 
therefore, the artificial metalloenzyme can be evolved through laboratory evolution techniques 
and catalytic performance can be optimised. The field of ArMs has been advanced greatly 
through the development of directed evolution. 
1.5.1. Directed Evolution of Metalloenzymes 
Darwinian evolution schemes can be fast-tracked in the laboratory via directed evolution which 
has revolutionised biosynthesis and biotechnology. Built upon the ground-breaking discoveries 
of George Smith and Greg Winter on phage display, which enabled protein libraries of slightly 
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mutated proteins to be screened for target affinity,60–62 Frances Arnold has developed and 
applied directed evolution to evolve natural enzymes into different catalysts.63,64 
Directed evolution is a method where the gene for the protein is subjected to iterative rounds 
of mutagenesis creating a library of gene variants. This gene library must be expressed as a 
protein library in a manner which couples the expression products (the different protein 
variants) and genetic sequence information (the nucleic acid), i.e. a linkage between the 
genotype and phenotype. Following this, the protein library is screened for catalysis via an 
activity assay, with the active variants then selected and the DNA recovered. Multiple rounds 
of directed evolution can lead to an optimisation in many different features of the enzyme, for 
example, stability and catalytic activity. In directed evolution of ArMs with an unnatural metal 
cofactor, there is an additional step, in which each individual member of a protein library is 
exposed to the metal cofactor, Figure 1.5. 
The choice of starting point for such a forced evolution campaign, which in the case of ArMs 
is the protein scaffold of choice and a metal complex, is of great importance. Since any 
particular enzyme follows a unique evolutionary trajectory as new mutations move it along the 
fitness landscape towards (potentially local) maxima, choice of the starting point may directly 
predetermine the result. By nature of the selection process, it is further possible, that trajectories 
leading to the global maximum fall beneath the cut-off limit, becoming inaccessible. 
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Figure 1.5: The general overview of a directed evolution campaign for artificial 
metalloenzymes. The Darwinian algorithm can be reproduced in the laboratory, greatly 
increasing the speed of evolution. Mutagenesis methods introduce mutations with various 
levels of randomness, depending on the method used, to the starting point gene, forming a gene 
library. This library can then be expressed in a manner that couples expression products and 
genetic sequence information to yield the different proteins. Upon addition of the metal 
cofactor, the artificial metalloenzymes are formed and can be selected for improved variants in 
regard to desired parameters (reaction rates, yield, stereoselectivity, stability etc.). The 
sequence information of the improved candidates is recovered and can be subjected to further 
rounds of directed evolution.  
There are three key practical considerations in the directed evolution of ArMs: (i) Expressing 
protein variants with a genotype-phenotype linkage, (ii) a clean and efficient metal 
modification step and (iii) a quick, sensitive and robust activity assay.  
First, crucial to any high-throughput directed evolution campaign is a genotype-phenotype 
linkage. Nature links genotype and phenotype by compartmentalising genes in cells. In-vivo 
directed evolution experiments have generally employed colony screening or cell surface 
display.65 In this methodology, each well plate contains cells expressing different variants of a 
protein and catalytic activity is assayed. In-vitro techniques use the desired gene and 
subsequently expressed protein outside of the cell and make use of readily available in-vitro 
translation systems originally from E.coli or yeast cells. Upon in-vitro expression a linkage, 
often covalent, must be established between the genotype and phenotype, or by artificial 
compartmentalisation, i.e. within a droplet.  
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Second, a clean and efficient metal modification step is required to ensure that any activity 
measured arises from the protein-metal hybrid and not from free metal complex. Performing 
this step in complex biological environments is particularly challenging as the cell has many 
reactive species that are potentially metal poisons, (e.g. glutathione) which will disrupt protein-
metal hybrid formation. The following section will explore different methodologies developed 
for efficient protein-metal modification.   
Finally, a quick, sensitive and robust activity assay is required to test a large number of ArM 
variants. Fluorescence-based assays are commonly used in high throughput screening and 
directed evolution due to their high sensitivity, variety of potential fluorophores and ease of 
operation.  
1.5.2. Introducing Unnatural Cofactors into Protein Scaffolds 
Four successful strategies have been employed to generate artificial metalloenzymes with a 
transition metal cofactor in a well-defined location in a host protein: 1) Metal substitution, 2) 
covalent anchoring, 3) supramolecular assembly, and 4) dative anchoring. This section will 
give a brief historical overview of artificial metalloenzymes, and then will go through the 
different anchoring methods giving examples of the most successful and recent ArMs to date.  
Historical Overview 
The first unnatural protein-metal hybrid was reported by Akabori and co-workers in 1956 
where a protein-palladium complex was prepared by adsorption of palladium chloride onto silk 
fibres. Asymmetric hydrogenation to yield optically-pure amino acid products was achieved.66 
In 1976 Yamamura and Kaiser reported metal substitution of an active-site zinc ion by a copper 
ion, in carboxypeptidase A, which resulted in the conversion of a powerful hydrolytic catalyst 
into an oxidase artificial metalloenzyme.67 Two years later, Wilson and Whitesides reported 
localising a biotinylated rhodium catalyst, capable of asymmetric hydrogenation, into the 
protein avidin via supramolecular assembly. Biotin and avidin have a very high association 
which is effectively irreversible, making this a unique way of ensuring that the metal is 
localised in the protein.68 
From the early 1980s to the early 2000s there are many examples of research papers involving 
the development of artificial metalloenzymes, mainly via metal substitution. The great 
limitation of the artificial metalloenzymes generated throughout this time was that they did not 
match the kinetic prowess, activity and selectivity of natural enzymes. Until the development 
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and application of directed evolution, the potential of artificial metalloenzymes was not fully 
realised.  
Metal Substitution 
Figure 1.6: Schematic representation of metal substitution. The natural cofactor (red) can be 
substituted with a suitable unnatural cofactor (blue). This may include the bare metal ion or 
larger cofactors such as haem. 
Many research groups have attempted to monitor how changing an active site metal impacts 
upon the metalloenzymes catalytic function, Figure 1.6. The most elegant method of metal 
substitution to date, was developed by Hartwig and co-workers, where an iridium methyl 
cofactor is substituted for the iron in two different haem containing proteins.  
In both examples, Ir(Me) units were substituted into a porphyrin in place of iron to catalyse the 
functionalisation of C-H bonds to C-C bonds by carbene insertion, Scheme 1.4. This reactivity 
was initially shown using modified myoglobins, with many other metal substitutions also 
tested, including a Ru(CO) unit, which was catalytically inactive.69 The reaction was then 
tested after replacing the iron in the variants of the cytochrome P450 enzyme CYP119. This 
led to a major breakthrough as through directed evolution, artificial iridium metalloenzymes 
were generated which showed 98% enantiomeric excess, 35,000 turnovers and 2500 hours-1 
turnover frequency. This confirmed that these ArMs were comparable with natural enzymes, 
in that they exhibit fast kinetics, high productivity and high selectivity.70 
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Scheme 1.4: Ir(Me) cytochrome P450 variants, capable of catalysing the functionalisation of 
C-H bonds to C-C bonds via carbene transfer. 
Covalent Anchoring 
Figure 1.7: Schematic representation of covalent anchoring. The metal cofactor (red) is 
attached to the protein by a reaction forming a covalent bond, for instance nucleophile (Nu) 
attacking an electrophile (E). 
The second method of localising an abiotic cofactor to a specific location is via a covalent 
linkage, Figure 1.7. There is extensive research interest in developing novel bioconjugation 
and protein modification techniques which fall into two broad categories: (a) modifying the 
protein template directly, via a nucleophilic – electrophilic reaction and (b) genetically 
manipulating the amino acid sequence before protein modification.71,72  
Many direct covalent modification reactions exist for the nucleophilic amino acids cysteine, 
lysine and tyrosine. In particular modification of cysteine has been widely applied for 
generation of artificial metalloenzymes. Due to the rarity of free cysteine in proteins (most in 
disulphide bonds and therefore unavailable), and its high nucleophilicity, modifying cysteine 
is an attractive methodology, as multiple modifications do not occur. Lysine residues are 
common on the surface of proteins and modification is rarely regioselective. Furthermore, there 
are many effective and reliable methods to modify a cysteine site, with three highlighted in 







OMe 0.17% Ir(Me)-PIX-CYP119 C317G
100 mM NaPi, 100 mM NaCl
pH = 6.0, 2 vol % DMF




Scheme 1.5: Classical methods used in cysteine modification of proteins: (a) thiol exchange, 
(b) alkylation of a-halocarbonyl electrophiles, X = Br or Cl and (c) maleimide Michael 
addition.  
Salmain and co-workers have modified the free Cys25 in the cysteine protease papain, using a 
variety of Ru(II)(h6-arene), CpFe, CpRu, Re(CO)3 and Rh(III)(h6-arene) complexes, all 
functionalised with either a maleimide or chloroacetamide group.73,74 The Rh(III)-papain 
conjugate showed some activity as a transfer hydrogenation catalyst, however, only a moderate 
enantiomeric excess of 7-10% was measured.75   
Cysteine residues have also been mutated into a variety of proteins, via site directed 
mutagenesis, and targeted with traditional conjugation techniques. Hayashi et al. reported an 
ArM with a maleimide functionalised Rh(Cp)(cod) unit covalently attached to a cysteine 
mutant Q96C of the b-barrel protein aponitrobindin. This hybrid was found to be a catalyst in 
the polymerisation of phenylacetylene, preferentially yielding the trans polymer.76  
Cysteine specific modifications can also be made prior to covalent anchoring to a metal 
complex, for example, cysteine residues can be selectively and simply reduced to 
dehydroalanine (Dha) which broadens the reactivity profile even further.77 When Dha has been 
installed, N, S and P nucleophiles can be covalently added under biocompatible conditions. If 
these nucleophiles were on the metal ligands, the linkage from the metal to the protein back-
bone could be very short, which is advantageous in localising a metal in a protein.72,78–81  
Genetic manipulation can also be used to introduce unnatural amino acids (UAAs) into a 
protein scaffold, which can then be covalently attached to the metal cofactor. In 1989, Peter 
Schultz reported a method to site-specifically incorporate UAAs into the enzyme b-lactamase, 
using modified transfer RNA responding to a stop codon substituted for the codon encoding 

























The most successful ArMs involving a covalent linkage to an UAA have been reported by Jared 
Lewis et al..83 This method involves covalently linking an alkyne-substituted dirhodium 
catalyst to a genetically encoded L-4-azidophenylalanine residue through strain-promoted 
azide-alkyne cycloaddition.84,85 In this study, the protein scaffold used was a b-barrel prolyl 
oligopeptidase from Pyrococcus furiousus selected for its cylindrical shape, large hydrophobic 
pocket for cofactor enclosure and high thermal stability.    
This rhodium-POP hybrid catalyses olefin cyclopropanation, and mutagenesis was employed 
to improve the enantioselectivity of the reaction. The effectiveness of this methodology is that 
the reaction is fast and irreversible, and the conjugation could be performed in a complex 
mixture, for example a cell, as the alkyne is selective for the azide. Although mutagenesis has 
been employed for this ArM, a full directed evolution campaign was not performed. Evolving 
enzymes with UAAs is complicated, as the UAA could be mutated out, and expression levels 
for these proteins are often very low.  
Supramolecular Assembly 
Figure 1.8: Schematic representation of supramolecular assembly. The metal cofactor (red) is 
localised by non-covalent interaction between a ligand bound recognition group (blue) and the 
protein. 
Artificial metalloenzymes have been generated where a catalytic metal complex has been 
attached to a small molecule with high affinity for a protein target, Figure 1.8. Building on the 
work of Wilson and Whitesides in the 1970s,86 Thomas Ward and co-workers have assembled 
ArMs based on the high supramolecular affinity of small molecule biotinylated metal catalysts 
for the protein streptavidin (Sav). As many as 12 different catalytic transformations have been 
performed by these metal-streptavidin hybrids, including ruthenium catalysed olefin 
metathesis,87 ruthenium-catalysed deallylation,88 iridium-catalysed transfer hydrogenation89 
and dirhodium-catalysed cyclopropanation,90 all in-vivo.  
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Where Ward’s work has really enhanced the field of ArMs is being able to carry out catalysis 
in complex cellular environments. Through molecular biology methods, the host protein, 
streptavidin is expressed by E.coli into the periplasm instead of the cytoplasm, so to avoid 
catalyst poisoning by glutathione. Catalyst reactivity, measured via TON and TOF, is often 
enhanced by having the streptavidin scaffold present in solution, which can form an ArM with 
the metal catalyst.  
This strategy has also been employed in a therapeutic application of ArMs that was reported 
by Tanaka et al. In this example, a coumarin derivative tagged with a ruthenium metathesis 
catalyst was localised to a hydrophobic binding site in human serum albumin. The 
metalloenzyme was directed to cancerous tissue (through specific glycosylation) and a pro-
drug was administered which upon metathesis induced cellular death.91 
One key benefit to supramolecular assembly is apparent in both examples described above, and 
that is that the conjugation between metal and protein is robust enough to be performed in 
complex cellular environments. Furthermore, unlike covalent attachment, supramolecular 
assembly can be a reversible process, which allows for component recycling. In a recent report 
of Duhme-Klair et al. catalytic transfer hydrogenation is demonstrated from a siderophore–
protein combination that enables strong but redox-reversible catalyst anchoring.92 
Dative Coordination 
Dative ArMs have coordination bond(s) directly from the metal to a Lewis basic amino acid 
residue (His, Cys, Ser, Glu, Asp, etc.) on the enzyme. There are few examples of ArMs with 
dative attachment presented in the literature most of which rely of 1st row transition metals, 
Figure 1.9.  
Fig 1.9: Schematic representation of cofactor attachment via direct coordination. The free 
metal cofactor (red) attaches to Lewis basic residues on the protein (LB) via ligand substitution 
reactions, forming a new protein-metal complex (blue). 
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One methodology in forming datively attached ArMs is to remove a prosthetic group e.g. haem 
and replace it with a metal complex which is structurally similar. This has been achieved with 
cobalt porphyrins, in the haem proteins myoglobin and cytochrome b562.93,94 Watanabe and co-
workers have applied this method in generating artificial myoglobin metalloenzymes, where a 
chromium Schiff-base is attached to the same His93 as the original haem group. These cobalt 
metalloenzymes are capable of catalysing the enantioselective sulfoxidation of thioanisole.95 
Unnatural amino acids that have well defined coordination sites for metals have also been used 
to generate dative artificial metalloenzymes. Bidentate bipyridine ligands can be genetically 
encoded into a protein sequence, and these ligands can strongly chelate a variety of transition 
metal ions including, Fe2+/3+, Cu2+, Co2+/3+ and Ru2+/3+.96 Through this method, Roelfes et al. 
generated copper ArMs which catalyse the Friedal-Crafts alkylation of a variety of indoles with 
a 94% conversion and high enantioselectivity.97 The protein scaffold used was the transcription 
factor Lactoccal multidrug resistant Regulator (LmrR) which, at the dimeric interface, has a 
hydrophobic cavity which is capable of accommodating many diverse substrates.98 
Although not technically focussed on artificial metalloenzymes, it is important to reference the 
pioneering research of Harry Gray who decorated many proteins with different ruthenium 
fragments and monitored electron transfer processes between ruthenium and iron metal 
centres.99 Ru(bipy) complexes were often used due to their well-defined photochemical and 
electrochemical behaviour. In one example [Ru(bipy)2(im)]2+ units were datively coordinated 
to surface histidine residues on cytochrome c, and distant Fe2+-Ru3+ electron couplings were 
extracted from intramolecular electron transfer rates for Ru(histidineX)) (where X = 33, 39, 62, 
72).100 
Assembly Driven Dative Coordination 
A bottom up approach of generating artificial metalloenzymes, from metal and peptidic starting 
materials has also proved to be fruitful. The theory behind this is to mimic nature and to use 
laboratory-enhanced evolution techniques, to generate comparable-to-nature, artificial 
metalloenzymes. Building upon the insight of Margaret Dayhoff,101 in early evolution, higher-
order metalloproteins were formed through the metal mediated assembly of simple, short 
peptides followed by polypeptide fusion and diversification.102  
In a 2018 research article, Hilvert et al. report the evolution of an active zinc metalloenzyme 
capable of accelerating ester cleavage with high enantiospecificity and large catalytic 
efficiency (kcat/KM = 106 M-1s-1).103 Starting from a homo-dimeric peptide MID1, with two 
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Zn(II)His3 binding sites, Zinc(II) ions were added and originally served as a template for 
protein assembly. The N and C termini of the dimer subunits were fused together to make a 
single polypeptide chain, and a combination of computational design with mutagenesis reduced 
the number of zinc sites to one. Through nine rounds of directed evolution, the resultant 
construct MID1sc10 had > 10,000-fold higher esterase activity, than the original construct. 
This remarkable improvement in activity, shows the power of directed evolution when applied 
to a metalloenzyme whereby the increase in activity is reliant on the protein providing ligands 
to the metal. However, the increase in activity is mainly due to evolving a protein which is 
specific for a given ester substrate, in particular a highly aromatic umbelliferone type 
derivative.  
Metal ions have also been employed to template the supramolecular assembly of four a-helical 
bundle components to generate larger protein constructs. Tezcan et al. reported the tetrameric 
assembly of cytochrome cb562 units, with zinc sites in the interface between two protein 
units.104 Following directed evolution, in vivo b-lactamase activity was monitored, with certain 
variants displaying catalytic proficiency for ampicillin hydrolysis.  
1.5.3. Critical Evaluation of Artificial Metalloenzymes to Date 
Evaluating these four methods of ArM formation, a key observation is that to for directed 
evolution to really optimise an ArM for catalytic function and improve both the kcat (the 
chemical turnover rate) and the KM (simplified in many systems to the substrate binding 
affinity), there must be direct coordination between the metal complex and the protein scaffold, 
as is the case for dative anchoring. In order for directed evolution to make measurable and 
significant improvements to kcat the protein scaffold must be able to have an electronic 
contribution to catalysis through direct protein-metal coordination. 
The work of Hilvert et al. has highlighted the catalytic possibilities of dative ArMs, in terms of 
the activity improvements that can be achieved through laboratory based evolutionary 
optimisation. In comparison to all other artificial metalloenzymes, Hilvert et al. have shown 
that when the metal is datively coordinated to the protein, directed evolution can have the most 
significant impact on catalytic efficiency (kcat/KM). Conceivably, if the protein is exposed to 
different substrates, different pathways of evolution can lead to a great increase in catalytic 
activity for each individual substrate. Henceforth, the initial ArM formed can be evolved from 
a generalist, with poor selectivity and activity, to a specialist, with enhanced activity; and this 
engineerability highlights the potential of dative artificial metalloenzymes. 
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Artificial metalloenzymes generated through covalent anchoring and supramolecular assembly 
do not have a direct bond from the metal to the protein, therefore there is a limited electronic 
contribution from the protein towards catalysis. Enantioselectivity and substrate selectivity can 
be evolved into these ArMs, however, achieving the kinetics, and high kcat/KM values of natural 
enzymes through directed evolution remains challenging. In many current examples, the 
protein is being used as a hydrophobic pocket, where enantioselective catalysis can occur, 
which does not utilise the full electronic, pre-organising and 3D properties that enzymes can 
provide. ArMs formed via covalent attachment rely on a chemical reaction to occur before 
catalysis, and often the catalyst is at the end of a flexible linker, therefore, the metal is not 
necessarily localised. In the particular case of streptavidin-biotin technology, the major 
limitation is that it is only applicable to one bacterial family, the avidins.  
ArMs generated through metal substitution have shown clear catalytic potential, as shown by 
the case of Hartwig’s iridium CYP119 metalloenzyme. Directed evolution has greatly 
optimised the binding and pre-organisation of the substrate for catalysis, lowering the value for 
KM, Figure 1.10. In this system there is no direct iridium-protein coordination; the iridium 
metal is coordinatively saturated by four haem nitrogens, one methyl ligand and coordination 
to the substrate. Therefore, the small increase in kcat cannot have come through an electronic 
(through bond) contribution to catalysis from amino acid side chain ligands and protein fold 
energy but from other minor contributors as indicated above. Another limitation of such a 
system is that it does not allow for the metal to bind more than one substrate, an essential 
feature of many interesting organometallic transformations e.g. metathesis. 
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Figure 1.10: Comparison of evolution regarding bare cofactor and initial artificial 
metalloenzyme. The data in this figure is taken from the work from Hartwig et.al.70 This elegant 
study is exemplary for the issue of using fully-substituted artificial cofactors. Whereas directed 
evolution was able to achieve an impressive 4000-fold increase in kcat/KM, the actual chemical 
turnover rate (kcat) was only moderately enhanced. 
1.5.4. Energetics of Dative Artificial Metalloenzymes 
Upon dative coordination of a metal complex to a protein, the energetics of the active site are 
dependent on a combination of multiple factors. Important interactions to consider are: (i) the 
metal to protein bond energies, (ii) the metal to ligand bond energies, (iii) the non-covalent 
interactions between the protein and the metal ligands and (iv) the non-covalent interactions 
between the protein and the substrate. All these factors impact the energetic landscape from 
which catalysis occurs.   
Considerations on Metal Chemistry 
One possible consequence of dative coordination in ArM formation is that the metal ion will 
organise around available protein ligands into the lowest energetic state, the proteins ground 
state configuration.105 Natural zinc finger proteins are a classic example of this, where in the 
absence of zinc the most stable protein confirmation is the denatured state, but upon addition 
of Zn(II), the metal adopts its favoured tetrahedral geometry, with four amino acid ligands, 
which stabilises the protein’s secondary and tertiary structure.106 These metalloenzymes often 
lie within thermodynamic wells therefore there is a large barrier towards catalysis.  
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Another possibility of dative coordination in ArM formation is a metal coordination 
environment pre-organised by a stable protein fold and upon metal addition the coordination 
site is at a higher energy than it would prefer.105 These energised coordination environments 
are often highly active catalytic centres, with the metal adopting a distorted coordination 
environment e.g. the hydrolytic enzyme carbonic anhydrase. These energised states, referred 
to as entatic active sites, describe a state that is ‘under tension’ and catalytically poised.107 In 
terms of artificial metalloenzymes these entatic states are very difficult to generate from bottom 
up, design-based approaches.  
Considerations of Non-Covalent Protein-Substrate Interactions 
With dative coordination highlighted as the optimal method of ArM formation, careful thought 
must be given to the selection of the starting protein scaffold to coordinate the metal complex 
and pre-organise the catalytic substrate for catalysis. Non-covalent interactions between the 
protein scaffold and catalytic substrate are vital in inferring natural metalloenzymes with their 
remarkable selectivity and reactivity. These interactions are crucial in placing the substrate into 
an optimum geometric arrangement which enhances molecular orbital overlap to the metal so 
that the energetic barrier to catalysis is lowered. 
Given the novelty of ArMs, the lack of reliable parameters for defining transition metal 
bonding, and the immense complexity of the many low energy interactions that determine 
binding of small molecules to proteins, it is beyond current computational capabilities to 
predict what primary sequence and cofactors are necessary to achieve the optimal arrangement 
for metal catalysis. It therefore becomes important to have a malleable, promiscuous starting 
system that can be used to sample a large space of different structures.108 Hence, while choosing 
proteins with well-defined properties and unique structures has some advantages from a design 
point of view, starting points that do not fold into one specific structure may be desirable, since 
they are not as closely constrained by any one particular energy well. Greater discussions will 
be made throughout this thesis into the optimum protein starting point for ArM development 
as coordination of metal complexes to a range of different protein scaffolds is explored.  
1.5.5. Summary and Challenges of Dative Artificial Metalloenzymes 
Dative attachment of unnatural metal cofactors to protein scaffolds is the most promising 
method to achieving artificial metalloenzymes which can match the activity of natural 
enzymes. There are a number of factors in support of this statement:  
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(i) In naturally evolved metalloenzymes, the direct coordination between the metal 
and the protein scaffold is integral to catalysis as the protein can attenuate metal 
activity through direct electronic contact as well as non-covalent contributions 
to catalysis, through intermolecular interactions that pre-organise substrates and 
stabilise transition states. 
(ii) ArMs with direct coordination have a vast scope in terms of engineerability and 
potential evolvability of the protein-metal hybrids generated. Mutations can be 
made which directly alter the energetic contribution of the protein which are 
crucial in activating metal centres for catalysis. Once catalytic activity has been 
identified in dative ArMs (even low levels) then evolutionary campaigns could 
make remarkable improvements on activity. 
(iii) Generating dative ArMs, enables the introduction of novel synthetic ligands 
(coordinated to the metal ion) into a protein scaffold. There is a direct linkage 
between the protein scaffold and synthetic ligands which are not present in 
biology.   
(iv) Finally, selection of a dynamic, malleable protein scaffold to coordinate a 
desirable metal complex is vital in the successful development of artificial 
metalloenzymes.  
An Activatable Metal Cofactor 
One vision of an optimal artificial metalloenzyme would involve an exogenous metal cofactor 
that is catalytically inert until localised in the desired protein fold, where catalytic activity is 
unmasked. To our best knowledge, all current ArMs presented in the literature involve metal 
species that are catalytically competent without the host protein being present. The only 
foreseeable method to activate an inert exogenous metal cofactor to generate an artificial 
metalloenzyme is through direct coordination to a Lewis basic residue and subsequent metal- 
ligand exchange. The subsequent ligand(s) provided by the protein and the strain energy 
provided by the protein fold, could potentially place the metal active site into an entatic state, 
which is poised for catalysis. Importantly the protein in absence of the metal cofactor must 
retain significant stability in order to generate this entatic state.  
Introducing 4d metals like ruthenium, as bare metal ion cofactors is chemically impossible, as 
the bare metal ion would coordinate to multiple positions; therefore, a coordinatively-saturated 
ruthenium complex must be exposed to a protein scaffold and a ligand exchange reaction must 
occur for ArM formation. 
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Chapter 2 
2. Project Aims 
2.1. Project Aims  
Previous research in the group has focussed on exploring the therapeutic potential of ruthenium 
complexes, particularly Ru(II)(h6-arene) complexes. Many of these complexes have been 
extensively studied by this group and others due to their ability to bring about cellular death at 
low concentrations, which has drawn comparisons to the anti-cancer drug cisplatin. The 
speciation of these complexes in cells, and how they bring about cellular death is poorly 
understood. The reactivity of Ru(II) arene complexes with proteins has drawn considerable 
interest as it is likely to play a crucial role in how many of these complexes induce cellular 
apoptosis. 
Further research goals of the group are centred around the development of artificial 
metalloenzymes which have a direct coordination bond between the protein scaffold and a 
metal complex. These hybrid catalysts have properties reminiscent of both homogeneous and 
enzymatic catalysis and could have applications in aqueous enantioselective catalysis and 
synthetic biology, where they could complement metabolic pathways.  
This overall aim of this project, which ties into both applications highlighted above (ruthenium 
therapeutics and artificial metalloenzymes), was to understand the reactivity and speciation of 
Ru(II) arene complexes with protein scaffolds, and explore the catalytic activity of the protein-
metal hybrids generated.  
Firstly, it is vital to identify the amino acid side chain residues that are capable of coordinating 
to a ruthenium metal centre in aqueous conditions and at biological pH. To do this, the aim was 
to develop novel spectroscopic approaches, particularly using solution-based NMR 
spectroscopy to track the speciation of bioactive Ru(II) arene complexes with free amino acids.  
Understanding where and to what extent a Ru(II)(h6-arene) complex is modifying a protein is 
challenging, but an extra level of complexity is being able to unmask catalytic activity upon 
protein coordination. At the beginning of this project, it was highlighted how controlled ligand 
exchange with a desirable protein scaffold could be crucial to this aim. Identifying the optimum 
protein scaffold and ruthenium complex to unmask catalytic activity upon coordination cannot 
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be predicted by simply analysing the metal complex and the protein tertiary structure. 
Therefore, the aim was to identify a system where the desired ligand exchange occurred and 




3. Experimental Methods and Protocols 
3.1.  General Methods 
General Considerations 
When necessary, all reactions were kept under an inert atmosphere or under a N2 flow using 
standard Schlenk line techniques. Methanol (MeOH), acetonitrile (MeCN), dichloromethane 
(DCM) and other required solvents were dried through distillation, stored over suitable drying 
agents and purged with N2 before use.  
Chemicals and Reagents 
Chemicals and solvents were purchased from chemical suppliers Sigma-Aldrich, Merck, Acros 
Organic and Insight Biotechnologies.  
3.2.  Instrumentation 
3.2.1. Nuclear Magnetic Resonance Spectroscopy 
All NMR data were collected at 298 K (unless stated) using Bruker Avance spectrometers with 
1H resonance frequencies of 400, 500, 600 MHz. All 1D 19F NMR spectra were recorded using 
an inverse gated decoupling pulse program so that integration values can be quantified.  
In proton NMR, chemical shifts (δH) are reported in parts per million (ppm), to the nearest 
0.01 ppm and are referenced to the residual non-deuterated solvent peak. Coupling constants 
(J) are reported in Hertz (Hz) to the nearest 0.1 Hz. Data are reported in the order: (i) chemical 
shift, (ii) multiplicity (s = singlet; d = doublet; t = triplet; q = quartet; sep = septet; m = 
multiplet; or as a combination of these, e.g. dd, dt etc.), (iii) coupling constant(s), (iv) 
integration and (v) assignment. In carbon NMR, chemical shifts (δC) are quoted in ppm, to the 
nearest 0.1 ppm, and are referenced to the residual non-deuterated solvent peak  
Collaborative NMR experiments were performed with Dr Stefan Freund and Dr Trevor 
Rutherford. Fluorine COSY and fluorinated protein NMR experiments were performed on a 
600 MHz Bruker spectrometer fitted with triple-resonance cryoprobes with 5% D2O added to 
each sample as a lock solvent. 
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All data was processed using Bruker’s Topspin software, including time-dependent spectra 
which used Bruker’s Dynamic Centre Package for kinetic analysis. 
3.2.2. X-Ray Crystallography 
Single-crystal X-ray diffraction data were collected at 180 K using either a Nonius Kappa CCD 
or Bruker D8-QUEST diffractometer, equipped with MoKa or CuKa radiation, respectively. 
Structures were solved using SHELXT109 and refined on F2 using SHELXL.110 Data collection 
and analysis were conducted by Dr Andrew Bond.  
3.2.3. Mass Spectrometry 
Low Resolution Mass Spectrometry 
Low-resolution electrospray ionisation mass spectrometry (LR-MS) was undertaken on a 
Micromass Quattro mass spectrometer (capillary voltage 1 – 3 kV, cone voltage 10 – 30 kV; 
desolvation temperature 320 K) infused manually from a Harvard syringe pump at a rate of 10 
µLmin-1. Mass values are reported within the error limits of ±0.05 mass units.  
High Resolution Mass Spectrometry 
High resolution mass spectrometry (HRMS) measurements were recorded with a Xevo G2-S 
TOF mass spectrometer spectrometer (capillary voltage 2 kV, cone voltage 40 kV; desolvation 
temperature 350 °C) with automatic injection. Mass values are reported within the error limits 
of ±5 ppm mass units. Nitrogen was used as the desolvation gas at a total flow of 850 L/h. 
Comparing Calculated and Observed Masses 
Where mass spectrometry has been used for the characterisation of ruthenium complexes, the 
major isotopes 102Ru (molecular weight 101.9034 g mol-1) and 35Cl (molecular weight 34.9689 
g mol-1) were used to compare observed and calculated masses. 
3.2.4. Liquid Chromatography Mass Spectrometry 
Measurement 
Protein LC–MS was performed on a Xevo G2-S TOF mass spectrometer coupled to an Acquity 
UPLC system using an Acquity UPLC BEH300 C4 column (1.7 μm, 2.1 × 50 mm). H2O with 
0.1 % formic acid (solvent A) and 95 % acetonitrile and 5 % water with 0.1 % formic acid 
(solvent B), were used as the mobile phase at a flow rate of 0.2 mL/min. The gradient was 
programmed as follows: 95% A for 0.93 min, then a gradient to 100% B over 4.28 min, then 
100% B for 1.04 minutes, then a gradient to 95% A over 1.04 min. The electrospray source 
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was operated with a capillary voltage of 2.0 kV, a cone voltage of 40 kV and a desolvation 
temperature of 350 °C . Nitrogen was used as the desolvation gas at a total flow of 850 L/h.  
Analysis 
The initial output from the LC-MS is a chromatogram that reports the total intensity counts 
(number of ions that hit the mass detector) over the course of the gradient. Combining and 
collecting all of these mass peaks generates an ion series for a protein or modified protein 
between a mass range of 200 – 2000 m/z. Total mass spectra were reconstructed from the ion 
series using the maximum entropy (MaxEnt) algorithm pre-installed on MassLynx software 
(v4.1 from Waters).  
The parameters used for this MaxEnt deconvolution algorithm are vital to achieve accurate 
zero charge mass spectra. Throughout this thesis, the MaxEnt procedure splits the deconvoluted 
spectra into 0.25 Da channels, and uses a width at half peak height of 0.75 Da. There is a large 
error associated with the MaxEnt procedure, however a 0.25 Da/channel aims to minimise this 
error, so that observed and calculated masses are ±3 Da apart. Importantly, in all experiments, 
the modifications theoretically possible within a given reaction mixture differ by > 100 Da, 
which allows for assignment of products to be given with some assurance.  
3.2.5.  Tandem MS/MS Experiments 
Protein samples (30 µM) were prepared for mass spectrometric analysis by hand, solution 
samples were digested with trypsin (Promega, UK) at a 1:50 ratio overnight at 37 °C. The 
resulting peptides were diluted in 2% v/v formic acid, 2% v/v acetonitrile. The digests were 
analysed by nano-scale capillary LC-MS/MS using an Ultimate U3000 HPLC 
(ThermoScientific Dionex, San Jose, USA) to deliver a flow of approximately 300 nL/min. A 
C18 Acclaim PepMap100 5 µm, 100 µm x 20 mm nanoViper (ThermoScientific Dionex, San 
Jose, USA), trapped the peptides prior to separation on a C18 T3 1.8 µm, 75 µm x 250 mm 
analytical UPLC column (Waters, UK). Peptides were eluted with a 30 minute gradient of 
acetonitrile (2% to 40%). The analytical column outlet was directly interfaced via a nano-flow 
electrospray ionisation source, with a quadrupole Orbitrap mass spectrometer (Q-Exactive 
HFX, ThermoScientific, USA). MS data were acquired in data-dependent mode using a top 10 
method, where ions with a precursor charge state of +1 were excluded. High-resolution full 
scans (R = 60,000, m/z 300-1800) were recorded in the Orbitrap followed by higher energy 
collision dissociation (HCD) (26 % Normalised Collision Energy) of the 10 most intense MS 
peaks. The fragment ion spectra were acquired at a resolution of 15 000 and dynamic exclusion 
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window of 20 s was applied. 
LC-MS/MS data were then searched against an in-house database using the Mascot search 
engine programme (Matrix Science, UK). Database search parameters were set with a 
precursor tolerance of 30 ppm and a fragment ion mass tolerance of 0.1 Da. One missed enzyme 
cleavage was allowed and variable modifications for ruthenium fragments allowed on the 
protein N-terminus, Cys, His, Lys, Asn, Gln, Arg and Trp were included. MS/MS data were 
validated using the Scaffold programme (Proteome Software Inc., USA).111 All data were 
additionally interrogated manually.  
3.2.6. UV-Vis Spectrometry 
All UV-vis spectra were recorded using Cary 400 or Cary 100 UV-Vis spectrophotometers. 
Standard 9/9/B quartz cuvettes with a 10 mm pathlength were used for recording absolute 
spectra. Data were recorded at 0.5 nm intervals using a spectral bandwidth of 2 nm, with full 
slit height. For all absolute spectra, a baseline of appropriate buffer was recorded and subtracted 
from all sample data. 
UV-Vis spectroscopy is used throughout this thesis to measure protein concentration, via the 
Beer Lambert law, Equation 3.1.  
																																																																										" = 	e$%																																																													(3.1)								  
3.2.7. Circular Dichroism 
CD spectra were recorded in 1 mm pathlength quartz cuvettes using a Chirascan CD 
spectrometer. CD data were recorded from 300 – 180 nm with sampling at 0.5 nm intervals. 
Samples were made to an expected concentration of approximately 5 µM in low buffer 
concentration.  
Temperature melt experiments were performed measuring ellipticity (q) with a fixed l = 222 
nm across a temperature range of 25 – 90 °C with a linear increase of 1 °C / min.    
3.2.8. Elemental Analysis 
Elemental microanalytical data were obtained from the University of Cambridge, Department 
of Chemistry microanalytical service. C,H,N analysis was carried out using an Exeter 
Analytical CE-440 Elemental Analyser by combustion of the sample under a pure O2 
atmosphere at 975 ºC.  
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ICP-OES analyses were carried out on a Thermo Scientific iCAP 7400 Duo. Double-deionised 
water was used for all analysis. The Ruthenium Specpure plasma standard (ruthenium chloride, 
1004 ± 5 μg/mL in 10% v/v hydrochloric acid) was diluted with HNO3 to 2% v/v HNO3 and 
calibrants were prepared at concentrations of 1 − 1000 ppb. Samples were prepared through 
dilution in 2% v/v HNO3. 
3.2.9. Fluorescence Measurements 
All fluorescence and UV-Vis spectroscopy in a 96-well plate format was performed on a 
SpectraMax i3x plate reader (Molecular Devices). Unless stated differently, all measurements 
monitoring transfer hydrogenation were taken with λEx = 370 nm, λEm = 460 nm and all 
measurements monitoring olefin metathesis were taken with λEx = 325 nm, λEm = 460 nm. All 
measurements used a bottom read, PMT = high, bandwidth - 9 nm excitation and 15 nm 
emission and catalytic time course experiments used 5 secs orbital shaking at the start and 1 
secs between each measurement. 
3.3. Synthetic Protocols and Characterisation 
3.3.1. Synthesis of the Fluorinated Bipyridines B – E   
Method 1 Fluorinated Bipyridine Synthesis 
The starting bromopyridine (1 mmol), Pd(OAc)2 (0.025 mol Eq.), K2CO3 (1 mol Eq.) and 
poly(ethylene glycol) (Mw 4000, 5.0 – 10g) were combined in a nitrogen purged flask. This 
mixture was heated to 120 °C and the temperature maintained for 48 hours with stirring. The 
mixture was cooled to 80 °C and 15 mL of warm water was added. Once at room temperature 
a further 10 mL of water was added and the suspension exhaustively extracted with ethyl 
acetate. The combined extracts were washed with saturated aqueous Na2S2O3 and three times 
with brine. The organic layer was then dried over MgSO4 and solvent removed in vacuo. The 
product was then purified via sublimation. 
Method 2 Fluorinated Bipyridine Synthesis112 
The starting bromopyridine (1.0 mmol), Pd(OAc)2 (0.025 mmol), indium (0.5 mmol) and 
lithium chloride (1.5 mmol) in dry DMF (2 mL) was stirred at 100 °C for 1 h under a nitrogen 
atmosphere. The reaction mixture was quenched with NaHCO3 (satd aq). The aqueous layer 
was extracted with ethyl acetate (320 mL) and the combined organic phase was washed with 
water (20 mL) and brine (20 mL), dried with MgSO4, and filtered. The residue was purified by 
silica gel column chromatography (EtOAc–hexane = 1:2). 
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Labelling of the Bipyridine 
 
Characterisation of 3,3’-difluorobipyridine (B) 
Synthesised using Method 1 with the starting material 2-bromo-3-fluoropyridine. Yield: 34 % 
(32.6 mg). Appearance: White solid 
1H NMR (400.13 MHz, CDCl3): d (ppm) 8.61 (d, 3JHH = 5.0 Hz, 2H, 6,6’-position), 7.54 (m, 
2H, 4,4’-position,), 7.52 (m, 2H, 5,5’-position).13C{1H} NMR (100.57 MHz, CDCl3): d (ppm) 
157.9 (dd, 1JCF = 265.1 Hz, 4JCF = 3.8 Hz, 3,3’-position), 146.1 (overlapping doublets, 4JCF = 
2.7 Hz, 4JCF = 3.8 Hz, 6,6’-position), 142.3 (dd, 2JCF = 8.3 Hz, 3JCF = 2.3 Hz, 2,2’-position), 
125.5 (overlapping doublets, 3JCF = 2.6 Hz, 3JCF = 2.1 Hz, 5,5’-position), 124.2 (d, 2JCF = 6.7 
Hz, 4,4’-position). 19F{1H} NMR (376.50 MHz, CDCl3): d (ppm) -121.9 (s). 
Characterisation of 5,5’-difluorobipyridine (C) 
Synthesised using Method 2 with the starting material 2-bromo-5-fluoropyridine. Yield: 78 % 
(74.9 mg). Appearance: White solid 
1H NMR (400.13 MHz, CDCl3): d (ppm) 8.50 (d, 4JHH = 2.8 Hz, 2H, 6,6’-position), 8.38 (dd, 
3JHH = 8.7 Hz, 4JHF = 4.5 Hz, 2H, 3,3’-position), 7.52 (m, 3JHH = 8.7 Hz, 4JHH = 2.8 Hz, 2H, 
4,4’-position). 13C{1H} NMR (100.57 MHz, CDCl3): d (ppm) 160.0 (d, 1JCF = 258 Hz, 5,5’-
position), 151.7 (d, 4JCF = 4 Hz, 2,2’-position), 137.4 (d, 2JCF = 24 Hz, 6,6’-position), 123.8 (d, 
2JCF = 18 Hz, 4,4’-position), 122.3 (d, 3JCF = 5 Hz, 3,3’-position). 19F{1H} NMR (376.50 MHz, 
CDCl3): d (ppm) -127.4 (s). 
Characterisation of 5,5’-di(trifluoromethyl)bipyridine (D) 
Synthesised using Method 2 with the starting material 2-bromo-5-(trifluoromethyl)pyridine. 
Yield: 65 % (94.9 mg). Appearance: White solid 
1H NMR (400.13 MHz, CDCl3): d (ppm) 8.99 (d, 4JHH = 1.8 Hz, 2H, 6,6’-position), 8.65 (d, 
3JHH = 8.4 Hz, 2H, 3,3’-position), 8.12 (dd, 3JHH = 8.4 Hz, 4JHH = 1.8 Hz, 2H, 4,4’-position). 
13C{1H} NMR (100.57 MHz, CDCl3): d (ppm) 157.8 (s, 2,2’-position), 146.5 (q, 3JCF = 3.9 Hz, 












123.7 (q, 1JCF = 273 Hz, CF3,), 121.4 (s, 3,3’-position). 19F{1H} NMR (376.50 MHz, CDCl3): 
d (ppm) -62.4 (s). 
Characterisation of 6,6’-difluorobipyridine (E)  
Synthesised using Method 1 with the starting material 2-bromo-6-fluoropyridine. Yield: 5 % 
(4.8 mg). Appearance: White solid 
1H NMR (400.13 MHz, CDCl3): d (ppm) 8.26 (dd, 3JHH = 7.8 Hz, 4JHH = 2.4 Hz, 2H, 3,3’-
position), 7.92 (overlapping dd, 3JHH = 7.8 Hz, 2H, 4,4’-position), 6.97 (dd, 3JHH = 7.8 Hz, 4JHH 
= 2.4 Hz, 2H, 5,5’-position). Lack of sample restricted analysis to 1H and 19F{1H} NMR. 
19F{1H} NMR (376.50 MHz, CDCl3): d (ppm) -67.1 (s). 
3.3.2. Synthesis of the Ruthenium Dimers I – IV   
Synthetic Procedure for Dimers I – III 113 
Ruthenium trichloride (9.6 mmol) was dissolved in ethanol (80 mL). The appropriate 
hexacyclic diene (38.4 mmol) was added slowly and the mixture was refluxed for 16 hours. 
The suspension was filtered and after being washed with EtOH (10 mL), Et2O (10 mL) and 
was dried in vacuo.  
Characterisation of [Ru(benzene)Cl2]2 
Synthesised from the starting diene 1,4-cyclohexadiene. Yield: 74 % (1.78 g). Appearance: 
Red solid 
 
1H NMR (400.13 MHz, D2O): 5.99 (s, 6H, PhH). 13C{1H} NMR (100.57 MHz, D2O): 80.5 (s, 
PhH). 
Characterisation of [Ru(toluene)Cl2]2 
Synthesised from the starting diene 1-methyl-1,4-cyclohexadiene. Yield: 82 % (2.08 g). 









1H NMR (400.13 MHz, D2O): 5.99 (overlapping dd, 3JHH = 5.7 Hz, 2H, 4-position), 5.71 (d, 
3JHH = 5.7 Hz, 2H, 3-position), 5.60 (t, 3JHH = 5.7 Hz, 1H, 5-position), 2.14 (s, 3H, 1-position). 
13C{1H} NMR (100.57 MHz, CDCl3): d (ppm) 105.7 (s, 2-position), 89.5 (s, 4-position), 84.9 
(s, 3-position), 82.2 (s, 5-position), 18.6 (s, 1-position). 
Characterisation of [Ru(p-cymene)Cl2]2 
Synthesised from the starting diene a - terpinene. Yield: 48 % (1.41 g). Appearance: Red solid 
 
1H NMR (400.13 MHz, D2O): 5.82 (d, 3JHH = 6.0 Hz, 2H, 5-position), 5.77 (d, 3JHH = 5.7 Hz, 
2H, 4-position), 2.83 (sept, 3JHH = 7.0 Hz, 1H, 2-position), 2.09 (s, 3H, 7-position), 1.19 (d, 
3JHH = 7.0 Hz, 6H, 1-position). 13C{1H} NMR (100.57 MHz, CDCl3): d (ppm) 106.4 (s, 5-
position), 100.1 (s, 4-position), 86.3 (s, 6-position), 85.5 (s, 3-position), 30.0 (s, 2-position), 
21.5 (s, 7-position), 17.9 (s, 1-position). 
Synthetic Procedure for Dimer IV 114 
A mixture of [Ru(p-cymene)Cl2]2 (0.21 mmol) and hexamethylbenzene (0.21mmol) was 
refluxed in diglyme (18 ml) with stirring under dry nitrogen atmosphere for around 9 hr. The 
solution was cooled to room temperature and the red brown product was filtered off, washed 
with hexane (510 ml) to remove excess hexamethylbenzene and p-cymene dimer and finally 






















Characterisation of [Ru(hexamethylbenzene)Cl2]2 
Yield: 42 % (58.9 mg). Appearance: Red solid 
 
1H NMR (400.13 MHz, D2O): 2.02 (s, 18H, 1-position), 13C{1H} NMR (100.57 MHz, CDCl3): 
d (ppm) 96.1 (s, 2-position), 15.3 (s, 1-position) 
3.3.3. Synthesis of the Ru(II)(h6-arene)(bipyridine) complexes [1] – [17] 
Synthetic Procedure for Complexes [1] – [17] 
The appropriate ruthenium arene dimer (I – IV) (0.06 mmol) and appropriate bipyridine (A – 
E) (0.12 mmol) were added to a nitrogen purged flask. Freshly distilled MeOH (25 mL) was 
added and the reaction was stirred for 24 hours at room temperature. The contents were filtered 
under gravity to remove excess ruthenium and the solution was reduced to approximately 5mL 
in vacuo. NH4PF6 (115 mg, 0.72 mmol) was added and the mixture was shaken and left at -10 










Structures of Complexes [1] – [17] 
 
Characterisation of [Ru(h6-benzene)(bipyridine)Cl][PF6] – [1] 
Synthesised from the starting dimer I and 2,2’-bipyridine. Yield: 74 % (44.0 mg). Appearance: 
Yellow  needles. 
Elemental: Anal. Calcd for C16H14ClF6N2PRu: C, 37.26; H, 2.74; N, 5.43. Found: C, 37.07; 
H, 2.57; N, 5.28. LRMS (ESI+): m/z 371.02 [M – PF6]+ (mcalc = 370.99). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 9.63 (d, 3JHH = 5.6 Hz, 2H, 6,6’-position), 8.64 (d, 3JHH = 8.1 Hz, 
2H, 3,3’-position), 8.29 (overlapping dd, 3JHH = 8.1 Hz, 3JHH = 7.9 Hz, 2H, 4,4’-position), 7.79 
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NMR (100.57 MHz, d6-DMSO): 156.0 (2,2’-position), 154.5 (6,6’-position), 140.0 (4,4’-
position) 127.4 (5,5’-position), 123.7 (3,3’-position), 87.0 (PhH, s).  
Characterisation of [Ru(h6-toluene)(bipyridine)Cl][PF6] – [2] 
Synthesised from the starting dimer II and 2,2’-bipyridine. Yield: 61 % (37.2 mg). Appearance: 
Yellow solid. 
Elemental: Anal. Calcd for C17H16ClF6N2PRu: C, 38.54; H, 3.04; N, 5.29. Found: C, 38.71; 
H, 2.61; N 4.85. LRMS (ESI+): m/z 385.00 [M – PF6]+ (mcalc = 385.00). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 9.55 (d, 3JHH = 5.4 Hz, 2H, 6,6’-position), 8.63 (d, 3JHH = 7.9 Hz, 
2H, 3,3’-position), 8.28 (overlapping dd, 3JHH = 8.4 Hz, 3JHH = 7.9 Hz, 2H, 4,4’-position), 7.78 
(overlapping dd, 3JHH = 8.4 Hz, 3JHH = 5.4 Hz, 2H, 5,5’-position), 6.30 (overlapping dd, 3JHH = 
6.2 Hz, 2H, 4-Tol-position), 5.96 (d, 3JHH = 6.2 Hz, 2H, 3-Tol-position), 5.83 (t, 3JHH = 6.2 Hz, 
1H, 5-Tol-position), 2.23 (s, 3H, 1-Tol-position). 13C{1H} NMR (100.57 MHz, d6-DMSO): 
156.3 (2,2’-position), 155.0 (6,6’-position), 140.3 (4,4’-position) 127.8 (5,5’-position), 124.1 
(3,3’-position), 106.4 (s, 2-Tol-position), 91.0 (s, 4-Tol-position), 83.3 (s, 3-Tol-position), 80.2 
(s, 5-Tol-position), 19.2 (s, 1-Tol-position). 
Characterisation of [Ru(h6-p-cymene)(bipyridine)Cl][PF6] – [3] 
Synthesised from the starting dimer III and 2,2’-bipyridine. Yield: 64 % (42.1 mg). 
Appearance: Yellow solid.  
Elemental: Anal. Calcd for C20H22ClF6N2PRu: C, 42.00; H, 3.88; N, 4.90. Found: C, 41.89; 
H, 3.86; N, 4.78 HRMS (ESI+): m/z 427.0625 [M – PF6]+ (mcalc = 427.0515). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 9.54 (d, 3JHH = 5.8 Hz, 2H, 6,6’-position), 8.64 (d, 3JHH = 8.0 Hz, 
2H, 3,3’-position), 8.29 (overlapping dd, 3JHH = 8.6 Hz, 3JHH = 8.0 Hz, 2H, 4,4’-position), 7.79 
(overlapping dd, 3JHH = 8.0 Hz, 3JHH = 6.5 Hz, 2H, 5,5’-position), 6.21 (d, 3JHH = 6.1 Hz, 2H, 
5-cym-position), 5.98 (d, 3JHH = 6.1 Hz, 2H, 4-cym-position), 2.57 (sept, 3JHH = 6.9 Hz, 1H, 2-
cym-position), 2.18 (s, 3H, 7-cym-position), 0.94 (d, 3JHH = 6.9 Hz, 6H, 1-cym-position). 
13C{1H} NMR (100.57 MHz, d6-DMSO): 155.7 (2,2’-position), 154.3 (6,6’-position), 139.9 
(4,4’-position) 127.5 (5,5’-position), 123.8 (3,3’-position), 104.1 (3-cym position), 104.0 (6-
cym position), 86.7 (5-cym-position), 83.9 (4-cym-position), 30.3 (2-cym-position), 21.6 (1-
cym-position), 18.3 (7-cym-position). 
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Characterisation of [Ru(h6-hexamethylbenzene)(bipyridine)Cl][PF6] – [4] 
Synthesised from the starting dimer IV and 2,2’-bipyridine. Yield: 54 % (37.3 mg). 
Appearance: Orange solid 
Elemental: Anal. Calcd for C22H26ClF6N2PRu: C, 44.04; H, 4.37; N, 4.67. Found: C, 44.18; 
H, 4.03; N 4.17. HRMS (ESI+): m/z 454.0855 [M – PF6]+ (mcalc = 454.0828). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 8.91 (d, 3JHH = 5.7 Hz, 2H, 6,6’-position), 8.60 (d, 3JHH = 8.0 Hz, 
2H, 3,3’-position), 8.24 (overlapping dd, 3JHH = 8.6 Hz, 3JHH = 8.0 Hz, 2H, 4,4’-position), 7.79 
(overlapping dd, 3JHH = 8.6 Hz, 3JHH = 6.7 Hz, 2H, 5,5’-position), 2.02 (s, 2-hmb-position). 
13C{1H} NMR (100.57 MHz, d6-DMSO): 154.9 (2,2’-position), 153.6 (6,6’-position), 139.5 
(4,4’-position) 127.7 (5,5’-position), 123.4 (3,3’-position), 95.4 (s, 2-hmb-position), 15.1 (s, 1-
hmb-position). 
Characterisation of [Ru(h6-benzene)(3,3’-difluorobipyridine)Cl][PF6] – [5] 
Synthesised from the starting dimer I and starting bipyridine B. Yield: 41 % (26.0 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Orange needles.  
Elemental: Anal. Calcd for C16H12ClF8N2PRu: C, 34.83; H, 2.19; N, 5.08. Found: C, 35.01; 
H, 2.22; N, 4.95. LRMS (ESI+): m/z 407.00 [M – PF6]+ (mcalc = 406.97). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 9.64 (d, 3JHH = 5.3 Hz, 2H, 6,6’-position), 8.34 (dd, 3JHH = 8.0 Hz, 
3JHH = 5.3 Hz, 2H, 5,5’-position), 7.97 (d, 3JHH = 8.0 Hz, 2H, 4,4’-position), 6.29 (s, 6H, PhH). 
13C{1H} NMR (100.57 MHz, d6-DMSO): d (ppm) 3,3’-bipy peak not resolvable, 153.9 (s, 6,6’-
position), 141.1 (dd, 2JCF = 8.2 Hz, 3JCF = 6.4 Hz, 2,2’-position), 130.0 – 129.0 (complex m, 
5,5’-position and 4,4’-position), 87.9 (s, PhH). 19F{1H} NMR (376.50 MHz, d6-DMSO): d 
(ppm) -69.8 (d, 1JPF = 711 Hz, PF6), -103.9 (s, 3,3’-position) 
Characterisation of [Ru(h6-toluene)(3,3’-difluorobipyridine)Cl][PF6] – [6]  
Synthesised from the starting dimer II and starting bipyridine B. Yield: 74 % (48.2 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Orange needles.  
Elemental: Anal. Calcd for C17H14ClF8N2PRu: C, 36.09; H, 2.49; N, 4.95. Found: C, 35.86; 
H, 2.38; N, 4.89. LRMS (ESI+): m/z 421.10 [M – PF6]+ (mcalc = 420.99). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 9.54 (d, 3JHH = 5.0 Hz, 2H, 6,6’-bipy-position), 8.32 (dd, 3JHF = 8.0 
Hz, 3JHH = 5.0 Hz, 2H, 4,4’-bipy-position), 7.95 (m, 3JHH = 5.0 Hz, 3JHH = 5.0 Hz, 4JHF = 3.1 
Hz, 2H, 5,5’-bipy-position), 6.30 (overlapping dd, 3JHH = 6.0 Hz, 2H, 4-Tol-position), 5.96 (d, 
3JHH = 6.0 Hz, 2H, 3-Tol-position), 5.85 (t, 3JHH = 6.0 Hz, 1H, 5-Tol-position), 2.24 (s, 3H, 1-
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Tol-position). 13C{1H} NMR (100.57 MHz, d6-DMSO): d (ppm) 157.1 (d, 1JCF = 264 Hz, 1H, 
3,3’-bipy-position), 153.2 (s, 6,6’-position), 140.8 (dd, 2JCF = 8.7 Hz, 3JCF = 6.4 Hz, 2,2’-
position,), 129.3 (s, 5,5’-position), 129.0 (d, 2JCF = 12.5 Hz, 4,4’-position), 106.8 (s, 2-Tol-
position), 91.2 (s, 4-Tol-position), 82.9 (s, 3-Tol-position), 80.2 (s, 5-Tol-position), 18.7 (s, 1-
Tol-position). 19F{1H} NMR (376.50 MHz, d6-DMSO): d (ppm) -69.8 (d, 1JPF = 711 Hz, PF6), 
-108.1 (s, 3,3’-position).  
Characterisation of [Ru(h6-p-cymene)(3,3’-difluorobipyridine)Cl][PF6] – [7]  
Synthesised from the starting dimer III and starting bipyridine B. Yield: 59 % (41.3 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Orange needles.  
Elemental: Anal. Calcd for C20H20ClF8N2PRu: C, 39.52; H, 3.32; N, 4.61. Found: C, 38.50; 
H, 3.31; N, 4.79. LRMS (ESI+): m/z 463.06 [M – PF6]+ (mcalc = 463.03). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 9.52 (d, 3JHH = 5.0 Hz, 2H, 6,6’-position), 8.34 (dd, 3JHF = 8.3 Hz, 
3JHH = 5.0 Hz, 2H, 4,4’-position), 7.97 (5,5’-position, 2H, m, 3JHH = 5.0 Hz, 3JHH = 5.0 Hz, 4JHF 
= 3.1 Hz), 6.23 (d, 3JHH = 6.4 Hz, 2H, 5-cym-position), 6.00 (d, 3JHH = 6.4 Hz, 2H, 4-cym-
position), 2.64 (sept, 3JHH = 7.0 Hz, 1H, 2-cym-position), 2.17 (s, 3H, 7-cym-position), 1.00 
(d, 3JHH = 7.0 Hz, 6H, 1-cym-position). 13C{1H} NMR (100.57 MHz, d6-DMSO): d (ppm) 3,3’-
bipy peak in baseline, 153.3 (s, 6,6’-position), 140.5 (dd, 2JCF = 6.8 Hz, 3JCF = 4.0 Hz, 2,2’-
position), 129.4 (s, 5,5’-position), 128.7 (d, 2JCF = 12.4 Hz, 4,4’-position), 105.1 (s, 3-cym-
position), 104.5 (s, 6-cym-position), 86.7 (s, 5-cym-position), 84.2 (s, 4-cym-position), 30.4 
(s, 2-cym-position), 21.7 (s, 1-cym-position), 18.2 (s, 7-cym-position). 19F{1H} NMR (376.50 
MHz, d6-DMSO): d (ppm) -69.8 (d, 1JPF = 711 Hz, PF6), -103.9 (s, 3,3’-position).  
Characterisation of [Ru(h6-hexamethylbenzene)(3,3’-difluorobipyridine)Cl][PF6] – [8] 
Synthesised from the starting dimer IV and starting bipyridine B. Yield: 55 % (40.2 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Orange/Red needles.  
Elemental: Anal. Calcd for C22H24ClF8N2PRu: C, 41.55; H, 3.80; N, 4.41. Found: C, 41.45; 
H, 3.73; N, 4.32. LRMS (ESI+): m/z 490.98 [M – PF6]+ (mcalc = 491.06). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 8.87 (d, 3JHH = 5.0 Hz, 2H, 6,6’-position), 8.27 (m, 3JHF = 8.0 Hz 
3JHH = 5.0 Hz, 2H, 4,4’-position), 7.94 (m, 3JHH = 5.0 Hz, 3JHH = 5.0 Hz, 4JHF = 3.0 Hz, 2H, 
5,5’-position), 2.02 (s, 18H). 13C{1H} NMR (100.57 MHz, d6-DMSO): 159.2 (d, 1JCF = 265 
Hz, 1H, 3,3’-position), 151.1 (s, 6,6’-position), 140.6 (dd, 2JCF = 8.0 Hz, 3JCF = 6.0 Hz, 2,2’-
position), 129.6 (s, 5,5’-position), 128.7 (d, 2JCF = 11.0 Hz 4,4’-position), 96.1 (s, 2-hmb-
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position), 15.0 (s, 1-hmb-position). 19F{1H} NMR (376.50 MHz, d6-DMSO): d (ppm) -69.8 (d, 
1JPF = 711 Hz, PF6,), -104.2 (s, 3,3’-position).  
Characterisation of [Ru(h6-benzene)(5,5’-difluorobipyridine)Cl][PF6] – [9]  
Synthesised from the starting dimer I and starting bipyridine C. Yield: 66 % (41.8 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Orange needles 
Elemental: Anal. Calcd for C16H12ClF8N2PRu: C, 34.83; H, 2.19; N, 5.08. Found: C, 35.03; 
H, 2.39; N, 4.85. LRMS (ESI+): m/z 407.01 [M – PF6]+ (mcalc = 406.97). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 9.78 (s, 2H, 6,6’-position), 8.71 (dd, 3JHH = 9.6 Hz, 3JHF = 4.6 Hz, 
2H, 4,4’-position), 8.36 (overlapping dd, 3JHH = 9.6 Hz, 4JHF = 7.8 Hz, 2H, 3,3’-position), 6.30 
(s, 6H, PhH). 13C{1H} NMR (100.57 MHz, d6-DMSO): d (ppm) 159.4 (d, 1JCF = 256 Hz, 5,5’-
position), 150.7 (s, 2,2’-position), 144.7 (d, 2JCF = 33 Hz, 6,6’-position,), 127.4 (d, 2JCF = 19.0 
Hz, 4,4’-position), 125.7 (d, 3JCF = 8.0 Hz, 3,3’-position), 87.2 (s, PhH). 19F{1H} NMR (376.50 
MHz, d6-DMSO): d (ppm) -69.8 (d, 1JPF = 711 Hz, PF6), -119.4 (s, 5,5’-position). 
Characterisation of [Ru(h6-toluene)(5,5’-difluorobipyridine)Cl][PF6] – [10] 
Synthesised from the starting dimer II and starting bipyridine C. Yield: 54 % (35.1 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Orange plates 
Elemental: Anal. Calcd for C17H14ClF8N2PRu: C, 36.09; H, 2.49; N, 4.95. Found: C, 35.75; 
H, 2.46; N, 4.73. LRMS (ESI+): m/z 420.88 [M – PF6]+ (mcalc = 420.99). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 9.68 (overlapping dd, 3JHF = 3.2 Hz, 4JHH = 2.5 Hz, 2H, 6,6’-bipy-
position), 8.71 (dd, 3JHH = 9.0 Hz, 4JHF = 4.8 Hz, 2H, 3,3’-bipy-position), 8.35 (ddd, 3JHH = 9.0 
Hz, 3JHF = 8.0 Hz, 4JHH = 2.5 Hz, 2H, 4,4’-bipy-position), 6.41 (overlapping dd, 2H, 3JHH = 6.0 
Hz, 4-Tol-position), 6.02 (d, 3JHH = 6 Hz, 2H, 3-Tol-position), 5.83 (t, 3JHH = 6.0 Hz, 1H, 5-
Tol-position), 2.26 (s, 3H, 1-Tol-position). 13C{1H} NMR (100.57 MHz, d6-DMSO): d (ppm) 
159.1 (d, 1JCF = 256 Hz, 5,5’-bipy-position), 150.7 (s, 2,2’-bipy-position) 144.6 (d, 2JCF = 33 
Hz, 6,6’-bipy-position), 127.3 (d, 2JCF = 19 Hz, 4,4’-bipy-position), 125.2 (d, 3JCF = 7.0 Hz, 
3,3’-bipy-position), 107.2 (s, 2-Tol-position), 90.9 (s, 4-Tol-position), 82.6 (s, 3-Tol-position), 
79.9 (s, 5-Tol-position), 18.9 (s, 1-Tol-position). 19F{1H} NMR (376.50 MHz, d6-DMSO): d 
(ppm) -69.8 (d, 1JPF = 711 Hz, PF6), -123.6 (s, 5,5’-position).  
Characterisation of [Ru(h6-p-cymene)(5,5’-difluorobipyridine)Cl][PF6] – [11] 
Synthesised from the starting dimer III and starting bipyridine C. Yield: 59 % (41.3 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Orange needles 
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Elemental: Anal. Calcd for C20H20ClF8N2PRu: C, 39.52; H, 3.32; N, 4.61. Found: C, 39.73; 
H, 2.99; N, 4.12. HRMS (ESI+): m/z 463.0370 [M – PF6]+ (mcalc = 463.0327). 1H NMR 
(400.13 MHz, d6-DMSO): d (ppm) 9.66 (overlapping dd, 3JHF = 3.2 Hz, 4JHH = 2.5 Hz, 2H, 
6,6’-bipy-position), 8.72 (dd, 3JHH = 9.0 Hz, 4JHF = 4.8 Hz, 2H, 3,3’-bipy-position), 8.36 (td, 
3JHH = 9.0 Hz, 3JHF = 8.0 Hz, 4JHH = 2.5 Hz, 2H, 4,4’-bipy-position), 6.34 (d, 3JHH = 6.4 Hz, 2H, 
5-cym-position), 6.06 (d, 3JHH = 6.4 Hz, 2H, 4-cym-position), 2.60 (sept, 3JHH = 7.0 Hz, 1H, 2-
cym-position), 2.21 (s, 3H, 7-cym-position), 0.94 (d, 3JHH = 7.0 Hz, 6H, 1-cym-position). 
13C{1H} NMR (100.57 MHz, d6-DMSO): d (ppm) 159.2 (d, 1JCF = 256 Hz, 5,5’-bipy-position), 
150.6 (s, 2,2’-bipy-position), 144.5 (d, 2JCF = 32.5 Hz, 6,6’-bipy-position), 127.4 (d, 2JCF = 18.3 
Hz, 4,4’-bipy-position), 124.2 (d, 3JCF = 8.0 Hz, 3,3’-bipy-position,), 105.1 (s, 3-cym-position), 
104.5 (s, 6-cym-position), 86.8 (s, 5-cym-position), 83.5 (s, 4-cym-position), 30.4 (s, 2-cym-
position), 21.8 (s, 1-cym-position), 18.4 (s, 7-cym-position). 19F{1H} NMR (376.50 MHz, d6-
DMSO): d (ppm) -69.8 d, 1JPF = 711 Hz PF6), -123.1 (s, 5,5’-position). 
Characterisation of [Ru(h6-hexamethylbenzene)(5,5’-difluorobipyridine)Cl][PF6] – [12] 
Synthesised from the starting dimer IV and starting bipyridine C. Yield: 59 % (43.1 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Red needles 
Elemental: Anal. Calcd for C22H24ClF8N2PRu: C, 41.55; H, 3.80; N, 4.41. Found: C, 41.63; 
H, 3.46; N, 3.86. HRMS (ESI+): m/z 491.0676 [M – PF6]+ (mcalc = 491.0640). 1H NMR 
(400.13 MHz, d6-DMSO): d (ppm) 8.89 (6,6’-bipy-position, 2H, t, 3JHF = 3.2 Hz, 4JHH = 2.3 
Hz), 8.72 (3,3’-bipy-position, 2H, overlapping dd, 3JHH = 9.0 Hz, 4JHF = 4.8 Hz), 8.34 (4,4’-
bipy-position, 2H, td, 3JHH = 9.0 Hz, 3JHF = 8.0 Hz, 4JHH = 2.3 Hz), 2.06 (18H, s, 2-hmb-
position). 13C{1H} NMR (100.57 MHz, d6-DMSO): d (ppm) 159.5 (d, 1JCF = 257 Hz, 5,5’-
position), 150.6 (s, 2,2’-position), 141.8 (d, 2JCF = 32 Hz, 6,6’-position), 127.3 (d, 2JCF = 19.5 
Hz, 4,4’-position), 125.3 (d, 3JCF = 8 Hz, 3,3’-position,), 95.8 (s, 2-hmb-position) 15.0 (s, 1-
hmb-position). 19F{1H} NMR (376.50 MHz, d6-DMSO): d (ppm) -69.8 (d, 1JPF = 711 Hz, PF6), 
-122.7 (s, 5,5’-position).  
Characterisation of [Ru(h6-benzene)(5,5’-di(trifluoromethyl)bipyridine)Cl][PF6] – [13] 
Synthesised from the starting dimer I and starting bipyridine D. Yield: 60 % (45.0 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Orange prisms. 
Elemental: Anal. Calcd for C18H12ClF12N2PRu: C, 33.17; H,1.86; N, 4.30. Found: C, 33.15; 
H, 1.80; N, 4.21. LRMS (ESI+): m/z 507.00 [M – PF6]+ (mcalc = 506.96). 1H NMR (400.13 
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MHz, d6-DMSO): d (ppm) 9.95 (s, 2H, 6,6’-position), 9.04 (d, 3JHH = 8.7 Hz, 2H, 3,3’-position), 
8.86 (d, 3JHH = 8.7 Hz, 2H 4,4’-position), 6.35 (s, 6H, PhH). 13C{1H} NMR (100.57 MHz, d6-
DMSO): 156.6 (s, 2,2’-position), 152.7 (q, 3JCF = 4.1 Hz, 6,6’-position,), 137.8 (q, 3JCF = 3.1 
Hz , 4,4’-position,), 128.7 (q, 2JCF = 34 Hz, 5,5’-position,), 125.5 (s, 3,3’-position) 122.1 (q, 
1JCF = 278 Hz , CF3,), 87.5 (s, PhH). 19F{1H} NMR (376.50 MHz, d6-DMSO): d (ppm) -69.8 
(d, 1JPF = 711 Hz, PF6,), -60.1 (s, CF3 groups). 
Characterisation of [Ru(h6-toluene)(5,5’-di(trifluoromethyl)bipyridine)Cl][PF6] – [14] 
Synthesised from the starting dimer II and starting bipyridine D. Yield: 61 % (76.6 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Orange needles.  
Elemental: Anal. Calcd for C19H14ClF12N2PRu: C, 34.28; H, 2.12; N, 4.21. Found: C, 34.34; 
H, 2.08; N, 4.15. LRMS (ESI+): m/z 520.97 [M – PF6]+ (mcalc = 520.98). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 9.84 (s, 2H, 6,6’-position), 9.01 (d, 3JHH = 8.5 Hz, 2H, 3,3’-position), 
8.83 (d, 3JHH = 8.5 Hz, 2H 4,4’-position), 6.46 (overlapping dd, 2H, 3JHH = 6.0 Hz, 4-Tol-
position), 6.11 (d, 3JHH = 6.0 Hz, 2H, 3-Tol-position), 5.84 (t, 3JHH = 6.0 Hz, 1H, 5-Tol-
position), 2.25 (s, 3H, 1-Tol-position). 13C{1H} NMR (100.57 MHz, d6-DMSO): 156.7 (s, 2,2’-
position), 152.4 (q, 3JCF = 4.2 Hz, 6,6’-position,), 137.7 (q, 3JCF = 3.5 Hz , 4,4’-position,), 128.7 
(q, 2JCF = 35 Hz, 5,5’-position,), 125.4 (s, 3,3’-position) 122.1 (q, 1JCF = 275 Hz , CF3,), 108.5 
(s, 2-Tol-position), 92.0 (s, 4-Tol-position), 81.9 (s, 3-Tol-position), 79.7 (s, 5-Tol-position), 
19.0 (s, 1-Tol-position). 19F{1H} NMR (376.50 MHz, d6-DMSO): d (ppm) -69.8 (d, 1JPF = 711 
Hz, PF6,), -60.7 (s, CF3 groups). 
Characterisation of [Ru(h6-p-cymene)( 5,5’-di(trifluoromethyl)bipyridine)Cl][PF6] – [15] 
Synthesised from the starting dimer III and starting bipyridine E. Yield: 62 % (81.4 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Yellow prisms. 
Elemental: Anal. Calcd for C22H20ClF12N2PRu: C, 37.33; H, 2.12; N, 4.21. Found: C, 37.59; 
H, 2.71; N, 3.59. HRMS (ESI+): m/z 563.0639 [M – PF6]+ (mcalc = 563.0263). 1H NMR 
(400.13 MHz, d6-DMSO): d (ppm) 9.83 (s, 2H, 6,6’-position), 9.04 (d, 3JHH = 8.5 Hz, 2H, 3,3’-
position), 8.85 (d, 3JHH = 8.5 Hz, 2H, 4,4’-position), 6.45 (d, 3JHH = 6.1 Hz, 2H, 5-cym-
position), 6.17 (d, 3JHH = 6.1 Hz, 2H, 4-cym-position), 2.62 (sept, 3JHH = 6.9 Hz, 1H, 2-cym-
position), 2.20 (s, 3H, 7-cym-position), 0.97 (d, 3JHH = 6.9 Hz, 6H, 1-cym-position). 13C{1H} 
NMR (100.57 MHz, d6-DMSO): 156.4 (s, 2,2’-position), 152.3 (q, 3JCF = 4.2 Hz, 6,6’-
position,), 137.8 (q, 3JCF = 3.3 Hz , 4,4’-position,), 128.9 (q, 2JCF = 34 Hz, 5,5’-position,), 125.7 
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(s, 3,3’-position) 122.0 (q, 1JCF = 273 Hz , CF3,), 105.7 (s, 3-cym-position), 104.9 (s, 6-cym-
position), 87.2 (s, 5-cym-position), 83.3 (s, 4-cym-position), 30.4 (s, 2-cym-position), 21.8 (s, 
1-cym-position), 18.4 (s, 7-cym-position). 19F{1H} NMR (376.50 MHz, d6-DMSO): d (ppm) -
69.8 (d, 1JPF = 711 Hz, PF6,), -60.4 (s, CF3 groups). 
Characterisation of [Ru(h6-hexamethylbenzene)(5,5’-
di(trifluoromethyl)bipyridine)Cl][PF6] – [16] 
Synthesised from the starting dimer IV and starting bipyridine E. Yield: 45 % (38.0 mg). 
Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Orange Needles. 
Elemental: Anal. Calcd for C22H20ClF12N2PRu: C, 39.17; H, 3.29; N, 3.81. Found: C, 38.94; 
H, 2.93; N, 3.50. HRMS (ESI+): m/z 591.0573 [M – PF6]+ (mcalc = 591.0576). 1H NMR 
(400.13 MHz, d6-DMSO): d (ppm) 9.16 (s, 2H, 6,6’-position), 9.08 (d, 3JHH = 8.4 Hz, 2H, 3,3’-
position), 8.88 (d, 3JHH = 8.4 Hz, 2H 4,4’-position), 2.08 (18H, s, 2-hmb-position). 13C{1H} 
NMR (100.57 MHz, d6-DMSO): 156.8 (s, 2,2’-position), 149.8 (q, 3JCF = 4.3 Hz, 6,6’-
position), 137.7 (q, 3JCF = 2.9 Hz , 4,4’-position,), 129.1 (q, 2JCF = 34 Hz, 5,5’-position,), 126.1 
(s, 3,3’-position) 122.6 (q, 1JCF = 274 Hz , CF3,), 96.7 (s, 2-hmb-position) 15.4 (s, 1-hmb-
position). 19F{1H} NMR (376.50 MHz, d6-DMSO): d (ppm) -69.8 (d, 1JPF = 711 Hz, PF6,), -
60.8 (s, CF3 groups). 
Characterisation of [Ru(h6-hexamethylbenzene)(6,6’-difluorobipyridine)Cl][PF6] – [17] 
Synthesised from the starting dimer I and starting bipyridine E. A synthesis at 10-fold lower 
molar concentration was used for this complex due to lack of starting bipyridine. Yield: 55 % 
(3.5 mg). Recrystallised via vapour diffusion Et2O:Acetone. Appearance: Yellow prisms. 
Elemental: Anal. Calcd for C18H12ClF12N2PRu: C, 34.83; H, 2.19; N, 5.08. Found: C, 34.61; 
H, 2.33; N, 4.84. LRMS (ESI+): m/z 407.02 [M – PF6]+ (mcalc = 406.97). 1H NMR (400.13 
MHz, d6-DMSO): d (ppm) 8.63 (d, 3JHH = 7.9 Hz, 2H, 3,3’-position), 8.52 (dd, 3JHH = 8.5 Hz, 
3JHH = 7.9 Hz, 2H, 4,4’-position), 7.91 (d, 3JHH = 8.5 Hz, 2H, 5,5’-position), 6.32 (s, 6H, PhH). 
Lack of sample restricted analysis to 1H and 19F NMR analysis. 19F{1H} NMR (376.50 MHz, 
d6-DMSO): d (ppm) -69.8 (d, 1JPF = 711 Hz, PF6), -49.7 (s, 6,6’-position) 
3.3.4. Synthesis of Catalytic Substrates for Chapter 6 
Fellow group member Jamie Klein performed all synthesis of catalytic substrates, including 
synthetic optimisation and characterisation required for this chapter.  
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Synthesis of this substrate was reported by Ward et al.,89 however, the method was modified 
by Jamie Klein and a much improved yield was reported. 
Transfer Hydrogenation Substrate (TH substrate) 
(2-methyl-6-quinolinyl)methanol (100 mg, 0.58 mmol, 1 eq.), methanesulfonic anhydride (110 
mg, 0.63 mmol, 1.1 eq.) and DMAP (7.3 mg, 0.06 mmol, 0.1 eq.) were weighed into a dry 
Schlenk tube and dried under vacuum for 1 h. The system was put under a N2 atmosphere 
CH2Cl2(5 mL), CH3CN (1 mL) and anhydrous pyridine (47 µL, 0.58 mmol. 1 eq.) were added 
and the mixture stirred at room temperature for 30 min., after which the solvent was removed 
in vacuo. Umbelliferone (113 mg, 0.70 mmol, 1.2 eq.) and caesium carbonate (331 mg, 1.02 
mmol, 1.75 eq.) were dried in vacuo before addition of CH3CN (10 mL). After stirring for 20 
min., the mesylated quinoline was taken up in CH3CN (10 mL) and small portions were added 
slowly to the umbelliferone mixture. After complete addition, the mixture was stirred at room 
temperature overnight. The mixture was filtered, the solvent was removed in vacuo and the 
residue taken up in EtOAc (20mL). The mixture was washed with 1N NaOH(aq) (3 x 20 mL), 
after which the combined aqueous phase was extracted with EtOAc (2 x 20 mL). The product 
(142 mg, 0.45 mmol, 77% yield) was obtained as a white solid after flash chromatography 
(EtOAc:Hexane 2:1). 
The coupled product (132 mg, 0.42 mmol, 1 eq.) was dissolved is dry toluene (30 mL) under a 
N2 atmosphere. Dimethyl sulphate (395 µL, 4.2 mmol, 10 eq.) was added and the mixture 
stirred for 24 h at 100 °C. The product was obtained by filtration and washing with Et2O and 
hexane as an off-white solid (57 mg, 0.13 mmol, 31% yield). 
 
1H NMR (400.13 MHz, d6-DMSO): d (ppm) 9.11 (d, J = 8.6 Hz, 1H), 8.64 (d, J = 9.2 Hz, 1H), 
8.47 (s, 1H), 8.29 (dd, J = 9.2, 1.9 Hz ,1H), 8.13 (d, J = 8.6 Hz, 1H), 8.02 (d, J = 9.5 Hz, 1H), 
7.69 (d, J = 8.6 Hz, 1H), 7.16 (d, J = 2.2 Hz, 1H), 7.11 (dd, J = 8.6, 2.4 Hz, 1H), 6.33 (d, J = 
9.5 Hz, 1H), 5.57 (m, 2H), 4.45 (s, 3H), 3.37 (s, 3H) 3.08 (s, 3H).  
N






Olefin Metathesis Substrate (OM substrate) 
Step 1: Protection to OM Intermediate 1: 
 
3,4-dihydro-2H-pyran (DHP) (3.02 g, 3.30 mL, 36.0 mmol) was added to a solution of 2,4-
dihydroxybenzaldehyde (4.14 g, 30.0 mmol) and pyridinium p-toluenesulfonate (754 mg, 3.00 
mmol) in dry DCM (60 cm3). The mixture was stirred for 3 h at room temperature under N2 
atmosphere. The mixture was quenched with saturated NaHCO3 (aq.) (90 cm3), the aqueous 
phase extracted with EtOAc (2 x 90 cm3) and the combined organic phases dried with MgSO4. 
The solvent was removed under reduced pressure to yield the product as colourless crystals 
(6.0 g, 90%), which was directly used for subsequent steps. 
Step 2: Wittig reaction to OM Intermediate 2: 
 
Under a N2 atmosphere, potassium tert-butoxide (3.0 g, 27.0 mmol) was added to a suspension 
of methyltriphenyl-phosphonium bromide (4.8 g, 13.4 mmol) in dry THF (50 cm3). The 
mixture was stirred at room temperature for 1 h, then cooled to -78 °C. OM Intermediate 1 (2.0 
g, 9.0 mmol) was dissolved in dry THF (30 cm3) then added dropwise to the reaction mixture. 
The mixture was warmed to room temperature and stirred for a further 30 min. The reaction 
was quenched with saturated NH4Cl(aq.) (100 cm3) and the aqueous layer extracted with EtOAc 
(2 x 50 cm3). The combined organic phases were washed with brine and dried over Na2SO4. 
The solvent was reduced under vacuum and the product (1.3 g, 5.7 mmol, 63%) was obtained 
as colourless solid after purification by flash chromatography (hexane:EtOAc, 3:1).  


















Triethylamine (1.4 cm3, 10 mmol) was added to a solution of OM Intermediate 2 (1.1 g, 5.0 
mmol) in dry DCM (60 cm3) under N2 atmosphere. Acrolyl chloride (0.6 cm3, 7.5 mmol) was 
slowly added and the mixture stirred for 30 min. at room temperature. The solvent was removed 
under reduced pressure and the resulting oil was taken straight to further reaction due to limited 
stability. 
Deprotection to OM Substrate: 
 
p-Toluenesulfonic acid monohydrate (77 mg, 0.4 mmol) was added to a mixture of OM 
Intermediate 3 (~1.1 g, 4.1 mmol) in MeOH/THF 1:1 (100 cm3). After stirring at 50 °C for 1 
h, the mixture was concentrated under reduced pressure and the residue taken up in DCM (80 
cm3). The mixture was washed with brine and dried over MgSO4. The product (0.46 g, 2.4 
mmol) was obtained as a colourless oil after purification via flash chromatography 
(cyclohexane/EtOAc 5:2). The product was rapidly stored as a ~0.2 M solution in DMSO (12 
cm3) at -20°C.  
1H NMR (400 MHz, d6-DMSO) δ = 9.90 (s, 1H), 7.51 (d, 3JHH = 8.6 Hz, 1H), 6.73 (dd, 3JHH = 
8.6, 2.4 Hz, 1H), 6.61-6.50 (m, 3H), 6.43 (dd, 3JHH = 17.3, 10.2 Hz, 1H), 6.16 (dd, 3JHH = 10.3, 
2JHH = 1.3 Hz, 1H), 5.64 (dd, 3JHH = 17.6, 2JHH = 1.1 Hz, 1H), 5.14 (dd, 3JHH = 11.2, 2JHH = 1.1 
Hz, 1H). 
3.3.5. Synthesis of Ruthenium Complexes for Chapter 7 
Synthetic Procedure and Characterisation of L1 and [18] 
Synthesis of ligand previously reported by Albrecht et al,115 however, the ruthenium complex 
is novel.  
Picolinic acid (1.23 g, 10 mmol) was refluxed at 85 °C in SOCl2 (10 mL, 0.14 mol) for 3 h 
under an N2 atmosphere. The excess of SOCl2 was removed under reduced pressure in a well-
ventilated fume hood. The residue was dissolved in dry THF (40 mL) and transferred via 
cannula to a solution of the 4-amino pyridine (0.94 g, 10 mmol) in THF (50 mL) with the 
presence of NEt3 (2.5 mL, 18 mmol). The mixture was refluxed for at 65 °C 48 h, filtered, and 




the solvent was removed under reduced pressure. The brown solid residue was purified by 
column chromatography (SiO2) in (4 : 1, EtOAc : Hexane) to yield a white solid. (1.40 g, 65 
%).  
The purified white solid (398 mg, 2.0 mmol) was dissolved in MeCN (15 mL) in a Schlenk 
tube. MeI (187 μL, 3.0 mmol) was added, and the reaction mixture was stirred for 12 h at 80 
°C. The solution was cooled to room temperature and concentrated to 5 mL. Et2O (50 mL) was 
added, and the formed yellow precipitate was filtered and washed with cold Et2O to yield the 
product L1 (578 mg, 85 %). 
 
1H NMR (400.13 MHz, d6-DMSO): d (ppm) 12.01 (s, 1H, NH), 8.83 (d, 3JHH = 4.7 Hz, 1H, 
H1), 8.80 (d, , 3JHH = 6.6 Hz Hz, 2H, H9), 8.50 (d, 3JHH = 6.6 Hz, 2H, H8), 8.24 (d, 3JHH = 7.8 
Hz, 1H, H4), 8.15 (td, 3JHH = 7.8 Hz, 4JHH = 1.7 Hz 1H, H3), 7.80 (ddd, 3JHH = 7.8 Hz, 3JHH = 
4.7 Hz, 3JHH = 1.4 Hz 1H, H2), 4.20 (s, 3H, H10). 13C{1H} NMR (100.57 MHz, d6-DMSO): 
164.7 (C6), 151.4 (C7), 148.8 (C5), 148.2 (C1), 145.9 (C9), 138.5 (C3), 128.2 (C2), 123.5 
(C4), 115.8 (C8), 46.5 (C10).  
Synthetic Procedure and Characterisation for Complex [18] 
Ligand L1 (86 mg, 0.25 mmol), [Ru(p-cym)Cl2]2 (91 mg, 0.15 mmol), AgPF6 (126 mg, 0.5 
mmol), and K2CO3 (69 mg, 0.50 mmol) were stirred in dry MeCN (10 mL) under N2 
atmosphere for 3 h. The volatiles were removed under reduced pressure, and dry CH2Cl2 (20 
mL) was added. The mixture was filtered through a short pad of Celite and washed with more 
CH2Cl2 (20 mL). All filtrates were combined and evaporated to dryness to obtain the Ru 
complex [18]. The crude product was purified by recrystallization from CH2Cl2/pentane (35 


















Elemental: Anal. Calcd for C22H25ClF6N3OPRu: C, 42.01; H, 4.01; N, 6.68. Found: C, 41.97; 
H, 4.10; N, 6.75. HRMS (ESI+): m/z 484.0721 [M – PF6]+ (mcalc = 484.0730). 1H NMR 
(400.13 MHz, d6-DMSO): d (ppm) 9.36 (d, 3JHH = 5.2 Hz, 1H, H1) 8.59 (d, 3JHH = 6.8 Hz, 2H, 
H9), 8.28 (d, 3JHH = 6.8 Hz, 2H, H8), 8.19 (td, 3JHH = 7.8 Hz, 1H, H4), 8.00 (d, 3JHH = 7.8 Hz 
1H, H3), 7.81 (ddd, 3JHH = 7.8 Hz, 3JHH = 4.7 Hz, 3JHH = 1.4 Hz, 1H, H2), 5.87 (d, 3JHH = 5.8 
Hz, 1H, H13), 5.72 (d, 3JHH = 5.8 Hz, 1H, H14), 5.60 (d, 3JHH = 5.8 Hz, 1H, H13), 5.49 (d, 3JHH 
= 5.8 Hz, 1H, H14), 4.18 (s, 3H, H10), 2.45 (sept, 3JHH = 5.8, 1H, H16), 2.21 (s, 3H, H11), 1.02 
(d, 3JHH = 6.9 Hz, H17), 0.95 (d, 3JHH = 6.9 Hz, H17). 13C{1H} NMR (100.57 MHz, d6-DMSO): 
168.3 (C6), 165.4 (C7), 155.4 (C1), 152.4 (C9), 144.3 (C5), 139.8 (C4), 128.7 (C2), 125.9 
(C3), 123.4 (C8), 102.7 (C15), 101.9 (C12), 85.9 (C13), 84.8 (C13), 83.1 (C14), 82.8 (C14), 
46.0 (C10), 30.4 (C16), 21.9 (C17), 21.5 (C17), 18.3 (C11). 
Synthetic Procedure and Characterisation of L2 and [19] 
This ligand and complexes are novel, however, build upon a synthesis developed by Albrecht 
et al.116 
Oxalyl chloride (1.29 mL, 15 mmol) and freshly distilled CH2Cl2 (20 mL) were added into a 
nitrogen purged Schlenk flask. 4-aminopyridine (2.82 g, 30 mmol) was added followed by the 
slow addition of freshly distilled NEt3 (5 mL, 36 mmol) under a nitrogen stream. The reaction 
mixture was stirred at room temperature overnight and then and a brown solid collected on the 
filter pad. Continual washes with H2O (3 x 25 mL) yielded an off-white solid which was dried 
on a high vacuum for 12 hrs (1.66 g, 46 %).  
The off white solid (0.94 g, 3.88 mmol) was dissolved in freshly distilled CH2Cl2 (30 mL) and 
stirred at 0 °C for 10 mins. Methyl trifluoromethanesulphonate (2.12 mL, 19.9 mmol) was 




















°C. The reaction mixture was stirred for a following 2 hrs at room temperature and then filtered 
and collected (1.84 g, 83 %).  
In some purifications, counter-ion exchange was performed here from [CF3SO3]- to [PF6]- 
through dissolving the product in a minimum amount of MeOH and adding 5 Eq. of NH4PF6.   
 
HRMS (ESI+): m/z 136.0627 [M – 2(OTf)]2+ (mcalc = 136.0631). 1H NMR (400.13 MHz, d6-
DMSO): d (ppm) 12.18 (s, 1H, NH), 8.82 (d, 3JHH = 7.5 Hz, 1H, H2), 8.39 (d, 3JHH = 7.5 Hz, 
1H, H3), 4.22 (s, 6H, H1). 13C{1H} NMR (100.57 MHz, d6-DMSO): 159.4 (C5), 151.1 (C4), 
146.7 (C2), 116.9 (C3), 47.7 (C1).  
Synthetic Procedure and Characterisation for Complex [19]  
L2 (162 mg, 0.33 mmol), Ag2O (250 mg, 1.09 mmol), [RuCl2(p-cymene)]2 (97.9 mg, 0.16 
mmol) and NMe4Cl (104 mg, 0.95 mmol) were dissolved in CH3CN (10 ml) and stirred at room 
temperature for 18 hrs in the absence of light. The resulting mixture was filtered through a 
short pad of Celite, concentrated in vacuo, and precipitated from Et2O (50 ml). The resulting 
solid was dissolved in the minimum amount of MeOH (ca. 2 ml) and filtered through and 
concentrated to 1 ml, and addition of Et2O (50 ml) afforded the product as a yellow solid (101.2 
mg, 49 %).  
Crystallisation quality crystals were achieved through a vapour diffusion method 



























HRMS (ESI+): m/z 541.0919 [M – OTf]+ (mcalc = 541.0944). 1H NMR (400.13 MHz, d6-
DMSO): d (ppm) 8.50 (d, 3JHH = 7.5 Hz, 4H, H2), 8.41 (d, 3JHH = 7.5 Hz, 4H, H3), 5.32 (d,  
J = 6.0 Hz, 2H, H9), 5.23 (d, J = 6.0 Hz, 2H, H8), 4.12 (s, 6H, H1), 2.38 (sept, 1H, H11), 2.22 
(s, 3H, H6), 1.03 (d, J = 6.0 Hz, 6H, H12). 
Synthetic Procedure and Characterisation of L3 and [20] 
Synthesis of ligand and ruthenium complex previously reported by Hartinger et al.117 Crystal 
structure report by Albrecht et al.118 
A mixture of imidazole (1.00 g, 15 mmol) and 2-bromopyridine (3.80 g, 24 mmol ) was 
suspended in a solution of degassed dimethyl sulfoxide (30 mL) and stirred for 5 min. 
Potassium phosphate (8.50 g, 40 mmol), l-proline 0.50g, 4 mmol), imidazole (1.00g , 15 mmol) 
and copper(I) iodide (0.40 g, 2 mmol) were added to the mixture and kept at 110 °C for 48 h. 
The crude product was filtered and washed with CH2Cl2 (3 × 10 ml), resulting in a brown 
filtrate which was collected. The organic phase was washed with water in an extraction funnel 
until the aqueous layer turned clear. Anhydrous sodium sulphate was used to dry the organic 
phase. The solvent was removed under reduced pressure and dried under reduced pressure to 
afford a brown solid.  
A mixture of the brown solid (0.50 g, 2.21 mmol) and iodomethane (0.55 ml, 8.83 mmol) in 
tetrahydrofuran (25 ml) was refluxed for 24 hrs to afford the product as an off white solid. The 
solvent was removed under reduced pressure, and the crude product was purified by trituration 
with acetone, affording the pure product (0.84 g, 2.9 mmol, 87%).  
 
1H NMR (400.13 MHz, d6-DMSO): d (ppm) 10.03 (s, 1H, H6), 8.65 (d, J = 4.4 Hz, 1H, H1), 
8.51 (t, J = 1.9 Hz, 1H, H8), 8.23 (t , J = 8.1 Hz, 1H, H3), 8.00 (d, J = 8.1 Hz, 1H, H4), 7.97 (t, 
J = 1.9 Hz, 1H, H7), 7.65 (overlapping dd, J = 8.1 Hz, J = 4.4 Hz, 1H, H2), 3.98 (s, 3H, H9). 
13C{1H} NMR (100.57 MHz, d6-DMSO): 149.1 (C1), 146.3 (C5), 140.6 (C3), 135.5 (C6), 














Synthetic Procedure and Characterisation for Complex [20] 
L3 (149 mg, 0.52 mmol) and silver hexafluorophosphate (52 mg, 0.21mmol) were added to 
dry CH3CN (6 ml) and MeOH (1 ml) in a dry Schlenk flask under N2. The flask was sealed, 
and the mixture was stirred in darkness at 55 °C for 3 h. Ag2O (144 mg , 0.62 mmol) was added 
and the mixture stirred in darkness for a further 24 hrs at 65 °C. A solution of [RuCl2(η6-p-
cymene)]2 (129 mg , 0.21 mmol) in dry 1,2-dichloroethane (3 ml) and dichloromethane (9 ml) 
was added and stirred at 70 °C in darkness overnight. The resultant suspension was filtered 
over Celite and the filtrate collected and reduced to dryness. The orange solid was then washed 
with toluene (3x10 ml) followed by pentane (10 ml). Purification was performed via column 
chromatography over silica (MeOH:CH2Cl2 1:25). The solvent of the collected fractions was 
evaporated, and the crude compound was dissolved in a minimal amount of MeOH and 
precipitated by addition of diethyl ether. The precipitate was dried in vacuo to afford the Ru(η6-
p-cymene) complex (45 mg, 0.097 mmol, 23%).  
 
HRMS (ESI+): m/z 461.1156 [M – PF6]+ (mcalc = 461.1172).1H NMR (400.13 MHz, d6-
DMSO): d (ppm) 9.33 (d, J = 5.7 Hz, 1H, H1), 8.41 (d, J = 1.8 Hz, 1H, H7), 8.34 (dd, J = 8.0 
Hz, 1H, H3), 8.15 (d, J = 8.0 Hz, 1H, H4), 7.79 (d, J = 1.8 Hz, 1H, H8), 7.50 (dd, J = 8.0 Hz, J 
= 5.7 Hz 1H, H2), 6.39 (d, J = 5.9 Hz, 1H, H13), 6.36 (d, J = 5.9 Hz, 1H, H12), 6.16 (d, J = 5.9 
Hz, 1H, H13), 5.73 (d, J = 5.9 Hz, 1H, H12), 4.10 (s, 3H, H9), 2.34 (sept, J = 6.8 Hz, 1H, H15), 
2.10 (s, 3H, H10), 0.84 (d, J = 6.8 Hz, 3H, H16), 0.83 (d, J = 6.8 Hz, 3H, H16). 13C{1H} NMR 
(100.57 MHz, d6-DMSO): 184.6 (C6), 156.3 (C1), 151.9 (C5), 142.1 (C3), 127.1 (C8), 123.6 
(C2), 116.9 (C7), 112.9 (C4), 99.5 (C14), 93.2 (C11), 91.3 (C13), 91.2 (C12), 87.0 (C13), 81.7 




















3.4.  Protein Production  
C2Am was kindly donated by the research group of Dr Gonçalo Bernardes, and used without 
further purification. 
A plasmid for expression of Ubq K63C was kindly donated by the group of Dr Gonçalo 
Bernardes.  
A plasmid for expression of Tev protease was kindly donated by the group of Prof. Jane Clarke. 
3.4.1. Buffers 
All buffers were prepared with ultrapure water, and filter-sterilised by passing through a 0.2 
µm cellulose acetate membrane (Sartorius Stedium Biotech). The pH of each buffer was 
checked by using a PHM210 pH-meter (Radiometer Analytical) following a two-point 
calibration with standard solutions (pH 4.005 and 10.012, Hannah Instruments). If necessary, 
the pH was adjusted using the appropriate set of acids and bases. The following buffers were 
used in protein production and incubations: 
- Sodium phosphate (NaPi) 
- Trisaminomethane (Tris) 
- Diethanolamine (DEA) 
- 2-morpholin-4-ylethanesulfonic acid (MES) 
- Sodium dodecyl sulfate (SDS) 
3.4.2. Reagents Used 
Ampicillin stock solutions were prepared at a concentration of 100 mg/mL in water, filter-
sterilised, aliquoted and stored at −20 °C.  
Kanamycin stock solutions were prepared to a concentration of 50 mg/mL in water, filter-
sterilised, aliquoted and stored at −20 °C. 
IPTG (isopropyl β-D-1-thiogalactopyranoside) stock solutions were prepared at a 
concentration of either 0.4 M or 1 M in water, filter-sterilised, aliquoted and stored at −20 °C.  
DTT (dithiothreitol) stock solutions were prepared at a concentration of either 0.1 M OR 1 M 
in water, filter-sterilised, aliquoted and stored at −20 °C. Stock solutions were used to reduce 
disulphide bonds at final concentrations ranging from 1–5 mM.  
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TCEP (tris(2-carboxyethyl)phosphine) stock solutions were prepared at a concentration of 
either 0.1 M OR 1 M in water, filter-sterilised, aliquoted and stored at −20 °C. Stock solutions 
were used to reduce disulphide bonds at final concentrations ranging from 1–5 mM. 
LB (lysogeny broth) medium was prepared by dissolving pre-prepared capsules which 
constitute 10 g of tryptone, 5 g of yeast extract and 10 g of NaCl in 1 L of water, and autoclaving 
for 20 min at 120 °C.  
2×TY (double yeast-tryptone) medium was prepared by dissolving pre-prepared capsules 
which constitute 6 g of tryptone, 10 g of yeast extract and 5 g of NaCl (added as capsules, MP 
Biomedicals) in 1 L of water, and autoclaving for 20 min at 120 °C.  
TB (terrific broth) modified medium was prepared by dissolving 12 g of tryptone, 24 g of 
yeast extract, 8 mL of glycerol, 2.31 g of K2HPO4, 12.54 g of K2HPO4, 3.75 g of aspartic acid 
and 0.5 g of MgSO4 and dissolving in 1 L of sterilised H2O. The media was autoclaved for 20 
min at 120 °C. 
3.4.3. SDS-Polyacrylamide Gel Electrophoresis 
SDS-PAGE analysis was performed using the NuPAGE mini-gel system with 4-12 % bis-tris 
gels. Samples were treated with SDS sample buffer with reducing agents. Gels were run in 
MES running buffer, and stained using 2.5 % (w/v) Coomassie blue in methanol-acetic acid.   
3.4.4. Protein Expression and Purification 
Method 1: Ubiquitin K63C Expression and Purification 
2.5 µL of ubiquitin plasmid #86589 (Addgene) was transformed into 50 µL of super-competent 
Bl21-Gold(DE3) cells by electroporation. Following this 1 mL of 2 x YT media was added to 
the cuvette which was incubated at 37 ºC for 45 minutes. 200 µL of cells was spread onto 
ampicillin plates and incubated at 37 ºC overnight to allow for colonies to grow. A single 
colony from this culture was transferred to 20 mL of LB media with ampicillin (100 µg/mL) 
and incubated overnight at 37 ºC and 180 rpm.  
This culture was used to inoculate 2 L of LB medium containing ampicillin (100 µg/mL) and 
cells were grown to OD600 of 0.6 (37 ºC, 180 rpm). Then expression of ubiquitin K63C was 
induced with 1mM IPTG and protein was expressed at 18 ºC overnight. Then, the cells were 
harvested by centrifugation at 4 ºC and 4000 g for 30 minutes. Supernatant was discarded and 
cells were resuspended in 50 mM NaPi buffer (pH 7.4) containing 250 mM of NaCl and, 25 
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mM imidazole and 1 mM TCEP and a protease inhibitor cocktail. Cells were lysed by 
sonication and cell fragments were collected and removed by centrifugation. The supernatant 
was purified by IMAC chromatography with a linear gradient of imidazole from 25 mM to 500 
mM. Samples containing ubiquitin K63C were combined and cleavage of the fusion partner 
maltose binding protein (MBP) was conducted by incubating a 1:20 molar ratio of TEV 
protease at 25 °C 24 hrs. Following cleavage, the protein was purified by IMAC 
chromatography to remove MBP and TEV protease. Further purification was often required 
(confirmed by SDS-gel electrophoreses) and this was performed through a Mono S cation 
exchange (high performance) in 20 mM MES buffer pH = 5.0 developed with a linear gradient 
of 0 – 200 mM KC1. The flow-through was pooled, concentrated and buffer exchange to 50 
mM NaPi buffer pH 8 was performed. The Beer-Lambert law was applied with an extinction 
coefficient of e280 = 1490 M–1 cm–1 to measure protein concentration.  
Method 2: Cytochrome b562 Expression and Purification 
1 - 2 µL of the required cytochrome plasmid was transformed into 50 µL of super-competent 
Bl21-Gold(DE3) cells by electroporation. Following this 1 mL of 2 x YT media was added to 
the cuvette which was incubated at 37 ºC for 45 minutes. 200 µL of cells was spread onto 
ampicillin resistant plates and incubated at 37 ºC overnight to allow for colonies to grow. A 
single colony from this culture was transferred to 20 mL of 2 x YT media with ampicillin (100 
µg/mL) and incubated overnight at 37 ºC and 180 rpm to give a pre-culture.  
10 mL of the pre-culture was inoculated into a 1 L culture 2 x YT media with ampicillin (100 
µg/mL) in a 2 L flask and this was shaken at 200 rpm at 37 ºC, conditions considered to be 
microaerobic. Innoculae were grown to an optical density at 600 nm of about 1 before induction 
with 0.1 mM IPTG, and the cultures continued into stationary phase before harvest by 
centrifugation at 18 h after induction. Then, the cells were harvested by centrifugation at 4 ºC 
and 4000 g for 30 minutes. Following cell growth, cytochrome b562 is found in both the 
periplasmic fractions and the culture medium, however, for practical reasons only cytochrome 
b562 proteins in the periplasm was harvested, therefore supernatant was discarded.  
Protein was harvested from E. coli cells by fractionation of the pelleted cells into spheroplasts 
and soluble periplasm contents using the lysozyme/EDTA method. The apo- and holo-
cytochromes in these fractions were separated on a Q-Sepharose anion exchanger in DEA 
buffer pH = 8.5 developed with a linear gradient of 0 – 200 mM KC1. Further purification was 
often required (confirmed by SDS-gel electrophoreses) and this was performed on a Superdex 
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S75 gel filtration column in 50 mM NaPi buffer with 1 mM TCEP. The Beer-Lambert law was 
applied with an extinction coefficient of e280 = 2980 M–1cm–1  o measure protein concentration.  
Method 3: Tev Protease Expressions and Purification 
1 - 2 µL of the plasmid pMHTDelta238 (pBR322 origin with T5 promoter and Kanamycin 
resistance) was transformed into 50 µL of super-competent Bl21-Gold(DE3) cells by 
electroporation. Following this 1 mL of LB media was added to the cuvette which was 
incubated at 37 ºC for 45 minutes. 100 µL of cells was spread onto 2 x TY kanamycin resistant 
plates and incubated at 37 ºC overnight to allow for colonies to grow. 10 mL of pre-culture 
with 10 µL kanamycin stock was pre-warmed to 37 ºC and inoculated with a generous scrape 
from the overnight colony and incubated at 37 ºC for 4 hrs. 1 L of media with 1 mL of 
kanamycin stock was pre-warmed to 37 ºC and inoculated with 10 mL of pre-culture, and this 
was shaken (200 rpm at 37 ºC). Innoculae were grown to an optical density at 600 nm of about 
0.6 before induction with 0.1 mM IPTG and protein expression was carried out for 3 hr (200 
rpm at 37 ºC). Then, the cells were harvested by centrifugation at 8 ºC and 5000 rpm for 15 
mins. The cell pellet was re-suspended in 20 mM Tris buffer (pH 7.5, NaCl 125 mM) and 
sonicated on ice (15 s on, 45 s off, 5 min) and centrifuged at 8 ºC and 18,000 rpm for 45 mins. 
The supernatant was purified by IMAC chromatography with a linear gradient of imidazole 
from 20 mM to 500 mM. This purification process also cleaved the maltose binding protein 
from the His7-Tev product. The protein solution and 5 mM EDTA was then dialysed with 
sterilised H2O to remove imidazole and then concentrated. The Beer-Lambert law was applied 
with an extinction coefficient of e280 = 32,400 M–1 cm–1 to measure protein concentration. 
Method 4: Preparation of purchased cysteine mutants 
Papain (102 mg crude powder) was dissolved in 50 mM NaPi buffer (7 mL) by vortexing for 
several minutes. The solution mixture was filtered through a 0.22 µM filter cartridge and flow 
through collected. DTT (6.1 mg, 0.04 mmol) was added and the mixture incubated at 37 °C for 
30 min. The resulting reduced protein solution (1 mL) was filtered through a de-salting column 
pre-equilibrated with phosphate buffer (2 mL, 7 kDa MWCO, GE Healthcare). The sample was 
eluted with 1.5 mL phosphate buffer, aliquoted and flash frozen. The Beer-Lambert law was 
applied with an extinction coefficient of e = 52,770 M–1 cm–1 to measure protein concentration. 
An identical procedure was used to prepare the human serum albumin stock solutions. The 
Beer-Lambert law was applied with an extinction coefficient of e280 = 34,445 M–1 cm–1 to 
measure protein concentration. 
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Mw – 8567 Da 
Cytochrome b562  
ADLEDNMETLNDNLKVIEKADNAAQVKDALTKMRAAALDAQKATPPKLEDKSPDS
PEMKDFRHGFDILVGQIDDALKLANEGKVKEAQAAAEQLKTTRNAYHQKYR 
WT Mw – 11780 Da 
R98C Mw – 11727 Da 
L10C H102M Mw – 11764 Da 
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3.5. Incubation Protocols 
3.5.1. Incubations with Small Molecules 
Deuterated Phosphate Buffer 
10 mM deuterated phosphate buffer solution was prepared using potassium dihydrogen 
orthophosphate in D2O and adjusted to different pD values with 1N NaOD. All pD values are 
corrected pH meter readings. Covington et al. stated that “the operational pH of buffer solutions 
in heavy water at 25 °C, measured with the glass electrode can be converted into a pD value 
by adding 0.41 (molar scale)”.119 
pKa Measurements 
The different buffers in a pD range of 4.7 to 11.2 were incubated with Complexes [1] – [4], 
[10] and [11] for 2 hours at 298 K and 1H and 19F{1H} NMR spectra recorded.  
Biomolecule interactions 
The incubations between ruthenium complexes and amino acids were performed in either a 1.5 
or 3 molar excess of amino acid / glutathione. Stock complex of each ruthenium complex were 
prepared in DMF and diluted with a solution of amino acid in D2O phosphate buffer pD = 7.2, 
to a final concentration of DMF 1 % v/v. 19F{1H} NMR spectra were recorded at 2, 4, 8 and 
24 hours, with mass spectra recorded at 8 and 24 hours.  
3.5.2. Incubations with Proteins  
To an eppendorf tube with NaPi (50 mM, pH 8.0) and DMF (10% of total volume), an aliquot 
of a stock solution of protein (final concentration either 10 μM, 50 μM or 200 μM) was added. 
Afterwards, a solution of the ruthenium complex (1 to 20 eq.) in DMF was added and the 
resulting mixture was vortexed for 10 seconds. The reaction was mixed for up to 24 h, at 37 
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°C. At desired time points, an aliquot was taken and diluted to a final concentration of 5 μM 
with water and analysed by LC-MS.  
For modifications with N-ethyl maleimide, from a stock 10 mM solution in DMF, 1 Eq. of 
reactant was added and the mixture vortexed for 10 secs, followed by incubation for 30 mins 
at 37 °C. Modification was confirmed by LC-MS.  
3.6. Catalytic Experiments 
Sample Preparation 
Ruthenium-protein hybrids prepared and tested for catalytic activity in Chapter 6 were purified 
by anion exchange chromatography. 
Upon modification, identified by LC-MS, protein – ruthenium hybrids were purified by anion 
exchange chromatography. The incubation was buffer exchanged into DEA (20 mM, pH 8.5), 
thus removing some of the excess ruthenium complex, and concentrated to the required volume 
for anion exchange. The anion exchange was performed with a linear gradient of 0 – 200 mM 
KCl. and protein components analysed by LC-MS.  
3.6.1. Transfer Hydrogenation Assay  
Ruthenium Dimers and Complexes 
Ruthenium compounds were dissolved in DMF to yield 5 mM stock solutions. These were 
diluted 1:5 with water fresh before each experiment. 80 µL of water, 10 µL of ruthenium 
solution, 10 µL of buffer (500 mM sodium phosphate, 1 M formate which upon 1 in 10 dilution 
gave a pH 8.0) and 1 µL substrate stock solution (100 mM in DMSO) were pipetted into a 
clear-bottom 96 well plate (final concentrations 100 µM ruthenium compound, 100 mM 
formate, 1 mM substrate). The wells were sealed with tape and the fluorescence measured over 
16 h. 
Protein-Ruthenium Hybrids 
90 µL of each protein sample (in water) of known concentration was pipetted into a clear-
bottom 96 well plate. 10 µL of buffer (500 mM sodium phosphate, 1 M formate which upon 1 
in 10 dilution gave a pH 8.0) and 1 µL of substrate stock solution (100 mM in DMSO) was 
added to each well (final concentrations 100 mM formate, 1 mM substrate). The wells were 
sealed with tape and the fluorescence was measured over 16 h. 
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3.6.2. Olefin Metathesis Assay 
Grubbs 2nd Generation Catalyst 
A stock solution of Grubbs 2nd generation catalyst was dissolved in DCM to yield 5 mM stock 
solutions. These were diluted 1:5 with water fresh before each experiment. 80 µL of water, 10 
µL of ruthenium solution, 10 µL of buffer (500 mM sodium phosphate, which upon 1 in 10 
dilution gave a pH 7.0) and 1 µL substrate stock solution (100 mM in DMSO) were pipetted 
into a clear-bottom 96 well plate (final concentrations Grubbs 2nd generation catalyst, 100 mM 
formate, 1 mM substrate). The metathesis substrate was dissolved in DMSO immediately 
before use and stored as a solid at -20 °C. The wells were sealed with tape and the fluorescence 
measured over 16 h. 
Protein-Ruthenium Hybrids 
90 µL of each protein sample (in water) of known concentration was pipetted into a clear-
bottom 96 well plate. 10 µL of buffer (500 mM sodium phosphate, which upon 1 in 10 dilution 
gave a pH 7.0) and 1 µL substrate stock solution (100 mM in DMSO) were pipetted into a 
clear-bottom 96 well plate (final concentrations Grubbs 2nd generation catalyst, 100 mM 
formate, 1 mM substrate). The metathesis substrate was dissolved in DMSO immediately 
before use and stored as a solid at -20 °C. The wells were sealed with tape and the fluorescence 




4. A Fluorinated Probe for Quantifying 
Ruthenium – Amino Acid Coordination 
4.1.  Introduction  
This chapter outlines the development of a quantitative method to characterise the coordination 
of Ru(II) arene complexes to amino acids and simple peptides. As discussed, the ability to 
quantify the coordination of Ru(II) arene complexes to preferred biological binding partners 
could further understanding in two key areas of research: (i) ruthenium artificial 
metalloenzymes and (ii) ruthenium metallo-pharmaceuticals.  
Ru(II) arene complexes have been extensively studied due to their potential as anti-cancer and 
anti-microbial complexes.27,120 Currently, the major limitation to the use of these complexes as 
pharmaceuticals is understanding their speciation within a complex biological environment. 
Ru(II) arene complexes have labile ligands which can exchange with a number of different 
biological nucleophiles, and identifying these biological nucleophiles is fundamental to 
understanding their cellular response. Proteins are known targets for a number of Ru(II) arene 
anti-cancer complexes,30,31 they contain a wide variety of possible metal binding sites that can 
form strong coordination bonds to ruthenium. By inhibiting a specific protein’s function via 
metal coordination, it is possible to induce a cascade of cellular events that result in cell 
apoptosis. 
Through incorporating fluorinated ligands to ruthenium in simple complexes, the aim was to 
enable the use of 19F NMR spectroscopy as a direct reporter of the solution-based behaviour of 
the metal coordination environment. Throughout this chapter, the quantitative nature of using 
19F NMR spectroscopy to monitor the speciation of Ru(II) arene complexes will be 
emphasised; individual species can be identified and quantified in complex biological 
environments via this method. 
Understanding how to localise and quantify the coordination of Ru(II) arene complexes to a 
specific protein site is important in the development of datively coordinated ArMs. As 
discussed, one future goal of this research, is to develop a ruthenium ArM where the ruthenium 
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cofactor is localised to a specific amino acid through a dative coordination bond. This requires 
analytical methods to confirm that coordination to the desired side chain residue has occurred, 
and that there is no unbound complex.  
4.1.1. Methods of Probing Ruthenium-Protein Coordination 
As discussed in Chapter 1, previous attempts to understand the speciation of Ru(II) arene 
complexes with proteins have focussed on using mass spectrometry and X-ray crystallographic 
methods. Although these methods are useful, they have limitations in that neither are 
quantitative, and neither are directly relevant to the context of in situ biological activity, since 
crystallography probes the sample in the solid phase, and mass spectrometry is a gas phase 
method.  
NMR spectroscopy is a quantitative, sensitive, direct reporter of behaviour in solution. 
However, using 1-Dimensional 1H NMR to follow the speciation of ruthenium complexes has 
proved testing for anything other than the simplest examples. The large number of observable 
proton signals together with their chemical similarity and hence proximity in the spectra 
severely restricts the usefulness of 1H NMR in this context. Instead 15N and 13C are commonly 
used to examine the structure and dynamics of proteins in vivo.121  
4.1.2. Fluorine NMR 
19F NMR spectroscopy can be used as a sensitive probe of specific metabolic signals when a 
fluorine atom is incorporated into a biomolecule as a reporter.122,123 Using 19F NMR 
spectroscopy to probe interactions of biological molecules is effective because: 19F is nearly 
totally absent from biology, it is small in size (van der Waals radius of 1.47 Å, hydrogen = 1.20 
Å), it is monovalent (same as hydrogen) and it has favourable NMR spectroscopic 
characteristics (spin 1/2, 100 % natural abundance, high gyromagnetic ratio and strong dipolar 
coupling allowing for 19F-19F and 1H-19F nuclear Overhauser effects to be measured).124 The 
work of Dalvit et al. using ligand-based fluorine NMR screening methods to rapidly identify 
biologically active fluorinated organic compounds has demonstrated the usefulness of being 
able to detect a 19F NMR signal from a small molecule reporter in complex environments.125,126   
4.2. Prior Work in the Group 
Building upon recent research in the group exploring the reactivity of Ru(II) arene bipyridine 
complexes, Dr Michael O’Neill synthesised complex [9], Figure 4.1, and probed its reactivity 
with amino acids using 19F NMR spectroscopy.  
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Using the Ru(II) arene fragment as a starting point, there are three further coordination sites, 
two of which were taken up by the bipyridine ligands in this work. Bipyridine ligands are 
known to form good coordination bonds to ruthenium centres that are stable to dissociation 
upon coordination of the ruthenium centre to a protein. The final ligand was chosen as a 
chloride ligand, which acts as a labile ligand that can undergo ligand exchange. Furthermore, 
ruthenium bipyridine complexes are relatively simple to synthesise and purify via a salt 
metathesis reaction. There is an extensive literature, pioneered by Prof. Harry Gray, exploring 
electron transfer processes in proteins, using ruthenium bipyridine complexes.100 Using a 
screening approach where all amino acids with nucleophilic side chain residues were incubated 
with complex [9], it was identified that different ruthenium-amino acid adducts, gave unique 
19F NMR spectra, with different chemical shifts and peak morphologies.127  
Figure 4.1: Structure of complex [9]. [PF6] counter ion removed for clarity. 
The hydrolysis of the chloride ligand in these Ru(II) arene complexes plays an important role 
in their reactivity, however, monitoring this reaction in solution in a quantitative manner is 
challenging. In an aqueous mixture of complex [9] with a Lewis basic amino acid, the following 
complexes are present in solution [9]-Cl, [9]-H2O, [9]-OH and [9]-Amino acid, Scheme 4.1. 
19F chemical shift values for the chloro, aquo and hydroxide species as well as a number of 
amino acid bound species were reported. Through a number of competition studies, it was 
found that the cysteine thiol and the carboxylate ligand formed the most stable complexes when 









Scheme 4.1: The equilibrium that exists upon exposure of [9] to a nucleophilic amino acid in 
water.  
4.3.  Results and Discussion 
The work of previous group members identified that a 19F NMR spectroscopic method could 
give an alternative solution-based approach to understanding the behaviour of biologically 
active Ru(II) arene complexes. To build upon these findings, a number of key areas were 
identified to research: 
1. Can the stability and speciation of Ru(II) arene complexes be quantified in phosphate 
buffer using 19F NMR spectroscopy? 
2. Can the stability and sensitivity of the Ru(II) arene fluorinated probe be improved by 
changing the position of fluorination, fluorine substituent and arene ligand? 
3. How does changing the arene ligand effect the concentration of different ruthenium-
amino acid adducts in competition experiments? 
4. Can quantitative parameters, e.g. rates of exchange of Ru(II) arene complexes with 
biomolecules be measured using 19F NMR spectroscopy? 
4.3.1. Synthesis of Ru(II) Arene Bipyridine Complexes 
A suite of novel Ru(II) arene bipyridine complexes have been synthesised and characterised 
using a variety of techniques. In the following section, all Ru(II) arene bipyridine complexes 

































summarised. For complete synthetic protocols and characterisation of these Ru(II) arene 
bipyridine complexes, refer to Section 3.3.3.  
Synthesis of Functionalised Bipyridines 
A number of literature preparations are available for the preparation of functionalised 
bipyridines,128 however, after achieving relatively poor yields using copper catalysed, Ullman-
type coupling reactions, the fluorinated bipyridines were initially synthesised using Method 
1.129 Ultimately this method continued to generate poor yields of the products so an alternative 
method, Method 2, was identified, based on the work of Lee et al.112 Both methods are outlined 
in Section 3.3.1, and both used palladium catalysed homocoupling of fluorinated 
bromopyridines, Scheme 4.2, however the solvent systems and additives differed significantly.  
Scheme 4.2: Palladium catalysed homocoupling of fluorinated bromopyridines, along with the 
favoured labelling system used for the bipyridine ligands.  
The fluorinated bipyridines 3,3’-difluorobipyridine (3,3’-FBipy) – B, 5,5’-difluorobipyridine 
(5,5’-FBipy) – C, 5,5’-di(trifluoromethyl) bipyridine, (5,5’-TFMBipy) – D, 6,6’-
difluorobipyridine (6,6’-FBipy)– E, were synthesised and characterised by NMR spectroscopy, 
ESI-MS, X-ray crystallography and, where possible, elemental analysis.  
Synthesis of the Ru(II) Arene Dimers 
At the beginning of this research project, there was a cost benefit to synthesising the ruthenium 
dimers using hydrated RuCl3 with the appropriate hexacyclic diene to give a chloro-bridged 
arene dimer.113 Hexacyclic dienes were used to form the dimers, [Ru(h6-benzene)Cl2]2 – I, 
[Ru(h6-tolyl)Cl2]2 – II and [Ru(h6- p-cymene)Cl2]2 - III. [Ru(h6-hexamethylbenzene)Cl2]2 – 
IV, was synthesised through an arene exchange reaction. As the cost of RuCl3 increased, 
purchasing dimers I and III became logical. 
Synthesis of Ru(II) Arene Bipyridine Complexes 
Synthesis of a suite of Ru(II) arene bipyridine piano stool complexes was performed by 
reacting 1 Eq. of I – IV with 2 Eq. of A-E. Upon addition of [NH4][PF6] the complexes [1] – 
[17] were isolated as their [PF6] salts, Scheme 4.3, Table 4.1. Crude products were purified 
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via a number of crystallisation techniques, and characterised by multinuclear NMR 
spectroscopy, ESI-MS, X-ray crystallography and, where possible, elemental analysis, see 
Section 3.3.3. The crystal structures of all complexes [1] – [17] are shown in Figure 4.2, with 
key bond lengths and angles summarised in Table 4.2, and complete crystallographic 
parameters given in Appendix A. 


















1. 2Eq. A-E, MeOH
2. [NH4][PF6]
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Figure 4.2: Molecular structures of the complexes [1] – [17] . Anionic salt and hydrogen atoms 
removed for clarity and thermal ellipsoids set to 30 %. Complex [14], one CF3 group is 
rotationally disordered, therefore modelled as three separate components with a common 
isotropic displacement parameter.  
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Table 4.1: Summary of the starting materials and how they combine to form complexes [1] – 
[17].  
 Benzene – I Tolyl – II p-Cymene – III 
Hexamethyl-
benzene – IV 
Bipy – A [1] [2] [3] [4] 
3,3’-FBipy – B [5] [6] [7] [8] 
5,5’-FBipy – C [9] [10] [11] [12] 
5,5’-TFMBipy – D [13] [14] [15] [16] 






Table 4.2: Key bond lengths for complexes [1] – [17].  
 Ru-Cl / Å Ru-N / Å Ru-Centroid / Å 
[1] 2.3671(9) 2.071(2) 1.674 
[2] 2.3967(9) 2.079(3) 1.691 
[3] 2.3988(10) 2.085(4) 1.680 
[4] 2.3990(14) 2.091(4) 1.707 
[5] 2.3970(20) 2.071(7) 1.683 
[6] 2.3680(20) 2.071(6) 1.697 
[7] 2.4066(11) 2.078(3) 1.699 
[8] 2.3972(12) 2.083(5) 1.708 
[9] 2.3754(7) 2.083(2) 1.681 
[10] 2.3772(12) 2.086(4) 1.688 
[11] 2.3898(7) 2.090(2) 1.687 
[12] 2.3809(6) 2.105(2) 1.703 
[13] 2.3910(20) 2.079(1) 1.684 
[14] 2.3892(8) 2.089(3) 1.692 
[15] 2.3908(12) 2.091(3) 1.687 
[16] 2.3850(7) 2.085(17) 1.723 
[17] 2.3855(13) 2.122(4) 1.680 
Analysis of Key Bond Length and Angles 
In complexes [1]-[17] the key ligands that have been functionalised are the bipyridine and the 
arene. The arene ligand is capable of donating electron density to the metal through s and p 
type interactions. The bipyridine ligand is a s-donor ligand through the N sp2 lone pair directed 
away from the ring skeleton. Both ligands are also capable of accepting electron density via p-
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backdonation. The electron-donating properties of the different arene ligands vary; on moving 
from benzene ® toluene ® p-cymene ® hexamethylbenzene the electron donation to the 
metal would be expected to become more significant because of the increased inductive effect 
of the organic substituents on the aromatic ring.  
Analysis of the Ru-N, Ru-Cl and Ru-arene bond lengths in complexes [1]-[4], shows a 
general trend (in some cases statistically significant) that these bond lengths increase moving 
from the benzene complex [1] to the hexamethylbenzene complex [4]. In particular, the average 
Ru-N bond length increases from 2.071(2) Å for the benzene complex [1] to 2.091(4) Å for 
the hexamethylbenzene complex [4]. Moving from complex [1] to complex [4] there is 
increased arene electron donation, therefore less electron donation is required from the 
bipyridine, thus weakening the sigma bonding component and increasing measured bond 
lengths. This general trend in Ru-N bond lengths is mirrored when changing the bipyridine 
ligand to 5,5-difluorobipyridine, as shown by increase in Ru-N bond length for complexes [9] 
to [12], which between complex [9] and [12] is statistically significant. The Ru-N bond lengths 
do not follow the same trend for complexes with the 5,5-di(trifluoromethyl)bipyridine ligand. 
In this series of complexes the p-cymene complex [15], has a longer Ru-N bond length 
(2.091(3) Å) than the hexamethylbenzene complex [16] (2.085(17)), however this is not a large 
enough difference considering the error to be determined statistically significant.     
Functionalising the bipyridine ligand with increasingly electron withdrawing substituents 
moving from fluorine to trifluoromethyl leads to slight variations in Ru-Cl bond lengths. In 
particular, for the benzene complexes, there is a significant, yet slight, increase in Ru-Cl bond 
length from 2.3671(9) Å for complex [1] to 2.3754(7) Å for complex [9] to 2.3910(20) Å for 
complex [13]. However, these trends in Ru-Cl bond lengths as affected by bipyridine 
functionalisation, are not reliably corroborated when the arene ligands are functionalised. 
Additionally, Ru-N and Ru-arene bond lengths do not always follow a predictable trend upon 
variation of the bipyridine ligands. Although complete structural analysis has been performed 
for these complexes the challenges in correlating structural information to solution-based 
behaviour have been highlighted throughout this research. There is precedence in the literature 
for bond length variations correlating with lability, however, from extensive experience of the 
solution-based behaviour of this family of complexes such comparisons cannot be relied upon 
absolutely. Other factors, such as sterics, mechanistic features of ligand exchange and subtle 
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difference between solid- and solution-state structures, will no doubt also affect the lability of 
ligands. 
4.3.2.  Quantitative Analysis of Speciation in Aqueous Phosphate Buffer 
Before exposing these fluorinated ruthenium complexes to amino acids, the speciation in 
deuterated aqueous phosphate buffer was explored. With a number of titratable groups 
involved in these systems, examining the ligand exchange behaviour of these complexes 
around conditions of pH relevant to biological conditions requires strong buffering. Phosphate 
buffer was chosen for its relevance to biological conditions. However, it was identified that at 
high phosphate concentration, and in the absence of other possible ligands, phosphate anions 
can compete as ligands to the ruthenium. Phosphate has been shown to be a poor ligand for 
Ru(II) arene complexes by Sadler et al. who identified that the structurally related [Ru(h6-
arene)(en)Cl]+ binds to the phosphate in the nucleobase 5-GMP before being displaced by the 
guanine N7 over time.130  
The 19F NMR spectrum of the 5,5’-FBipy complex [10] in 10 mM phosphate buffer, Figure 
4.3 (Left), identified three different fluorine environments, which were attributed to three 
different molecular species, [10]-OD2, [10]-Cl and [10]-Phosphate. The presence of [10]-
Phosphate, was confirmed by ESI-MS, Figure 4.3 (Right), which showed higher ion counts 
for this species at a higher phosphate concentration.  
Figure 4.3: (Left): 19F{1H} NMR spectra of complex [10] incubated in D2O and buffered D2O 
of different phosphate concentration (2 mM Ru, pD = 7.2 (when buffered), 2 hr, 310 K). 
(Right): ESI-MS spectra recorded of the solution mixture when complex [10] is incubated in 
D2O and buffered D2O, expected masses quoted in Appendix B, Table B.1. 
Identifying and quantifying the presence of these three different complexes over time was 
possible using 19F NMR spectroscopy. Figure 4.4 plots the integration of the chloride, water 
and phosphate peaks of complex [9] in 10 mM phosphate buffer. Upon placing complex [9]-
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Cl in phosphate buffer there is a rapid formation of the aquo-bound species [9]-OD2, which is 
a more labile ligand as there is a weaker ionic contribution to bonding in the neutral D2O ligand. 
[9]-OD2 will undergo ligand exchange to form a phosphate bound species, [9]-Phos. Being able 
to accurately quantify this solution behaviour provided a foundation upon which more complex 
biological environments could be understood.  
The hydrolysis of [9]-Cl is consistent with a 1st order process where k = 0.000836 ± 0.000005 
s-1. This is presumably following pseudo 1st order kinetics, where the water is in large excess. 
After approximately 4500 s, the reaction reaches an apparent equilibrium where the 
concentration of the three species remains relatively constant.  
Figure 4.4: Plot of the integration values of the chloride, aquo and phosphate peaks of complex 
[9] in 10 mM phosphate buffer (2 mM Ru, pD = 7.2, 1 hr, 310 K). Blue trace - [9]-Cl, black 
trace - [9]- D2O, red trace - [9]-Phos.  
Through observing the reactions of [9]-[12] in phosphate buffer, it is clear that the benzene and 
toluene complexes are not indefinitely stable. If left in phosphate buffer, the solution will 
change colour from a pale yellow to blue which intensifies over time, Figure 4.5. It has not 
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been possible to isolate and identify any new species by NMR, mass spectrometry or X-ray 
crystallography, however it is possible that some form of ruthenium phosphate dimers or 
clusters are forming, which could involve oxidation of the metal in the complex to Ru(III).131–
133   
Figure 4.5: Pictures of complex [9] incubated in 10mM D2O phosphate buffer after 0 hrs and 
after 6 hrs at 310 K.  
pH Dependency of the Ruthenium Aquo Complex 
In deuterated aqueous solution, an equilibrium exists between the Ru-[OD2] and Ru-[OD] 
species, Scheme 4.4.  
Scheme 4.4: Equilibrium of complex [9] with a deuterated aquo ligand and deuteroxide ligand. 
These species are in rapid exchange on an NMR timescale, thus yielding a single peak which 
is an average of the exchanging species, [Ru-OD2] and [Ru-OD]. The chemical shift of the 
fluorine atoms (red circles in Scheme 4.4) for the aquo/hydroxide species are pH dependant, 
Figure 4.6 (b), therefore a pKa for the deprotonation of the bound aquo ligand can be measured, 
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The same pKa can also be measured, using 1H NMR, for the complexes where the arene ligand 
is benzene, as it is possible to identify the peaks which correspond to the six arene protons 
(green circles in Scheme 4.4) for the aquo/hydroxide species.  
The effect on the pKa of changing the arene ligand in the 5,5’-FBipy complexes [9]-[12], and 
changing the bipyridine ligand in complexes [1], [9] and [13] has been measured, Figure 4.6 
(b). The pKa values presented are measured from the pD values without a correction factor 
applied.  
Figure 4.6: (a): pH dependence of the chemical shifts of the aquo coordinated ruthenium 
species and determination of the pKa in the following complexes [9] - Red circles; [10] - Blue 
squares; [11] - Pink triangles; [12] - black circles; [13] - Green squares; [1] - Orange triangles. 
19F chemical shifts of the 5,5’-difluorobipyridyl fluorine’s or 1H chemical shift of the 
coordinated benzene ligand were plotted against pD. (b): The pKa values of a series of 
ruthenium complexes measured using 19F{1H} NMR and 1H NMR. (c): A series of 19F{1H} 
decoupled spectra of complex [1] in D2O phosphate buffer at differing pD values. 
The observed differences in pKa are entirely consistent with the changes in electron density at 
the metal due to the subtleties of the electron withdrawing effects of fluorines on the bipyridine 
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ligand and the electron donating effects of the different arenes.134 In other words, the trend 
observed going from complex [9] – [12] shows that the increasing electron donating capability 
of the h6-arene ligand to the ruthenium centre leads to a higher measured pKa value; an 
increased electron density on the metal lowers its Lewis acidity. The electron withdrawing 
capabilities of the trifluoromethyl group on complex [13] significantly increases the Lewis 
acidity, reflected in the lowest pKa (6.88) measured for any of these complexes. For complex 
[9], the pKa has been measured using both 1H and 19F NMR spectroscopy, and the values are 
consistent, 7.03 and 7.07 respectively. These data have also identified that these species have 
pKa values close to the working pD of the reactions. 
Comparing the analytical techniques for monitoring the speciation of Ru(II) arene complexes, 
NMR can be used to measure both kinetic parameters and dissociation constants, but this is not 
possible for traditional mass spectrometry, X-ray crystallography and UV spectroscopy 
methods. Furthermore, comparing 1H and 19F NMR spectroscopy, when many species are 
present in solution the 1H NMR spectra become very complex, but when fluorine atoms are 
present, the spectra are dramatically simplified. For the fluorinated complexes, if the aquo 
species is present at any time in solution, then a direct read out of the apparent pH can be 
measured, which is particularly useful.   
4.3.3.  Amino Acid Coordination 
Reaction of these fluorinated ruthenium complexes with all naturally occurring amino acids 
gave a series of characteristic 19F NMR signals for each Ru-amino acid adduct. Throughout 
this study, four amino acids were selected which had the most reactive side chain ligands. All 
four amino acids have been protected at the amino-group, and the carboxylic acid group has 
been esterified, Figure 4.7. This is to ensure that there is a focus on side chain – metal 
coordination, to mimic reactivity with a polypeptide, where the amino and carboxylate groups 
form peptide bonds.  
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Figure 4.7: Structures of four protected amino acids, with their nucleophilic side chains 
highlighted. 
Identification of Amino Acid Peaks 
As shown in Section 4.3.2, the chemical shifts for all chloro, aquo and phosphate bound species 
were identified for all ruthenium complexes , therefore, through incubating the complexes with 
amino acids and monitoring the 19F NMR spectra over time it was possible to identify any new 
peaks corresponding to amino acid coordination. The presence of any Ru-amino acid adducts 
were confirmed by ESI-MS, Appendix B, Table B.2.  
Effect of Position of Fluorination – 3,3’ vs 5,5’ 
The fluorine atoms on the bipyridyl ring are enantiotopic when an achiral ligand is coordinated 
to the metal e.g. Cl or H2O, and once a chiral amino acid ligand is coordinated they become 
diastereotopic and hence magnetically inequivalent.135 Therefore, despite the symmetry of the 
starting molecule, the amino acid coordinated adducts of these complexes do not always give 
rise to single resonances in the proton decoupled 19F NMR spectra. This is clearly observed 
when exploring the coordination of Cys to the 5,5’-difluorinated complexes [9] – [12]. 19F 
NMR spectra show that, a Cys coordinated species, gives rise to two peaks, which are very 

























N-benzoyl-L-histidine-methyl ester - His N-acetyl-L-cysteine-methyl ester - Cys
N-benzylozycarbonyl-glutamic acid-methyl ester - Glu N-acetyl-L-methionine-methyl ester - Met
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Figure 4.8: (Left): 19F{1H} NMR spectra of complexes [9], [10], [11] and [12] incubated with 
N-acetyl cysteine methyl ester (2 mM Ru, 3 eq. amino acid, 12 hr, 310 K). The signals 
highlighted in the grey box are assigned to Ru-[Amino Acid] adducts (Right): Time course 
19F{1H} NMR spectra of complex [11] with N-acetyl cysteine methyl ester (2 mM Ru, 3 eq. 
amino acid, 310 K). 
Looking in more detail at the coordination of Cys to complex [11] over time, Figure 4.8 
(Right), the peaks for each fluorine are in fact doublets. That these signals originate from the 
same species is clearly evidenced by the 8JF-F coupling of 1.49 Hz observed in the high 
resolution 19F NMR spectra and a clear cross-peak in a proton decoupled 19F-19F COSY 
experiment, Figure 4.9. 
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Figure 4.9: (Insert): Structure of [11]-Cys with the magnetically inequivalent fluorine atoms 
highlighted. (Spectrum) 19F{1H} - 19F{1H} COSY spectrum from the incubation of complex 
[11] with N-acetyl cysteine methyl ester (2 mM Ru, 3 eq. amino acid, 12 hr, 310 K).  
The origin of these Ru-Cys peaks have been explored in great detail. Variable temperature 
analyses are consistent with there being free rotation around the Ru-S bond at room 
temperature, Appendix C, Figure C.1. Complex [9] has also been incubated with the achiral 
substrates glycine, cysteamine, 3-mercaptopropianoate, which all give rise to a singlet Ru-
adduct peak, indicating that the chiral environment is crucial to peak complexity, Appendix 
C, Figure C.2.  
In comparison, when the 3,3’-difluorinated derivative, complex [7], is incubated with Cys, only 
one singlet peak is attributed to a Ru-Cys adduct, [7]-Cys, Figure 4.10. Although, the fluorine 
atoms are diastereotopic, this does not manifest itself in the spectra, as the fluorine atoms 
resonate at the same frequency and they do not couple. A combination of the proximity of the 
fluorine atoms in space and F-F electronic repulsion forces the fluorine atoms as far apart as 
possible, slightly twisting the bipyridine ligand, which is observed in the crystal structures of 
3,3’-FBipy complexes [5] – [8]. The metal-ligand coordination sphere is flexible enough in 
solution for there to be fluxionality between the two non-planar pyridyl rings such that the two 
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fluorine environments appear equivalent and we observe only one 19F NMR signal, the achiral 
average. 
Figure 4.10: (Left): Structure of complex [7]-Cys. (Right): Time course 19F{1H} NMR 
spectra of complex [7] with N-acetyl cysteine methyl ester (2 mM Ru, 1 eq. amino acid, 310 
K, 0 hr = bottom spectrum, 4 hr = middle spectrum and 8 hr = top spectrum). Green squares 
[7]-D2O, red squares [7]-Cys, blue squares [7]-Cl, purple squares [7]-Phos.  
The peaks observed when the 5,5’- and 3,3’- FBipy derivatives are incubated with the protected 
amino acids, Cys, Glu, His and Met are presented in Figure 4.11. For the 5,5’-FBipy, when a 
chiral amino acid coordinates to the metal centre, two peaks are observed, one for each fluorine 
atom. These fluorine atoms are capable of long-range coupling, therefore these peaks can 
appear as doublets, e.g. for Cys and His. There is extra complexity for histidine coordination 
as there are two sets of doublets, with a different integration ratio, which is interpreted as due 
to coordination at either the d-N or the e-N on the imidazole ring.  
The subtleties in peak width, coupling constants and peak separation, particularly with 5,5’ 
fluorinated complexes, give each different Ru-amino acid a unique fingerprint which can help 
in identifying coordination partners for Ru(II) arene complexes. Furthermore, these unique 
fingerprints could be invaluable for identifying coordination environments in the context of 
more complex peptide and protein environments. 
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Figure 4.11: Comparison of 19F NMR peaks observed for the amino acid adducts of complex 
[7] and complex [11]. 
Effect of Fluorinated Substituent Group F vs CF3 
The purpose of changing the substituent group from a fluorine to a trifluoromethyl group was 
to increase the number of equivalent fluorine atoms in the ruthenium complex. By increasing 
the number of fluorine atoms from two to six the 19F NMR signal intensity should increase, 
enabling experiments to be performed at lower complex concentrations. Complexes [13] – [16] 
were synthesised and incubated with different amino acids, however, the overlap in the 19F 
NMR spectra from peaks assigned to Ru-OD2 and Ru-Cl made it more difficult to determine 
those peaks attributed to ruthenium amino acid coordination. The extra bond between the 
fluorine atoms and the metal, result in the fluorine being less sensitive to changes in metal 
coordination environment (Appendix C, Figure C.3).    
4.3.4. Competition Experiments 
With an understanding of the nature and 19F NMR chemical shifts of the different Ru-amino 
acid adduct peaks, competition experiments were performed to identify and quantify preferred 
amino acid coordination sites. To do this, all four 5,5’-FBipy complexes, [9]-[12] were 
incubated with a slight excess of each amino acid individually and collectively and temporally 
monitored by 19F NMR spectroscopy, Figures 4.12 to 4.15. 
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Figure 4.12: A series of 19F{1H} NMR spectra of complex [9] incubated with the protected 
amino acids, N-Ac-Cys-OMe, N-Z-Glu-OMe, N-Bz-His-OMe, N-Ac-Met-OMe, and a mixture 
of all amino acids together, (2 mM Ru, 3 eq. each amino acid, 24 hr, 310 K).  
Figure 4.13: A series of 19F{1H} NMR spectra of complex [10] incubated with the protected 
amino acids, N-Ac-Cys-OMe, N-Z-Glu-OMe, N-Bz-His-OMe, N-Ac-Met-OMe, and a mixture 
of all amino acids together, (2 mM Ru, 3 eq. each amino acid, 24 hr, 310 K).  
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Figure 4.14: A series of 19F{1H} NMR spectra of complex [11] incubated with the protected 
amino acids, N-Ac-Cys-OMe, N-Z-Glu-OMe, N-Bz-His-OMe, N-Ac-Met-OMe, and a mixture 
of all amino acids together, (2 mM Ru, 3 eq. each amino acid, 24 hr, 310 K).  
Figure 4.15: A series of 19F{1H} NMR spectra of complex [12] incubated with the protected 
amino acids, N-Ac-Cys-OMe, N-Z-Glu-OMe, N-Bz-His-OMe, N-Ac-Met-OMe, and a mixture 
of all amino acids together, (2 mM Ru, 3 eq. each amino acid, 24 hr, 310 K).  
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Some key findings from these experiments are summarised as follows.  
In all competition experiments, preference for cysteine coordination is absolute. Although this 
is not chemically surprising, (Ru(II) is a soft metal centre and the sulphur thiol is a soft ligand) 
solution based 19F NMR spectroscopy has been used to confirm this for these complexes. What 
is apparent, is that cysteine coordination, almost completely out-competes coordination to other 
soft nucleophiles (e.g. the histidine imidazole and the methionine thioether), therefore making 
it an attractive residue for localising a ruthenium cofactor in a protein.  
Increasing the electron donating capability of the arene ligand from benzene ® 
hexamethylbenzene, drives the equilibrium towards the Cys bound adduct and at a faster rate. 
To quantify this, rates of formation of the Cys bound adducts with different arene ligands were 
measured, through integration of the relevant peaks in the 19F NMR spectra. The formation of 
the [Ru]-Cys adduct peak was adequately described by a 1st order process, with the p-cymene 
and hexamethylbenzene complexes [11] and [12] being faster than the benzene and tolyl 
complexes [9] and [10], Table 4.2.  
Table 4.2: A comparison of the observed rates for the complexes [9] – [12] for the formation 
of a ruthenium cysteine adduct (2mM Ru, 3 eq. amino acid, 310 K). 
Complex kobs / x 10-4 s-1  
[9] 2.17 ± 0.03 
[10] 2.08 ± 0.05 
[11] 2.76 ± 0.04 
[12] 3.71 ± 0.08 
As previously discussed, there is an initial equilibrium in aqueous solution between the [Ru]-
Cl, [Ru]-OH2 and [Ru]-OH species. The rate of formation of a [Ru]-Cys adduct is dependent 
on the formation of the [Ru]-OH2 species, a theory that has been well studied, in contrast to the 
mechanism observed for cisplatin and Ru(II) anticancer complexes.136,137 The increased 
electron density of the ruthenium in the p-cymene and hexamethylbenzene, complexes [11] 
and [12], drives the equilibrium more towards a [Ru]-OH2 complex, contributing to an 
increased rate of formation of the [Ru]-Cys adduct.  
This theory is also supported by the measured pKa data in Section 4.3.2. The aquo complexes 
of [11] and [12] have much higher pKa values therefore at an initial pD of 7.2 the equilibrium 
will lie heavily towards the [Ru]-OH2 complex.  
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4.3.5. Binding to Glutathione 
In a cellular environment the most abundant biological thiol is the tripeptide glutathione which 
is at millimolar concentration in the cytoplasm of many different cells. Glutathione, 
equilibrates between reduced monomer (GSH, containing a thiol) and oxidised dimer (GSSG, 
containing a S-S bridge), Scheme 4.5. One role of glutathione in cells is to maintain the 
intracellular redox potential, and also stop the accumulation of toxic metabolites. Glutathione 
also plays an important role in iron-sulphur cluster assembly.138  
Scheme 4.5: The equilibrium between the reduced monomeric glutathione, GSH, and the 
oxidised dimeric form, GSSG. 
Complexes [9] – [12], were incubated with different ratios of reduced (GSH) and oxidised 
(GSSG) glutathione, and the 19F NMR spectra were recorded, Figure 4.16. The 19F NMR 
spectra show quantifiably that binding to the carboxylate groups is preferred in the absence of 
free thiolate, but that binding to the cysteine thiolate group is markedly preferred in 





































Figure 4.16: A series of 19F{1H} NMR spectra of complex [12] incubated with defined 
mixtures of reduced and oxidised glutathione (2 mM Ru, 3 eq. glutathione, 24 hr, 310 K). 
4.3.6. An Aside – Exploring Cysteine Oxidation  
Alongside incubating Ru(II) complexes with small molecules, Ru(II) complexes were also 
incubated with different proteins, which will be discussed in detail in the following chapters. 
In some reactions where Ru(II) arene complexes were coordinating to proteins the measured 
and expected masses differed by 16 mass units, which was hypothesised to be due to the 
cysteine thiol being oxidised after ruthenium coordination. The literature precedence for this 
reactivity was reported by Sadler et al. who suggested that the free thiol of Cys34 in human 
serum albumin was being oxidised to a sulfenate by molecular oxygen after ruthenium 
coordination, as the sulphur atom is more electrophilic upon metal coordination.139 Sadler et 
al. also reported oxidation of ruthenium-thiolate adducts to ruthenium-sulfenate adducts on a 
small molecule scale by LC-ESI-MS.21  
Oxidation of ruthenium-cysteine adducts was explored using both ESI-MS and 19F NMR 
spectroscopy. Many different oxidation states of cysteine are capable of coordinating to a 
ruthenium centre, summarised in Scheme 4.6. 
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Scheme 4.6: Different biological cysteine oxidation states, with potential coordination of 
ruthenium to the sulphur atom. 
Via ESI-MS, coordination of ruthenium to cysteine was monitored upon addition of the reactive 
oxygen species (ROS), H2O2, Figure 4.17. After addition of 1 Eq. of H2O2 to an incubation of 
complex [12] with 1 Eq. of Cys, an oxidation product at a mass of 649.27 was observed. This 





























Figure 4.17: ESI-MS spectra recorded of the solution mixture when complex [12]-Cys is 
incubated with initially 1 Eq. of N-acetyl cysteine methyl ester, followed by different 
equivalents of the oxidant H2O2. Experimental and calculated values given in Appendix B, 
Table B.3. 
Oxidation of the thiolate ligand with 0.5 Eq. of H2O2 leads to dramatic changes to the 19F NMR 
spectrum of an incubation of N-acetyl cysteine methyl ester with complex [12]. The two 
doublets observed upon formation of a [Ru]-Cys adduct, are split even further to give two 
additional sets of doublets of unequal intensity, analogous to a histidine bound species, Figure 
4.18. On addition of 1 Eq. of H2O2 the doublets corresponding to ruthenium thiolate 
coordination are no longer observed and there is an increase in peak intensity of the Ru-
sulphenate species.  
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Figure 4.18: 19F{1H} NMR spectra when the incubation of complex [12] with 1Eq. of N-acetyl 
cysteine methyl ester is spike with different number of equivalents of the oxidant H2O2. 
The 19F NMR peaks corresponding to a Ru-sulphenate species are downfield shifted compared 
to the Ru-thiolate species. In this 19F NMR spectroscopy method, negatively charge ligands 
(e.g. chloride, phosphate, thiolate) are upfield of neutral ligands (methionine and histidine). 
Upon thiolate oxidation the negative charge on the sulphur will be delocalised across the S=O 
bond weakening the ionic contribution to bonding. The current hypothesis for the Ru-
sulphenate species giving rise to two sets of doublets is that oxidation of the sulphur introduces 
a chiral centre; ruthenium coordination to each enantiomer therefore gives rise to a set of 
doublets of equal intensity, Figure 4.19, from the resulting diastereomers. 










This chapter has outlined a spectroscopic approach, using 19F NMR spectroscopy, to monitor 
the speciation of a suite of Ru(II) arene bipyridine complexes with amino acid side chain 
residues.  
The 19F NMR spectra provide quantitative, solution-based information on the reactions of these 
complexes with amino acid Lewis bases which could not be gathered using traditional 1H 
NMR, ESI-MS and crystallographic methods. The introduction of a fluorinated substituent on 
a ruthenium ligand, enables the reactivity of specific metal species in a complex mixture of 
biological nucleophiles to be explored. The quantitative nature of this 19F NMR spectroscopic 
method presented enables a deeper understanding of the preferred biological nucleophiles for 
Ru(II) arene complexes. Furthermore, rate constants and pKa values can be measured from the 
integration and chemical shifts of carefully assigned peaks.  
In the Ru(II) arene complexes presented, there are two key ligands, the h6-arene and the 
fluorinated bipyridine ligand. The electronic properties of both these ligands have been varied 
and the effect this has on the speciation to biological nucleophiles has been monitored. The 
position of fluorination around the bipyridine ligand has also been varied and the 19F NMR 
spectra monitored upon amino acid coordination to the ruthenium centre. When the fluorine 
atoms are in the 5,5’-position on the bipyridine ring, they are remarkably sensitive to changes 
in coordination at the ruthenium centre. This results in a unique fingerprint that leads to 
unequivocal assignment of the 19F NMR spectra of Ru-amino acid adducts. 
For all Ru(II) arene bipyridine complexes synthesised, the cysteine thiol was the preferred 
coordination partner in solution for Ru(II)(h6-arene)(bipyridine) complexes, confirmed by 19F 
NMR spectroscopy. Furthermore, from incubations with the tripeptide glutathione, cysteine 
was confirmed as the preferred coordination site for the Ru(II) complexes explored.  
Understanding the speciation of Ru(II) arene complexes when exposed to biological 
nucleophiles was a key goal for this research. Introducing fluorinated ligands as reporters has 
proven to be a quantitative and information rich method of understanding how Ru(II) arene 
complexes coordinate to amino acids. In terms of sensitivity, it has been possible to detect 
metal-amino acid complexes at relatively low adduct concentrations, however this often 
requires longer collection times. 
With a long-term goal of developing an artificial ruthenium metalloenzyme with direct protein 
coordination, being able to confirm and quantify in solution that Ru-cysteine adduct formation 
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has occurred is very useful. It was hypothesised that a cysteine residue could act as an initial 
anchoring residue before subsequent ligand exchange to generate a protein-metal hybrid with 
the potential of catalytic activity. This 19F NMR spectroscopic method has been used in future 
chapters in characterizing Ru-protein adducts, where multiple ligands are available on the same 
protein molecule.   
Finally, in the development of Ru(II) arene anticancer complexes, understanding the 
fundamental solution behaviour will contribute to deciphering the mechanism of action which 
brings about apoptotic response in cells. As researchers attempt to identify new protein targets 
for Ru(II) arene complexation, this study provides an alternative insight into how Ru-target 
interactions could be characterised.  
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Chapter 5 
5. Coordination of Ruthenium Fragments 
to Proteins 
5.1.  Introduction 
The results presented in Chapter 4 increased our understanding of how Ru(II) arene complexes 
bind to simple amino acids and short peptides. This enabled a strategy for the controlled 
coordination of different Ru(II) arene complexes to protein scaffolds to be developed. The 
purpose was two-fold: (i) to understand where and to what extent different Ru(II) arene 
complexes coordinate to a variety of proteins and (ii) to assess the usefulness of 19F NMR 
spectroscopy to characterise Ru-protein adducts. As discussed in Chapter 4, cysteine was 
identified as the preferred amino acid binding site for a suite of Ru(II) arene bipyridine 
complexes. Therefore, the aim was to confirm, through a range of analytical techniques, 
whether this preference was translated to free cysteine residues in the context of folded 
proteins.   
5.1.1. The Chemistry of Cysteine 
Cysteine (Cys) is one of the least abundant of the twenty common amino acids in proteins, 
however, due to the nucleophilic sulfhydryl side chain and redox potential, Cys plays vital 
structural, catalytic and regulatory roles in functionally diverse proteins.140  
A further consequence of the high nucleophilicity of the cysteine thiol side chain is that there 
are few proteins with free surface cysteines. Buried cysteines are either often in unique catalytic 
environments or linked through a disulphide bond to another cysteine residue. Therefore, in 
order to coordinate to a ruthenium complex, the Cys in a folded protein needs to be accessible 
and in the reduced, thiol form.  
When coordinating a ruthenium complex to a protein it is desirable for the protein-metal 
conjugation to be selective for a specific amino acid. The unique properties of Cys, discussed 
above, make it a good target for selective ruthenium protein modification.141  
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5.1.2. Ruthenium Coordination to Cysteine Containing Proteins 
This chapter deals with two categories of Cys containing proteins: (i) naturally occurring 
proteins with free Cys sites and (ii) proteins with engineered Cys sites. Site-directed 
mutagenesis is a method enabling specific modifications of a DNA sequence and, in terms of 
protein engineering, these modifications manifest themselves as mutation of the protein’s 
primary structure. Through mutagenesis, Cys residues can be incorporated into a wide variety 
of proteins, however, it is noteworthy that any mutation can affect the structure, stability or 
function of the protein.  
5.1.3. Engineered Cysteine Mutants 
Ubiquitin 
Ubiquitin (Ubq) is a small (8.6 kDa, 76 residue) protein expressed in all eukaryotic cells. Ubq 
is rich in lysine residues and performs a number of functions through covalent attachment to 
other proteins, thus altering the stability, localisation and activity of the target protein.142 Poly-
ubiquitination is a process where a number of Ubq units are covalently linked, and these Ubq 
chains target unwanted or damaged proteins to the proteasome for degradation. In this study, a 
lysine residue at position 63 has been mutated to a cysteine. Lysine residues are hydrophilic, 
and often found on the surface of proteins to enhance solubility, therefore the cysteine residue 
is solvent exposed.   
Figure 5.1: Structure of Ubq (Protein Data Bank: 1UBQ) determined by X-Ray 
Crystallography.143 
Cytochrome b562 
Cytochrome b562 (Cyt b562) is a periplasmic haem-binding protein (11.8 kDa, 106 residues) 
from Escherichia coli and is the only member of the family of 4-a-helical bundle cytochromes 
to not have a covalently bound haem cofactor. Figure 5.2 shows a structure, determined in 
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solution by NMR spectroscopy, of apocytochrome b562 where the four helices are apparent, 
although there are significant distortions. In the absence of haem, many of the residues that 
comprise the nascent haem binding pocket are accessible to solvent and small molecules.144 
The Barker group has engineered many cysteine mutants of Cyt b562, where the cysteine 
residues are directed into the region where haem coordinates.145 The purpose of this study was 
to convert this unique cytochrome to a c-type cytochrome with covalent linkage (Cys-haem) 
through a thioether bond.146  
Although the availability of the NMR structure of the apocytochrome b is invaluable, the highly 
dynamic nature of this protein when haem is not coordinated means one must be careful when 
predicting the position and orientation of the amino acid side chains. With cysteines introduced 
at different sites (L10C, R98C) the differential activity of these residues could be explored. 
There are other Lewis basic positions located in the hydrophobic region of the wild-type (WT) 
protein, including His63 and His102, which have the potential to coordinate to ruthenium. 
Figure 5.2: Structure of apo-Cyt b562 (Protein Data Bank: 1APC) determined by NMR 
spectroscopy.  
C2Am 
The C2A domain of the synaptic vesicle protein synaptotagmin I (C2Am: 16.2 kDa, 145 
residues) plays a fundamental role in Ca2+ sensing and regulating exocytosis. The presence of 
Ca2+ triggers a cellular response to fuse the synaptic vesicle, which is full of neurotransmitters, 
to the presynaptic membrane. The C2A domain is rich in aspartic acid residues which bind 
Ca2+.147 Previous studies, have introduced a single cysteine mutant at position 95, to attach a 
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radionuclide or fluorescent probe, in order to study cell apoptosis in vivo.148 Figure 5.3, shows 
the b-bulge structure of this C2 domain.149 
Figure 5.3: Structure of C2Am (Protein Data Bank: 1RSY) determined by X-Ray 
crystallography. 
5.1.4. Naturally Occurring Proteins with Free Cysteine Sites 
Human serum albumin (HSA) 
HSA is the most abundant protein in human plasma at a concentration of 640 µM and plays an 
important role as a transporter of hormones, fatty acid and metals (66.5 kDa, 585 residues), 
Figure 5.4. To perform its role, HSA has a number of potential ligand binding sites, including 
a free thiol, Cys34. This protein is thought to play a vital role in the transport of metal-based 
drugs to tumours, and it has even been suggested that adducts of Ru-HSA are the active forms 
of administered pro-drugs in-vivo.150,151  
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Figure 5.4: Structure of Human Serum Albumin (Protein Data Bank: 1AO6) determined by 
X-Ray crystallography.152 
Papain 
Papain is a cysteine protease from the latex of the papaya fruit (23.3 kDa, 212 residues). The 
active site contains the catalytic dyad, which is formed from the single free cysteine, Cys25, 
and His159, Figure 5.5. The cysteine nucleophilicity is enhanced as the histidine deprotonates 
the thiol side chain, enabling it to catalyse the hydrolysis of the peptide bond. Papain has a 
further 6 cysteine residues which are involved in disulphide bridges.  
Figure 5.5: Structure of Papain (Protein Data Bank: 9PAP) determined by X-Ray 
crystallography.153 
Papain 9PAP 7 cysteines 3 disulfide bridges 
Cys 25 active
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Tobacco Etch Virus Protease 
Tev protease is a cysteine protease from the tobacco etch virus. The entire viral genome is 
translated as a single polypeptide which is cleaved into functional units by three different 
proteases, with Tev protease itself being one. The enzyme is specific for the amino acid 
sequence ENLYFQ\S, where \ represents the cleavage site, and is often used to cleave 
engineered fusion proteins and solubility enhancing proteins (e.g. the maltose binding protein) 
from the protein of interest. Tev protease has a surface Cys130, the active-site Cys151, and a 
disulphide bridge. The active residue Cys151 has been mutated to an alanine in the crystal 
structure, shown by Figure 5.6.  
Figure 5.6: Structure of Tev Protease C151A (Protein Data Bank: 1Q31) determined by X-
Ray crystallography.154 The protein is crystallised as a dimer, however, in solution acts as a 
monomer, therefore the monomeric protein is shown here.  
These seven different proteins were explored due to their variety in structure and function, and 
the presence of free cysteine residues which could be excellent targets for ruthenium 
bioconjugation.  
5.2. Results and Discussion 
5.2.1. Experimental Strategy 
Throughout this chapter the ruthenium complexes incubated with different proteins either had 
the h6-p-cymene arene ligand (complexes [3], [11] and [15]) or the h6-hexamethylbenzene 
arene ligand (complexes [4], [12] and [16]).  
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To initially gauge the reactivity of each individual cysteine containing protein, the proteins 
were incubated with a 20-fold excess of the non-fluorinated p-cymene complex [3], Section 
5.2.2. 
Figure 5.7: Structure of complex [3]. Anion omitted for clarity.  
Two proteins, Ubq K63C and Cyt b562 L10C were then incubated with a suite of p-cymene and 
hexamethylbenzene bipyridine complexes; both the non-fluorinated complexes [3] and [4] and 
the fluorinated complexes [11], [12], [15] and [16], summarised in Section 5.2.3 (for Ubq 
K63C) and Section 5.2.4 (for Cyt b562 L10C).  
An incubation involved mixing known concentrations of protein, ruthenium complex (from a 
stock solution in DMF) and sodium phosphate buffer in a temperature-controlled shaker. 
Incubations were periodically analysed by liquid chromatography mass spectrometry (LC-MS) 
(full details in Section 3.2.4). LC-MS is the most efficient method of separating and confirming 
the presence of ruthenium-protein adducts. The instrument used in this research is routinely 
capable of detecting proteins in samples with concentrations as low as 1 µM. A typical 
methodology in going from the chromatogram to the ion series and then to the deconvoluted 
mass spectra is demonstrated in Appendix B, Figure B.1. 
Critical Evaluation of Mass Spectra 
To monitor the extent of protein modification a C4 reverse-phase column was used to separate 
small molecules from proteins, then the protein components were analysed via mass 
spectrometry under denaturing conditions. For significantly different ions, mass spectrometry 
is not considered to be a quantitative method where the peak integrals of ion counts correlate 
with concentration, however, throughout this research, peak heights of modified and un-
modified protein have been compared. This is possible through a maximum entropy algorithm 
which deconvolutes the detected ion series of the protein components to give a so called ‘zero 







a good signal to noise ratio. Further detail of the measurement and analysis procedure is given 
in Section 3.2.4.  
5.2.2. Reactivity of Ru(II) Arene Complexes with Different Proteins 
After optimizing conditions for reaction of these ruthenium complexes with cysteine 
containing proteins, mass spectra can quickly be compared to reveal different reactivities. In 
these incubations a 20-fold excess of the ruthenium complex was used and modification was 
monitored at a number of different time points, with spectra chosen after 1 hr to give a clear 
representation of the reactivity of the different proteins. Figure 5.8 shows results from 
incubation of complex [3] with six different proteins.  
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Figure 5.8: Mass spectra of samples from incubations of complex [3] with six different 
cysteine containing proteins (50 µM protein, 20 Eq. [3], 310 K, 1 hr).  
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The cysteine mutant of ubiquitin is very reactive to ruthenium modification. This single 
cysteine site is on the surface of the protein and complete modification occurs within 1 hr. The 
two cytochrome b562 cysteine mutants differ in reactivity quite markedly towards the ruthenium 
complex. This protein is highly dynamic and complete modification of residue Cys10 occurs 
after 1 hr, alongside modification at a slower rate at another residue. In a series of time course 
experiments varying the number of equivalents of complex [3], the reactivity of the different 
cytochrome cysteine mutants has been explored further. From initial analysis of the NMR 
structure, it is difficult to predict whether or not the Cys at position 98 would be much less 
reactive, however, with 20 Eq. of complex [3] this variant takes over 12 hrs to be completely 
modified. Complete modification of the L10C mutant can be achieved with 2 Eq. of complex 
[3] incubated for 4 – 6 hrs.  
The final cysteine mutant C2Am S95C shows presence of two species, one with a single 
ruthenium addition to the protein and another with an additional modification at a secondary 
amino acid residue. For C2Am, the presence of multiple coordination sites is not surprising, as 
this protein domain is rich in acidic side chain residues, which, as shown in Chapter 4, can 
coordinate to Ru(II) arene complexes. 
Papain has one free cysteine residue which is at the heart of the protease active site. The mass 
spectrum of complex [3] with papain is not shown in Figure 5.8, as no modification is observed 
at all which is probably because access to this cysteine residue is restricted. The other cysteine 
protease explored was Tev protease, which shows moderate reactivity with complex [3]. It is 
unlikely that this is modification at the active site cysteine as this Cys residue is buried, so 
conjugation to an alternative surface exposed residue is more likely.   
Finally, HSA initially shows little reactivity with the ruthenium complex, however, when 
incubated for a 24-hour period a number of different ruthenium modifications are observed. 
Due to the increased reactivity of a number of residues on HSA it makes it difficult to localise 
a ruthenium cofactor to a specific location on this protein.  
Confirming Cysteine Coordination using N-Ethyl Maleimide 
After identifying that Ubq K63C and Cyt b562 L10C were the most reactive cysteine containing 
proteins, the next step was to confirm cysteine as the site of ruthenium conjugation. Figure 5.9 
(Top) demonstrates, how the organic molecule N-ethyl maleimide (NEM) is reactive towards 
thiols, therefore modifying the cysteine residue, which can be detected via LC-MS. If, however, 
the free cysteine site is blocked by coordination to a metal complex then addition of the 
 107 
maleimide to the reaction mixture will not further change the mass of the modified protein, 
Figure 5.9 (bottom). Example spectra of how N-ethyl maleimide is used throughout this thesis 
to confirm the presence of a free cysteine residue is shown in Appendix B, Figure B.2.  
Figure 5.9: (Top): How N-ethyl maleimide reacts with free accessible thiol residues on 
proteins. (Bottom): When the cysteine thiol is coordinated to ruthenium no change in mass is 
observed via LC-MS upon reaction with the maleimide  
5.2.3. Reactivity of Ubiquitin with a Suite of Ruthenium Complexes 
Six ruthenium complexes were incubated with Ubq K63C (8565 Da). The h6-arene ligand was 
varied from p-cymene to hexamethylbenzene, and the bipyridine ligand from bipyridine (Bipy) 
to 5,5’-difluorobipyridine (5,5’-FBipy) to 5,5’-di(trifluoromethyl)bipyridine (5,5’-TFMBipy). 
These modifications gave changes in the electronic and steric properties of the ligands and the 
mass spectra after 1 hr of incubation are summarised in Figure 5.10.  
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Figure 5.10: Mass spectra from incubations of complexes [3], [4], [11], [12], [15] and [16]  
with Ubq K63C (50 µM protein, 20 Eq. Ru, 310 K, 1 Hr).The structures of the singly charged 
complexes (PF6 removed) added at the start of the incubation are given.  
In all cases, complete conversion to modified protein is observed after 1 hour with 20 Eq. of 
ruthenium complex, i.e. no unmodified Ubq K63C of mass 8565 Da is observed. When the 
fluorinated complexes [12], [15] and [16] are incubated with Ubq K63C, ruthenium-protein 
adducts are detected that have masses consistent with the dissociation of the fluorinated 
bipyridine ligand (either 5,5’-FBipy or 5,5’-TFMBipy) from the metal.  
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From an incubation of complex [11] with Ubq K63C the major mass peak observed is at 8993 
Da which is consistent with the adduct Ubq + [Ru(Cym)(5,5’-FBipy)]. Note here, that the 
ruthenium complex has exchanged its chloride ligand to coordinate to the protein. On 
incubation of Complex [16] with Ubq K63C the only significant mass peak observed is at 8828 
Da. This mass is consistent with a Ubq + [Ru(HMB)] adduct where the 5,5’-TFMBipy ligand 
has dissociated. Data from an incubation of complex [12] with Ubq K63C demonstrate that 
dissociation of the 5,5’-FBipy ligand can also occur, when  h6-HMB is coordinated. 
Additionally, 5,5’-TFMBipy dissociation can occur when the p-cymene ligand is bound, as 
evidenced from mass spectra of complex [15] with Ubq K63C.  
Observing bipyridine dissociation from the metal upon coordination to a protein is an 
unexpected and key result. Bipyridine dissociation leaves two free coordination sites at the 
ruthenium centre, and alongside chloride exchange there are three free ruthenium coordination 
sites available. The observed masses reveal that no solvent molecules or buffer salt ions are 
coordinated to the metal centre, therefore, for the metal to become coordinatively saturated, the 
protein must provide three ligands. Determining the mechanism and identifying these amino 
acid ligands is challenging, particularly when the fluorinated probe is no longer coordinated to 
the metal centre. All masses observed rule out any dimerization or higher order aggregation 
that could potentially arise from the metal centre cross-linking two protein species.  
The differential reactivity of the varied complexes shows that dissociation of bidentate 
bipyridine ligands is increased by two key factors: (i) changing the h6-arene ligand from p-
cymene to hexamethylbenzene and (ii) changing the bipyridine ligand from Bipy to 5,5’-FBipy 
to 5,5’-TFMBipy. As previously discussed in Chapter 4, the hexamethylbenzene ligand is a 
more electron donating ligand than the p-cymene ligand, resulting in a more electron rich metal. 
When (h6-HMB) is coordinated to ruthenium there is a lesser requirement for electron density 
from the bipyridine ligands leading to weaker Ru-N bonds and a more labile bipyridine ligand. 
Following the same logic, introducing electron withdrawing substituents on the bipyridine ring 
with increasing strength H®F®CF3 reduces the electron donation to the metal from the 
nitrogen lone pairs and weakens the Ru-N bonds. This hypothesis does not, however, consider 
the p contribution to bonding, as all three bipyridine ligands are capable of p-accepting electron 
density. The logic here would be that the more electron-donating arene ligand, coupled with 
the more inductively electron-withdrawing bipyridine ligands should increase the Ru-N p-
back-bonding and lead to a strengthening of the Ru-Bipy bonds. The data from incubation of 
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the above complexes with Ubq K63C suggest that the lability of these complexes is dominated 
by s rather than p interactions.  
Attempts to Crystallise Ubq-Ruthenium Adducts 
Attempts have been made to identify the other amino acids ligands coordinated to the 
ruthenium centre upon bipyridine dissociation via X-ray crystallography. Many Ubq-Ru 
adducts were isolated and purified via cation-exchange chromatography. Attempts to 
crystallise these hybrids were performed using a Mosquito robot to dispense nanolitre samples 
into a variety of solvent conditions in 96 well plates. Although initial promising results were 
observed, Figure 5.11, no diffraction quality crystals have been generated yet. This is most 
likely because ubiquitin contains a high surface density of lysine residues, which will inhibit 
packing conditions and impede crystallisation.155  
Figure 5.11: Initial crystals of a Ubq-Ru hybrid.   
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5.2.4. Reactivity of Cytochrome b562 L10C with a Suite of Ruthenium Complexes 
Figure 5.12: Mass spectra from incubations of complexes [3], [4], [11], [12], [15] and [16] 
with Cyt b562 L10C (50 µM protein, 20 Eq. Ru, 310 K, 1 Hr). The structures of the singly 
charged complexes (PF6 removed) added at the start of the incubation are given. 
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From incubations of Cyt b562 L10C with the non-fluorinated bipyridine complexes [3] and [4], 
the major species are observed at 12154 Da and 12184 Da, respectively, consistent with one 
addition of the relevant [Ru(h6-arene)(Bipy)] fragment in both cases. Masses consistent with 
two additions of the [Ru(h6-arene)(Bipy)] fragment are also observed in the mass spectra for 
both [3] and [4] at 12543 Da and 12602 Da, respectively.   
Incubations of the 5,5’-FBipy complexes [11] and [12] with Cyt b562 L10C gave major species 
at 12189 Da and 12217 Da, which, similar to the non-fluorinated bipyridine complexes, are 
consistent with coordination of the relevant [Ru(h6-arene)(5,5’-FBipy)] fragment. The minor 
species in both incubations at 11997 Da and 12025 Da, can be explained by 5,5’-FBipy 
dissociation, as seen following reaction of complexes [11] and [12] with Ubq K63C. Cyt b562 
L10C is a dynamic and flexible protein, therefore upon 5,5’-FBipy dissociation, amino acid 
ligands from other helices on the protein are possibly satisfying the ruthenium coordination 
environment. 
The increased lability of the 5,5’-TFMBipy ligand, compared to 5,5’-FBipy, is clear when 
complex [16] is incubated with Cyt b562 L10C; the major species in this incubation, with a mass 
of 12581 Da, is consistent with Cyt b562 L10C with two ruthenium modifications. The mass, 
which is + 816 greater than the apoprotein is consistent with addition of one fragment of 
[Ru((h6-HMB)(5,5’-TFMBipy)] and one of [Ru((h6-HMB)].  
Although direct injection LC-MS is a powerful tool for identifying the different adducts that 
form upon incubations of different ruthenium complexes with Cyt b562, information on the 
location of coordination and protein stability is not accessible. Therefore, further 
characterisation techniques, in particular, NMR, UV-visible spectroscopy and circular 
dichroism were required in order to probe coordination sites and the influence of metal 
coordination on the protein chemistry  
5.2.5. Characterising Cytochrome b562 L10C – Ruthenium Adducts 
To further characterise some of these Ru-protein adducts it was necessary to complete the 
incubations on a larger scale and purify the protein adducts. Once pure samples were obtained, 
19F NMR, UV-Vis spectroscopy and circular dichroism experiments were performed. Initially, 
size exclusion chromatography was used to separate unreacted metal complex and protein 
based on size. On further analysis of the protein fractions eluted from the column, (by LC-MS 
and UV-Vis) it was concluded that excess metal complex was non-coordinatively associated 
with Cyt b562. The hydrophobic ligands can form non-covalent interactions with the 
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hydrophobic regions of this protein without metal coordination occurring. Changing 
purification method to anion exchange chromatography with a salt gradient, successfully 
removes all excess small molecules, and non-coordinatively bound metal complex, leaving just 
coordinatively bound protein-ruthenium adducts.  
A series of experiments were performed to purify a number of Cyt b562 – Ruthenium adducts 
at a higher concentration. To do this, 20 Eq. of the ruthenium complex were incubated with 2 
mL of Cyt b562 L10C at a concentration of 200 µM for 1 hr. The solution was then buffer 
exchanged into a high pH buffer and purified via anion exchange chromatography, Figure 
5.13. 
Figure 5.13: (Blue) The UV trace at 280 nm from an anion exchange purification of 20 Eq. of 
complex [4] with Cyt b562 L10C. The first peak to come off the column is excess complex [4] 
which is positively charged therefore has no affinity to the positively charged resin. The major 
peak (highlighted in red) corresponds to the adduct Cyt b562 L10C + [Ru(HMB)(Bipy)], as 
shown by the deconvoluted mass spectrum (insert) Mobs = 12182, Mcalc = 12184.  
Following the incubation of complex [4] with Cyt b562 L10C, larger scale incubations were 
performed with the fluorinated complexes [11], [12], [15] and [16]. In these experiments the 
major adducts were isolated via ion exchange with high levels of control, and the mass spectra 
demonstrate a high level of purity in the samples, Figure 5.14. The masses of these isolated 
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adducts are shown in Table 5.2. Cyt – [11], Cyt – [12] and Cyt – [15] all correspond to a single 
[Ru] addition with the arene ligand and fluorinated bipyridine ligand remaining coordinated to 
the metal centre. Cyt – [16] corresponds to an adduct with two ruthenium additions, one 
addition of [Ru(HMB)(5,5’-TFMBipy)] and one addition of [Ru(HMB)] where the 5,5’-
TFMBipy has dissociated from the metal centre. 
Table 5.2: Modifications and names of Ru-Cyt b562 L10C adducts purified by ion exchange. 
 
Name Mobs Mcalc Modification 
Cyt – [11] 12193 12191 Cyt b562 L10C + [Ru(p-cym)(5,5’-FBipy)] 
Cyt – [15] 12293 12291 Cyt b562 L10C + [Ru(p-cym)(5,5’-TFMBipy)] 
Cyt – [12] 12221 12220 Cyt b562 L10C + [Ru(HMB)(5,5’-FBipy)] 
Cyt – [16] 12582 12583 Cyt b562 L10C + [Ru(HMB)(5,5’-TFMBipy)] + [Ru(HMB)] 
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Figure 5.14: Mass spectra from purified Ru-Cyt b562 L10C adducts. Insert top right: The ion 
series of these species. Insert left: Cartoon representation of ruthenium modifications on the 
protein, shown via ChemDraw structures.  
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 19F NMR of Cytochrome b562 L10C – Ruthenium Adducts 
This section of work was done collaboratively with the NMR spectroscopy department in the 
Medical Research Council Laboratory of Molecular Biology (MRC-LMB). In particular, Dr 
Stefan Freund and Dr Trevor Rutherford helped design and perform a number of 19F NMR 
experiments.  
The Cyt b562-Ru adducts isolated Cyt – [11], Cyt – [12], Cyt – [15] and Cyt – [16] all had a 
fluorinated ligand present, therefore 19F NMR experiments could be used to identify the amino 
acid coordinated to the metal centre. Optimum T1 relaxation times were measured using an 
inversion recovery sequence to determine the T1 null point, and TR = 1.5.T1 was used.  
Figure 5.15: 19F{1H} NMR spectra of four different Ru-cytochrome b562 L10C adducts. 
Adducts were placed in 90% Buffer : 10% D2O and a 256-scan experiment was performed.  
In all spectra the Cyt b562-Ru adduct gives rise to two peaks of equal integrals, one peak from 
each fluorine atom on the bipyridine ring. The chemical shifts are consistent with Ru-cysteine 
coordination, when compared with the diagnostic spectra in Chapter 4. Additionally, a lack of 
reaction with NEM confirms that the cysteine is blocked. Taken together, these results confirm 
that there is a Ru(h6-arene)(fluorinated bipyridine) unit coordinated to the cysteine 10 position 
in all four of these adducts.   
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In contrast to ruthenium coordination to the thiol of N-acetyl cysteine methyl ester, described 
in Chapter 4, the 19F NMR signals from the ligand in the spectra after protein coordination have 
different peak geometries, but the same integral values. Therefore, in the Cyt b562-Ru adducts 
the two fluorine atoms on the bipyridyl ring have different relaxation properties, which 
suggests they are subtly affected by the local environment they are in. A simple model of Cyt 
– [11], Figure 5.16, shows how the ruthenium fragment [Ru(p-Cym)(5,5’-FBipy)]2+ could be 
accommodated into the hydrophobic region of Cyt b562 L10C, normally used for haem binding, 
and coordinate to the cysteine residue. One fluorine atom, shown in turquoise, is solvent 
exposed, whereas the fluorine on the opposite side of the bipyridyl ring would be buried from 
solvent. This leads to the hypothesis that the exact local environments of nearby amino acids 
are determining the relaxation properties of the two fluorine atoms, thus leading to different 
peak shapes.  
As discussed Cyt – [11], Cyt – [12] and Cyt – [15] all contain only one site of modification by 
a ruthenium, whereas Cyt – [16] has two sites of modification, one where the bipyridine has 
dissociated from the metal. The NMR chemical shifts of Cyt – [16] suggests that the fluorinated 
fragment [Ru(HMB)(5,5’-TFMBipy)] is coordinated to a cysteine residue. The other site of 
modification in Cyt – [16] (a [Ru(HMB)] fragment) must therefore be coordinated elsewhere. 
Figure 5.16: A PyMOL generated figure of Cyt – [11]. This is not an energy minimised 
structure, and uses an NMR structure of apo-Cyt b562 and elemental Van der Vaals radii. Yellow 
– sulphur, orange – ruthenium, turquoise – fluorine, green – organic component of [11].  
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UV-Vis Spectroscopy of Cytochrome b562 L10C – Ruthenium Adducts 
Figure 5.17: UV-visible spectra recorded of Cyt b562 L10C and Cyt b562-Ru adducts purified 
via ion-exchange chromatography. Spectra recorded between 200 – 600 nm. Free protein 
concentration = 600 µM, complex [15] concentration = 50 µM and the concentration of the 
adducts is unknown due to the overlapping transitions at 280 nm. 
As can be seen from the UV spectra in Figure 5.17, the free protein shows absorption bands 
in the range 235 – 290 nm, which are due to the p - p* electronic transitions present in the 
tyrosine and phenylalanine residues. The Ru(h6-arene)(bipy) complexes all absorb strongly in 
the region of 265 – 330 nm, which is due to p - p* transitions in the bipyridine and arene 
ligands.156 These ligand absorption bands are evident in the Ru-cytochrome adducts, 
particularly between 300 – 330 nm. The overlap in the bands at 280 nm makes quantification 
of the concentration of these adducts particularly difficult, as the extinction coefficient for each 
ruthenium fragment is different. What is of particular interest in Figure 5.17 is the subtle 
differences in the UV-vis spectra of the adducts, particularly with distinct bipyridine ligands 
coordinated. It is, however, challenging to extrapolate the changes in the spectra to an 
understanding of the ligand exchange behaviour of Ru(II) arene complexes with protein 
scaffolds.  
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The Ru(h6-arene)(bipyridine) complexes also absorb weakly in the region of 360 – 440 nm. 
These bands are particularly evident for the 5,5’-TFM adducts Cyt – [15] and Cyt – [16] and 
arise from metal to ligand charge transfer (MLCT). The photochemistry of ruthenium 
tris(bipyridine) complexes has been studied in detail, and these bands have been assigned to 
originate from a d-electron from the ruthenium being excited into a bipyridine anti-bonding 
orbital.157   
Circular Dichroism of Cytochrome b562 L10C – Ruthenium Adducts 
The purpose of measuring the CD spectra of these Ru-Cyt adducts was to monitor whether the 
coordination of the ruthenium complexes changes the secondary structure of the protein, in 
particular whether the protein retains a folded alpha helical structure upon ruthenium 
coordination. The signature spectral features of helical proteins are a positive band at 190 nm 
and negative bands at 222 nm and 208 nm. Evident in Figure 5.18, the protein-ruthenium 
hybrids retain their secondary helical structure upon ruthenium coordination, with the 
characteristic bands at 222 nm and 208 nm clearly shown.  
Figure 5.18: CD spectra of the Cyt b562 L10C – ruthenium adducts, Cyt – [11], Cyt – [12], Cyt 
– [15] and Cyt – [16] (5 µM adduct concentration, 10 mM sodium phosphate buffer). 
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5.2.6. Reactivity of Cytochrome b562 WT with a Suite of Ruthenium Complexes 
This section of work was done collaboratively with the mass spectrometry department in the 
Medical Research Council Laboratory of Molecular Biology (MRC-LMB). In particular, Dr 
Mark Skehel and Sarah Maslen helped design and perform a number of the tandem MS/MS 
experiments.  
The results shown in the previous two sections are focussed on the reactivity and coordination 
of ruthenium fragments to the cysteine residue in the Cyt b562 L10C mutant. In this section, the 
reactivity of the same Ru(II) arene complexes with Cyt b562 wild-type (WT) is shown. In these 
incubations, shown in Figure 5.19, there is no free cysteine for the ruthenium centre to 
coordinate to. Attempts were made to characterise the Cyt b562 WT – Ru adducts formed using 
a combination of LC-MS and tandem mass spectrometry (MS/MS) methods.  
In stark contrast to the reactivity of complexes [3] and [4] with Cyt b562 L10C, Figure 5.12, 
there is no modification of Cyt b562 WT by the bipy complexes [3] and [4], further emphasising 
their preference to coordinate to cysteine residues. Additionally, the fluorinated cymene 
complexes [11] and [15] also show very limited coordination to Cyt b562 WT. However, the 
fluorinated hexamethylbenzene complexes [12] and [16] show increased reactivity towards Cyt 
b562 WT, demonstrating how subtle modulation of the electronic and steric properties of the 
metal-bound ligands can greatly influence the reactivity with proteins.  
In the incubation of complex [16] with Cyt b562 WT, the mass spectrum shows two major 
species at 12303 Da and 12042 Da which correlate to the adducts Cyt b562 WT + 2 [Ru(HMB)] 
and Cyt b562 WT + [Ru(HMB)] respectively. Upon ruthenium coordination to the protein 
scaffold the trifluoromethylbipyridine ligand dissociates from the metal centre. Attempts were 
therefore made to isolate these species and identify the coordination environment of the 
[Ru(HMB)] fragment. 
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Figure 5.19: Mass spectra from incubations of complexes [3], [4], [11], [12], [15] and [16]  
with Cyt b562 WT (50 µM protein, 20 Eq. Ru, 310 K, 1 Hr). The structures of the singly charged 
complexes (PF6 removed) added at the start of the incubation are given. 
Where does the [Ru(HMB)] Fragment Coordinate to Cytochrome b562 WT? 
Initial attempts to purify the doubly modified adduct Cyt b562 WT + 2 [Ru(HMB)] (12303 Da) 
via anion exchange proved challenging due to the small overall negative charge of the protein 
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adduct, which reduces its affinity for the positively charged resin. However, through reducing 
the number of equivalents of complex [16] from 20 Eq. to 2 Eq., isolation of the adduct Cyt 
b562 WT + [Ru(HMB)] (12042 Da) was achieved. After 1 hr the reaction mixture was purified 
by anion exchange chromatography and four species eluted from the column, identified by 
Peaks 1 – 4 on the chromatogram, Figure 5.20 (top). Peak 1 corresponds to unreacted 
ruthenium complex [16], and Peak 4 corresponds to unreacted Cyt b562 WT. The species present 
in Peak 2 and Peak 3 were analysed by mass spectrometry and found to have the same mass of 
12042 Da which is a consistent mass to the adduct Cyt b562 WT + [Ru(HMB)], where complex 
[16] has undergone both chloride and TFMBipy dissociation to coordinate to the protein. 
Analogous purifications were performed when complex [12] was incubated with Cyt b562 WT, 
and two species of mass 12042 Da were isolated (in Chapter 6 called Hybrid 5 and 6) with 
different retention times in the anion exchange separation. This section will focus on the 
differences between the species isolated from an incubation of Cyt b562 WT with complex [16]. 
These two species, Cyt WT – [16] – P2 and Cyt WT – [16] – P3 (in Chapter 6 called Hybrid 7 
and Hybrid 8) not only have different retention times, but have a different charge state 
distribution in the ion series observed in the mass spectra Figure 5.20 (middle and bottom, 
insert). Analysing the LC-MS, the Cyt b562 WT – Ru adduct which elutes off the column first, 
peak 2, has a major ion of 1095.65 Da corresponding to a +11 charge state under denaturing 
conditions. The second adduct to elute off the column, peak 3, has a major ion of 861.15 Da, 
corresponding to a +14 charge state. The influence of tertiary structure on the charge state 
distribution of proteins is well explored with most data supporting the theory that a shift in 
charge state distribution towards lower m/z values is induced by protein unfolding. Two major 
hypothesises have been put forward to interpret this shift: (i) lower solvent accessibility of 
acidic and basic residues in a more folded structure inhibits ionisation of these residues and (ii) 
unfolded confirmations can stabilise higher charge states by increasing the distance between 
two charges of the same polarity.158  
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Figure 5.20: (Top): An ion exchange chromatogram, from an incubation of complex [16] with 
Cyt b562 WT. Blue trace – UV absorbance, brown trace – conductivity (S/m), green trace - % 
salt buffer. (Middle and Bottom): Deconvoluted mass spectra and ion series (insert) of the 
different species that come off the ion exchange column, 
The differences in charge state distribution observed between Cyt WT – [16] – P2 and Cyt WT 
– [16] – P3 suggests that the two protein adducts have different folding properties. To explore 
this further, CD spectroscopy was used to measure the melting temperatures for the following 
species, Cyt WT, Cyt WT – [16] – P2, Cyt WT – [16] – P3 and Cyt L10C – [4], Figure 5.21. 
Similar to the ruthenium modified cysteine mutants shown in Figure 5.18, the raw CD spectra 
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between 185 – 300 nm showed little variation in peak shape upon metal coordination, with the 
negative bands at 208 nm and 222 nm retained. The intensity of the peak at 222 nm for the four 
different adducts was monitored whilst raising the temperature incrementally from 25 to 90 °C. 
Fitting these data to a standard logistic function enabled the melting temperatures to be 
measured.  
Figure 5.21: Normalised measure of proportion of unfolded protein as a function of 
temperature for Cyt b562 WT and three different Cyt b562 – Ru hybrids. The melting 
temperatures, Tm, i.e. the temperature where 50 % of the protein is unfolded, are given for the 
four different protein species.  
Upon coordination of the [Ru(HMB)] fragment to Cyt WT the protein species which elutes 
from the column first, Cyt WT – [16] – P2, has an increased melting temperature, 64.0 °C, 
compared to 59.1 °C for the WT. This indicates that for this adduct, ruthenium coordination is 
stabilising the helical fold of the protein. The protein species which elutes off the column 
second, Cyt WT – [16] – P3 has melting temperature of 57.8 °C which is similar to the WT 
protein. This suggests that in this species, the addition of the [Ru(HMB)] unit does not stabilise 
the fold of the protein. Similarly, the addition of a [Ru(HMB)(Bipy)] fragment to Cyt b562 L10C 
does not increase the stability of the protein fold, as this species has a melting temperature 
slightly lower than the WT protein of 57.7 °C. 
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The initial hypothesis was that Cyt WT – [16] – P2 and Cyt WT – [16] – P3 had different 
retention times, charge state distributions and melting temperatures because the [Ru(HMB)] 
fragment coordinated to different amino acid residues. To test this hypothesis and to determine 
the coordination sites of the [Ru(HMB)] fragment a tryptic digest procedure and mass 
spectrometry analysis was performed on Cyt WT – [16] – P2 and Cyt WT – [16] – P3. Unlike 
the [Ru(Cym)(Bipy)] fragment the [Ru(HMB)] fragment is likely to be coordinated to more 
than one amino acid residue in order to be coordinatively saturated. The [Ru(HMB)] fragment 
has three vacant coordination sites.  
Upon direct infusion of the digested sample into a mass spectrometer, masses of peptides were 
detected between 300 – 2000 m/z. Figure 5.22 focusses upon the 900 – 1200 m/z region, with 
selected masses and assignments shown in Table 5.3. 
Table 5.3: Assignment of peptidic fragments modified and un-modified by [Ru(HMB)] 
fragments.  
Figure 5.22: An ESI-MS spectrum of the adducts observed when the Cyt b562 – Ru species Cyt 
WT – [16] – P2 and Cyt WT – [16] – P3 have undergone tryptic digestion. Two ruthenium 
modified peptides are highlighted with the masses and assignments given in Table 5.3.   
In these spectra two peptides containing the coordinated [Ru(HMB)] fragment can be 
identified. This was aided by the unique isotopic pattern of ruthenium, which can be seen in 
the highlighted sections of Figure 5.22. Both Cyt WT – [16] – P2 and Cyt WT – [16] – P3 had 
Mass Charge m/z Assignment 
1058.55 +1 1058.55 EAQAAAEQLK – Peptide 86-95 
1995.81 +2 998.91 ADLEDNMETLNDNLK – Peptide 1-15 + [Ru(HMB)] 
1901.89 +2 951.95 HGFDILVGQIDDALK – Peptide 63-77 + [Ru(HMB)] 
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similar mass spectra upon tryptic digest, therefore it was concluded that they were coordinating 
to the same peptides.  
Tandem mass spectrometry experiments were performed on both ruthenium modified peptides 
(Peptide 1-15 + [Ru(HMB)] and Peptide 63-77 + [Ru(HMB)]) for each Cyt b562 WT – 
[Ru(HMB)] species (Cyt WT – [16] – P2 and Cyt WT – [16] – P3), with the spectra shown in 
Figures 5.23 to 5.25. A detailed explanation of how the tandem MS/MS data was analysed is 
given in Section 3.2.5.  
MS/MS of Peptide 63-77 + [Ru(HMB)] – Coordination to Histidine 63 
Figure 5.23: ESI-MS/MS spectra for CID of the ruthenium-modified peptide 63-77 with an 
actual mass of 1901.89 for two species Cyt WT – [16] – P2 and Cyt WT – [16] – P3. The 
presence of ions with a mass consistent to b1 + [Ru(HMB)] indicates histidine coordination.  
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MS/MS of Peptide 1-15 + [Ru(HMB)] – Coordination to Alanine 1 
Figure 5.24: ESI-MS/MS spectra for CID of the ruthenium-modified peptide 1-15 with an 
actual mass of 2011.80 for two species Cyt WT – [16] – P2 and Cyt WT – [16] – P3. The 
presence of ions with a mass consistent to b1 + [Ru(HMB)] indicates alanine coordination. 
MS/MS of Peptide 1-15 + [Ru(HMB)] – Coordination to Asparagine 6 
Figure 5.25: ESI-MS/MS spectra for CID of the ruthenium-modified peptide 1-15 with an 
actual mass of 1995.81 for two species Cyt WT – [16] – P2 and Cyt WT – [16] – P3. The 
presence of ions with a mass consistent to b6 + [Ru(HMB)] indicates asparagine coordination. 
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Discussion of Tandem Mass Spectrometry Results 
This tandem MS/MS data suggests that when the [Ru(HMB)] fragment coordinates to Cyt b562 
WT in both Cyt WT – [16] – P2 and Cyt WT – [16] – P3 the metal centre is coordinated to the 
following residues: 
(i) Histidine 63 (on peptide 63-77) 
(ii) Alanine 1 (on peptide 1-15) 
(iii) Asparagine 6 (on peptide 1-15).  
If all three of these residues were coordinated to the [Ru(HMB] fragment through side chain 
coordination then the ruthenium metal centre would be coordinatively saturated with the 
following ligands: A histidine imidazole nitrogen, the N-terminal amino group and either the 
amide oxygen or amide nitrogen from the asparagine, Figure 5.26. It is also possible that 
coordination occurs to the backbone carbonyls that make up the protein backbone. It is unlikely 
that the backbone nitrogen atoms will coordinate to the metal centre due to their relatively high 
pKas and delocalised lone pair. 
Figure 5.26: Two coordination environments possible when the [Ru(HMB)] fragment is 
coordinated to the Ala1, Asn6 and His63. Asn6 could either coordinate through the carbonyl 
or amino ligand.    
Throughout the 19F amino acid NMR experiments previously presented, it was found that the 
amide ligand (i.e. asparagine) and amino ligand (i.e. N-terminal alanine) were very weak 
ligands to ruthenium when free in solution. Additionally, these amide and amino ligands are 
reported to be weak ligands in natural systems, and incubations of the free amino acids 
(asparagine and alanine) with Ru(II) arene complexes were poorly yielding. The histidine 
imidazole, however, was found to be a satisfactory ligand for ruthenium coordination in 
solution. It is therefore feasible that when complex [16] is exposed to Cyt b562 WT that there is 














free coordination sites, which, due to the chelate effect, are then occupied by the weak ligands 
provided by Ala1 and Asn6.  
These data disprove the initial hypothesis that the Cyt b562 WT – [Ru(HMB)] adducts with 
different retention times ((Cyt WT – [16] – P2 and Cyt WT – [16] – P3) are coordinated to 
different residues. Determining why these two species, which appear to be coordinated the 
exactly the same residues, have different retention times, charge state distributions and melting 
temperatures is challenging.  
This could be due to a number of potential reasons, such as the [Ru(HMB)] fragments being in 
different conformations within the protein, i.e. the arene ligand being above or below the 
ruthenium in the protein. The protein being in a different conformation should also be 
considered, as these adducts have clear differences in protein stability as indicated by the 
temperature melt studies. Another potential reason, which was eluded to previously, is that the 
ruthenium is coordinated to different parts of the same residues, for example the amide nitrogen 
or the carbonyl backbone of Asn6. These subtle changes could potentially bring about large 
differences in the fold of the protein-metal hybrid. In order to further investigate this, structural 
based studies are underway within the research group involving X-ray crystallography and 
NMR spectroscopy.  
5.2.7. Discussion on the Dynamics of Cytochrome b562 
Cyt b562 is a four helical bundle protein (α1-α2-loop-α3-α4) that has evolved to coordinate the 
haem cofactor non-covalently, with His102 and Met7 providing axial ligands to iron. There are 
three key structures of Cyt b562 reported: (i) a crystal structure of the holo-protein,159 (PDB: 
256B) (ii) an NMR solution structure of the holo-protein with the iron oxidised,160 (PDB: 
1QPU) and (iii) an NMR solution structure of the apoprotein (PDB: 1APC).144 The NMR 
structure of the holo-protein is essentially identical to what is observed in the crystal structure, 
with the biggest differences coming between residues 50-57 which is a portion of the loop 
between α2 and α3. This region is highly disordered in the crystal structure indicating a number 
of alternative conformations in equilibrium.160  
In order to understand the coordination of the [Ru(HMB)] fragment to Cyt b562, an awareness 
of how haem effects the structure and folding kinetics of Cyt b562 is crucial. The haem cofactor 
and [Ru(HMB)] have different structures. How the protein coordinates the metal as well as 
how it forms non-covalent interactions with the metal ligands (porphyrin or arene) are likely 
to be very different; an appreciation of how this particular protein fold (the four helical bundle) 
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accommodates haem is useful. Many haem proteins fold independently of the haem cofactor 
to form an apoprotein, with the nascent potential for haem cofactor-binding whereas others 
require the cofactor to be present for productive and correct folding.  
The folding kinetics of denatured apo- and holo-Cyt b562 were explored by Garcia et al. through 
a series of detailed solution NMR experiments. It was found that high concentrations of 
denaturant were required to fully denature the holo-protein to the denatured apoprotein and 
non-coordinated haem.145 To reform the holo-protein, the apoprotein will slowly refold, then 
the protein fold will recognise the porphyrin ring through non-covalent interactions before the 
haem iron coordinates. Cyt b562 is therefore an example of haem protein which folds 
independently of the cofactor. The non-covalent interactions are vital in Cyt b562 coordinating 
haem, for example the orientation of haem entering the hydrophobic pocket is crucial in haem 
coordination. The non-covalent interactions observed between ruthenium complexes and Cyt 





Figure 5.27: A PyMol generated cartoon of apo- and holo-Cyt b562 from a side on view (Top) 
and a view from the top (bottom). Each helix is colour coded, a1 – red, a2 – cyan, a3 – orange 
and a4 – blue, with the loops coloured magenta.     
Upon haem coordination to the folded apoprotein the protein becomes more organised and 
tightly packed. Comparing the NMR structures of apo- and holo-Cyt b562, Figure 5.27, α1 and 
α4 (beyond Gln93), become significantly more ordered. There is also significant flexibility in 
the loop between α2 and α3 with this region becoming much more ordered moving from the 
apoprotein to the oxidised holoprotein. The residues of the loop leading into α3 also become 
substantially more ordered, and a helical turn becomes apparent in this dynamic region.     
Upon coordination of the [Ru(HMB)] fragment to Cyt b562 WT, a1 and a3 are crosslinked 
through coordination to Ala1, Asn6 and His63. Figure 5.28 shows the apoprotein structure 
with these three residues highlighted.  
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Figure 5.28: A PyMol generated cartoon of apo Cyt b562 from a side on view (Left) and a view 
from the top (Right). Residues for ruthenium coordination are highlighted: Ala1 – Green, Asn6 
– Magenta and His63- Red.  
Evidently from Figure 5.28, in order for the [Ru(HMB)] fragment to coordinate to all three of 
these residues, there must be a significant conformational change of the apoprotein to bring 
these three residues closer. The apoprotein structure indicates that His63 is orientated away 
from the central hydrophobic pocket, where haem binds. The flexibility in the loop between 
a2 and a3 could be essential for the conformational change required for a [Ru(HMB)] 
fragment to coordinate.  
An Initial Comparison of Haem and [Ru(HMB)] Coordination to Cytochrome b562 WT 
The coordination of the iron cofactor haem and the ruthenium fragment [Ru(HMB)] to apo - 
Cyt b562 differs greatly. Haem coordination to Met7 and His102 crosslinks a1 and a4, whereas 
ruthenium coordination to Ala1, Asn6 and His63 crosslinks a1 and a3. The 3d metal Fe and 
the 4d metal Ru have very different ligand exchange rates and electronic requirements. 
Furthermore, haem and [Ru(HMB)] coordination will have different steric implications and 
form very different non-covalent interactions with the protein; haem is a planar cofactor, 
whereas the Ru(II) arene cofactor adopts a pseudo-octahedral geometry capable of forming 
directional bonds to the protein scaffold, and this will determine how the apoprotein folds upon 
cofactor uptake. With His102 available for coordination, it is intriguing that the [Ru(HMB)] 
fragment coordinates to the His63 residue instead. One might predict that, like haem iron, the 
[Ru(HMB)] fragment would coordinate to His102 as this residue points towards the 
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hydrophobic pocket, but the clear preference for His63 emphasises the difficulty in predicting 
and designing metal coordination sites for exogenous metal complexes.  
5.3. Conclusions 
Understanding the speciation of Ru(II) arene complexes with proteins has formed a large part 
of this research. In particular, the reactivity of Ru(II) arene complexes with three proteins has 
been explored: (i) ubiquitin K63C; (ii) cytochrome b562 L10C and (iii) cytochrome b562 wild-
type. When a cysteine is present and accessible, Ru(II) arene complexes will preferentially 
coordinate to the thiol. This has been confirmed by 19F NMR, LC-MS, and experiments 
involving blocking the cysteine with the small molecule N-ethyl maleimide.  
The coordination of the fluorinated Ru(II)(h6-arene)(5,5’-FBipy) and Ru(II)(h6-arene)(5,5’-
TFMBipy) complexes to Cyt b562 L10C has been explored by 19F NMR spectroscopy. The deep 
understanding of the reactivity of fluorinated ruthenium complexes with protected amino acids 
and of their 19F NMR spectra, as outlined in Chapter 4, enabled this spectroscopic approach for 
probing the protein adducts formed. The 19F NMR spectra are very sensitive and reveal, 
through the intricacies of protein-metal coordination, how the diastereotopic fluorine atoms on 
the bipyridine ligand have different peak geometries and peak widths, indicative of different 
relaxation properties. This demonstrates the differential effect that placing an organometallic 
complex within a protein scaffold can have on the electronic environment on the atoms which 
form the organometallic cofactor. These results confirm that the metal fragments have been 
incorporated into the structured environment of the protein. If the ruthenium fragment was 
coordinated on the surface of the protein, it is likely that the fluorine atoms would have the 
same relaxation properties, therefore identical relaxation properties and peak shapes.  
This chapter has outlined a systematic study of the coordination behaviour of Ru(II)arene 
complexes with two variants of four helical bundle protein cytochrome b562 (Cyt b562 L10C and 
Cyt b562 WT) and revealed that minor changes to the small molecule complex led to drastically 
different conjugates being formed. Of particular interest, was the observation that even 
bidentate ligands can be exchanged for protein derived ligands. Considerations on the origin 
of these results allowed for carefully designed metal precursor complexes, containing labile 
ligands that maintain complex integrity in aqueous solution but upon contact with 
apocytochrome b562 variants undergo bipyridine exchange.  
This was most clearly evidenced when [Ru(h6-HMB)(5,5’-TFMBipy)Cl]+ is incubated with 
Cyt b562 WT, resulting in a species where a [Ru(HMB)] fragment is coordinated to three 
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residues Ala1, Asn6 and His63 and crosslinks two of the four helices that form this protein (a1 
and a3). Based on results presented in Chapter 4, we hypothesise that the complex undergoes 
an initial chloride exchange to an aquo ligand in aqueous buffer, followed by subsequent 
coordination to the imidazole of His63, which is a more thermodynamically favourable ligand 
than the potential ligands of Ala1 and Asn6. The complex then undergoes bipyridine 
dissociation with Ala1 and Asn6 providing the necessary donor ligands to satisfy the metal.  
Bipyridine dissociation is also observed, but to a much lesser extent when Ru(II)(h6-
arene)(fluorinated bipyridine) complexes are incubated with the cysteine mutant Cyt b562 
L10C. As previously discussed, if a thiol is present and accessible this will be the preferred 
binding site for a Ru(II) (h6-arene)(bipyridine) as the bond enthalpy of forming a Ru-S bond 
is thermodynamically favourable. Based on the mass spectra presented throughout this chapter 
(particularly for the [Ru(h6-HMB)(fluorinated bipyridine)Cl]+ complexes [12] and [16]) we 
hypothesise that, bipyridine dissociation is much more favourable when initial coordination 
occurs at His63 instead of Cys10 (which is only present in Cyt b562 L10C).  
One factor that could be a potential driving force for bipyridine dissociation and coordination 
to a potentially weaker ligand set is the protein fold energy which places the cofactor under 
steric pressure within the protein. Upon the predicted initial coordination, to His63 on a3, or 
Cys10 on a1, the cofactor is under different steric pressures within the protein, with it being 
more thermodynamically favourable to undergo bipyridine dissociation when the initial ligand 
is the histidine imidazole. Another potential that could favour bipyridine dissociation at the 
histidine is the electronic contributions from either the imidazole or the thiol. The strength of 
the Ru-bipyridine bonds will be greatly influenced by the other metal bound ligands and the 
different electronic contributions of imidazole vs thiol coordination could  
To generate an artificial metalloenzyme based on coordination between a ruthenium cofactor 
and a protein scaffold, Cyt b562 has emerged as a potentially excellent candidate for a starting 
protein structure. The dynamic nature of the protein, the presence of a hydrophobic pocket and 
the distinct reactivity with different ruthenium organometallic fragments is promising. This 
dynamic four helical bundle protein is capable of coordinating a variety of different ruthenium 
fragments and has the conformational flexibility to provide ligands to saturate the ruthenium 
centre even when the dissociation of apparently strong ligands occurs. The Cyt b562 – Ru 
adducts presented within this chapter have the potential to be catalytically active.    
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For the majority of transition metal catalysed reactions, the metal centre must be able to 
undergo ligand exchange, often in order to coordinate catalytic substrates. The Cyt b562 – Ru 
adducts generated throughout this chapter are all coordinatively saturated, so to be catalytic 
they must undergo ligand exchange. The Cyt b562 WT – [Ru(HMB)] adducts coordinated to 
Ala1, Asn6 and His63 have two relatively labile ligands to ruthenium (from Ala1 and Asn6) 
which could potentially undergo ligand dissociation to coordinate a catalytic substrate and 





6. Cytochrome b562 – Ruthenium Hybrids 
for Catalysis 
Preface: The work reported in this section was in collaboration with fellow PhD student Jamie 
Klein. I carried out all protein production, synthesis of ruthenium compounds, protein-
ruthenium incubations (including purification and characterisation), whereas Jamie Klein 
carried out the organic synthesis of the assay substrates and prepared all catalytic experiments 
that were carried out on the plate reader.  
6.1.  Introduction 
Chapter 1 outlined in detail the benefits and opportunities of developing ArMs with direct 
protein–metal coordination bonds. In particular, these systems have the advantage of the 
protein having a direct structural and electronic influence on the reactivity of the metal centre 
and, coupled with directed evolution, hybrid catalysts can be generated with significant 
improvements in catalytic efficiency. 
This introduction will revisit four key considerations in developing dative ArMs for a given 
catalytic transformation, and introduce how these factors have identified cytochrome b562 – 
ruthenium adducts as potential starting points to search for catalysis. These four key 
considerations are: (i) the protein starting point, (ii) a controlled ligand exchange reaction 
activating a metal cofactor for catalysis, (iii) protein-metal bonds – realising an entatic state 
and (iv) the possible reactions that the chosen metal cofactor could catalyse.  
6.1.1. The Protein Starting Point 
A number of protein scaffolds have been used in the formation of ArMs and research groups 
in the field have used different parameters to select their protein scaffold. One of the key 
features of the ArMs reported is a hydrophobic pocket capable of accommodating an artificial 
cofactor and the catalytic substrate. This is most clearly evidenced in the work of Roelfes et al. 
and Lewis et al. who use the scaffolds LmrR and prolyl oligoptidase respectively; both these 
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proteins were chosen because they have a large central hydrophobic cavity where catalysis 
occurs.  
Another key feature in the selection of the starting protein scaffold is how evolvable the protein 
is. In the development of an ArM the protein scaffold will undergo directed evolution in order 
to introduce mutations which could potentially bring about catalytic rate enhancements. 
Predicting whether or not a protein can withstand laboratory evolution based on inspection of 
the structure is challenging, if not impossible. In the pioneering work of Tawfik and co-
workers, the concept of catalytic promiscuity is explored, i.e. whether an existing enzyme 
evolved for a given reaction and substrate can be evolved to also perform another function, 
with native activity retained.161 From this study Tawfik highlights two key features from 
natural enzymes which can help predict the evolvability of the desired protein scaffold; 
robustness and protein dynamism (plasticity).162 Robustness refers to the ability of a protein to 
withstand multiple mutations without significant loss of structure. Second, protein dynamism 
and flexibility are vital to enable the metal complex and substrate to be positioned for catalysis. 
Molecular dynamics and NMR studies can be used to assess the dynamism of a protein, and 
have shown that mutations in flexible loop regions can be crucial in rate enhancements.163,164   
Instead of selecting a naturally existing protein scaffold many groups have used computational 
design to build up desired protein scaffolds. De novo design of metalloenzymes aims to use 
computational methods to predict what primary sequence and cofactors are necessary to 
achieve the optimal protein arrangement for metalloenzyme catalysis. Degrado and co-workers 
have pioneered the design of a number of synthetic proteins which directly coordinate bare 
metal atoms or metal cofactors.165,166 The design of ArMs from scratch is particularly 
challenging due to the lack of reliable parameters for defining transition metal bonding and the 
immense complexity of the many low energy interactions that determine binding of small 
molecules to proteins. However, the designed protein structures that have shown particularly 
promising catalytic activity, with a designed metal binding site incorporated, are four helical 
bundle proteins.108   
Assessing the optimal features for a starting protein scaffold, from both a natural 
metalloenzyme and a de novo design viewpoint, the natural four helical bundle protein 
apocytochrome b562 can be highlighted as an excellent potential starting point. First, without 
the haem present, there is a relatively large, nascent, hydrophobic pocket between the four 
helices. Second, as explored by the Barker group, the protein is robust and can withstand 
multiple mutations without the loss of structure. Third, as discussed in Chapter 5, the 
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apoprotein is dynamic, particularly in a1 and a4 and a flexible loop region between a2 and 
a3, evidenced through NMR structural studies.160 The hypothesis is that this loop region and 
the nascent cofactor binding pocket are of significant importance to accommodating ruthenium 
complexes.  
Apocytochrome b562 is smaller in comparison to other proteins used as scaffolds for artificial 
metalloenzymes, which could limit the formation of defined metal and substrate binding sites. 
However, the fewer residues could prove to be beneficial for an evolutionary campaign as a 
greater proportion of evolutionary space can be explored in comparison to larger proteins. The 
Barker group has also engineered apocytochrome b562 with additional helices at both the N and 
C termini which means the protein can me made bigger. 
6.1.2. Controlled Ligand Exchange Activating a Metal Cofactor for Catalysis 
As discussed in Chapter 1, a hugely desirable system for artificial metalloenzymes is to have 
both the protein and initial metal complex catalytically inactive and stable, but upon 
incorporation of the metal complex into the protein scaffold, activity is unmasked. This ensures 
that the only catalysis being measured is from the artificial metalloenzyme and not the free 
metal complex. We hypothesised that the optimum method to unmask catalytic activity from 
an initially inactive species, is through a controlled ligand exchange reaction with a protein 
scaffold. Chapter 5 has outlined a series of controlled ligand exchange reactions of Ru(II) arene 
complexes with variants of apocytochrome b562. Of particular interest are the ligand exchange 
reactions which result in protein-metal hybrids with multiple protein-metal coordination bonds 
of varying strength. For catalysis to occur within the artificial metalloenzyme, further ligand 
exchange must also occur with a catalytic substrate. Having protein ligands which satisfy the 
metal in the absence of a catalytic substrate (i.e. ligands that can come on and off) is highly 
advantageous.  
6.1.3. Protein-Metal Bonds – Realising an Entatic State  
In small molecule transition metal catalysts, the ligands arrange around the metal centre to 
maximise bonding interactions. In the context of dative artificial metalloenzymes at least one 
of the ligands to the metal is provided by the protein scaffold. These peptidic ligands are not 
only influenced by the coordination bond(s) to the metal, but also by the intramolecular 
interactions that make up the protein fold. The immediate complex can therefore be distorted 
into a suboptimal geometry that is not a global energy minimum on the coordination energy 
landscape. The whole protein can be seen as a secondary coordination sphere where the protein 
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fold energy is used to poise the metal centre for reactivity. These energised, or entatic states 
have a reactivity that is not easily realised in conventional, synthetic metal catalysts. 
From the perspective of the protein scaffold, the formation of an entatic state requires the 
peptide to be at least partially folded before binding the metal; the more defined the fold, the 
greater the ability of the fold to energise the metal complex. As such, fully folded rigid proteins, 
that impart a distorted, unfavoured geometry on a metal centre are optimal for adopting an 
entatic or energised state. This is in contrast to the desirable dynamic system for the 
evolutionary process. A potential compromise can be struck by using a starting scaffold that is 
partially folded as the apoprotein and upon cofactor binding rigidifies to a completely folded 
form, hence the attractiveness of apocytochrome b562 as a starting scaffold. The initial folding 
energy can be used to poise the metal in an activated state, while the folding process occurring 
during cofactor binding allows for the system to adapt during directed evolution. Once the ArM 
becomes more specialised after rounds of evolution, the apoprotein will probably approach a 
more fully folded form, yielding an ArM after cofactor addition that is less promiscuous but 
contains a more energised and active metal centre. 
6.1.4. The Potential Reactions that the Chosen Metal Cofactor Can Catalyse 
Throughout this research there has been a focus on the reactivity and speciation of Ru(II) arene 
bipyridine complexes with proteins. Ru(II) arene complexes have shown a wide application in 
a number of catalytic transformations, including transfer hydrogenation and C-H bond 
activation. Their broad reactivity scope and compatibility in aqueous biological systems has 
made them an attractive starting point to explore catalytic activity with ArMs.  
Fluorescence-based assays are excellent methods for fast online monitoring of catalytic activity 
in directed evolution experiments. These assays are applicable for use in high-throughput 
screening, including micro-fluidics assays, due to the high sensitivity of fluorescence 
spectroscopy. In comparison to chromatographic screening, fluorogenic screens allow for an 
increased number of experiments, with high temporal resolution, to be performed.  
In this research, transfer hydrogenation and olefin metathesis have been highlighted as 
potential reactions to monitor in aqueous systems with ruthenium-protein hybrid molecules. 
These reactions are well studied, catalysed by a variety of different ruthenium catalysts and 
have shown compatibility within aqueous systems, although water is not necessarily the 
optimal solvent. Furthermore, as this chapter will illustrate, a number of different fluorescence-
based assays have been developed to monitor these catalytic reactions.  
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In the generation of ArMs with direct protein-metal coordination, the ligand exchange process 
has the potential to change the electronics of the metal centre. The cytochrome b562 – ruthenium 
adducts in this research are unlikely to be a specialist catalyst for a particular substrate or 
reaction, however, if initial activity is observed, they offer an excellent initial starting point for 
evolutionary campaigns.   
6.2. Experimental Goals 
Throughout this chapter, the aim was to generate a suite of cytochrome b562 – ruthenium 
hybrids and test them for transfer hydrogenation and metathesis activity using fluorescence-
based assays. This required the development of a method to accurately quantify the 
concentration of the cytochrome b562 – ruthenium hybrids and the incorporation of 
fluorescence-based assays for transfer hydrogenation and metathesis.  
6.3. Results and Discussion 
6.3.1. Quantifying Cytochrome b562 – Ruthenium Adducts 
Chapter 5 described how different protein-ruthenium hybrids can be purified as individual 
species using ion exchange chromatography. Having these hybrids as individual species, for 
example a species with a single [Ru(HMB)] addition, rather than a mixture of species, is crucial 
in identifying catalytically active species. For catalytic testing, 8 different cytochrome b562 – 
ruthenium adducts have been obtained as individual species from purifying large scale 
incubations of different ruthenium complexes with either the Cyt b562 L10C mutant or Cyt b562 
WT, Table 6.1.  
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Table 6.1: Cytochrome b562 – ruthenium adducts - the major products from a variety of protein-
ruthenium incubations purified via anion exchange chromatography.  
Hybrids 1 – 4 arise from incubations of the desired ruthenium complex with the cysteine mutant 
Cyt b562 L10C. From a combination of 19F NMR spectroscopy and competition experiments 
with N-ethyl maleimide the cysteine residue is confirmed to be coordinating to ruthenium. In 
all four of these species the bipyridine ligand has remained coordinated to the metal centre.  
Hybrids 5 – 8 are species which correspond to the modification of Cyt b562 WT with a 
[Ru(HMB)] fragment. Hybrids 7 and 8 have been discussed in detail in Chapter 5 and result 
from an incubation of Cyt b562 WT + 2 Eq. of complex [16]. Upon purification, two hybrids 
with the same mass are isolated, Cyt WT – [16] – P2 = hybrid 7 and Cyt WT – [16] – P3 = 
hybrid 8. Hybrids 5 and 6 appear to be analogous to the species purified from an incubation of 
Incubation Species Isolated Mobs Mcalc Hybrid Number 
Cyt b562 L10C H102M 
Cyt b562 L10C + 20 
Eq. complex [3] 
Cyt b562 L10C + 
[Ru(Cym)(Bipy)] 
12154 12156 1 
Cyt b562 L10C + 20 
Eq. complex [11] 
Cyt b562 L10C + 
[Ru(Cym)(5,5’-FBipy)] 
12190 12191 2 
Cyt b562 L10C + 2 Eq. 
complex [15] 
Unable to Isolate Individual Species 
Cyt b562 L10C + 20 
Eq. complex [4] 
Cyt b562 L10C + 
[Ru(HMB)(Bipy)] 
12182 12184 3 
Cyt b562 L10C + 20 
Eq. complex [12] 
Cyt b562 L10C + 
[Ru(HMB)(5,5’-FBipy)] 
12217 12220 4 
Cyt b562 L10C + 2 Eq. 
complex [16] 
Unable to Isolate Individual Species 
Cyt b562 WT 
Cyt b562 WT + 20 Eq. 
of complex [12] 
Cyt b562 WT + [Ru(HMB)] 12043 12043 5 
Cyt b562 WT + [Ru(HMB)] 12043 12043 6 
Cyt b562 WT + 2 Eq. 
of complex [16] 
Cyt b562 WT + [Ru(HMB)] 12042 12043 7 
Cyt b562 WT + [Ru(HMB)] 12042 12043 8 
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Cyt b562 WT + 2 Eq. of complex [16], however the protein was incubated with 20 equivalents 
of complex [12] instead of 2 equivalents of complex [16]. 
In order to standardise catalytic experiments, it is essential to know the concentration of the 
protein-ruthenium adduct. Typically, measuring approximate protein concentration is straight 
forward through the Beer-Lambert law which correlates UV absorbance at 280 nm, with 
protein concentration, through the extinction coefficient e280. However, in all samples the 
ruthenium fragment coordinated to the protein contributes significantly to the absorbance at 
280 nm, therefore a direct concentration read out via UV spectroscopy is not possible. 
Furthermore, depending on the exogenous ligands, ligands provided by the protein and the non-
covalent interactions of the metal complex, each ruthenium fragment has a different extinction 
coefficient, which is challenging to measure in this context.  
Quantifying ArM concentration with an unnatural metal cofactor has previously been 
performed through a variety of methods. Lewis et al. standardised the concentration of all 
rhodium-prolyl oligopeptidase ArMs generated by multiplication of the ESI-MS peak 
intensities of the ArM and scaffold in these mixtures.85 Ward et al. measured the concentration 
of all biotin-streptavidin variants assuming complete 1:1 conversion and therefore assumed the 
protein concentration before cofactor attachment was equivalent to final ArM concentration. 
These methods outlined above, do not give accurate and consistent quantification of ArM 
concentration, therefore alternative methods were explored.  
Throughout this project, cytochrome b562 – ruthenium adducts have been quantified through 
ICP-OES (inductively coupled plasma optical emission spectroscopy). This method takes a 
liquid sample of known dilution (in HNO3) and runs it through a plasma which vaporises the 
atoms and ions so that each element’s characteristic wavelengths are emitted. The intensity of 
the different wavelengths corresponds to the concentration of each individual element.  
ICP-OES was used to measure the concentration of ruthenium in a protein-ruthenium hybrid 
and by knowing the number of ruthenium modifications on the protein (through LC-MS) the 
concentration of the protein can be determined. 
6.3.2. A Transfer Hydrogenation Assay 
Self-immolative chemistry involves molecules that link, through covalent bonds, ‘trigger’ 
moieties with functional substrates of interest, such as drugs or fluorophores. This chemistry 
has found applications within the fields of high throughput screening, prodrugs, biosensing and 
biomolecular imaging.167 Upon activation of the trigger moiety by a specific analyte or 
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chemical modification, there is a cascade reaction that causes the release of the fluorophore, 
Figure 6.1.  
Figure 6.1: Schematic of self-immolative molecules that release fluorescent dyes.  
Recently, there have been a raft of studies which look to design novel, self-immolative 
molecules which are activated by different chemical modifications. In a particular study, a 
quinolinium substrate has been designed which, upon C=N reduction, may undergo self-
immolation to release a fluorogenic umbelliferone derivative, Scheme 6.1.89  
Scheme 6.1: Reduction of the TH substrate which undergoes self-immolation to release a 
fluorogenic umbelliferone molecule which is highlighted in yellow.  
Asymmetric transfer hydrogenation of imines168 and quinolines169 has been reported using a 
chiral Ru(II)(h6-arene) catalyst. The general mechanism for ruthenium catalysed transfer 
hydrogenation of imines involves initial coordination of formate to the metal centre, followed 
by b-hydride elimination to form a ruthenium hydride species. This hydride is transferred onto 
the C=N, carbon electrophilic centre, and the N picks up a H+ from the aqueous solvent 
resulting in reduction of the imine to an amine.170 These ruthenium catalysts have chiral ligands 
coordinated to the metal centre in order to control the enantioselectivity of the reaction, 
however, using an ArM means that the secondary coordination sphere provided by the protein 












Synthesis of the TH substrate was performed using a modified preparation and reported in 
Section 3.3.4. All catalytic experiments in this section were performed in 96-well plates with 
transfer hydrogenation activity measured by fluorescence output using a SpectraMax i3x plate 
reader, as described in Section 3.2.9.  
The fluorescent properties of umbelliferone have been extensively studied.171 Umbelliferone 
exhibits an intense blue fluorescence band at 460 nm over a wide range of pH and excitation 
wavelengths. As shown by Figure 6.2, the emission at 460 nm is greatest with an lex = 325 nm 
at pH 7.0, and with lex = 370 nm at pH 8.0. This can be attributed to the deprotonation of the 
phenolic proton at the 7-position moving to slightly basic conditions. The anionic form of 
umbelliferone absorbs more effectively at an lex = 370 nm. 
Figure 6.2: Excitation spectra of umbelliferone in different pH sodium phosphate (NaPi) buffer 
between 280 – 400 nm with a fixed lem of 460 nm.  
In the transfer hydrogenation reaction mixture, the coupled quinolinium – umbelliferone 
substrate is in excess concentration, at 1 mM. As shown by Figure 6.3, this substrate absorbs 
very strongly between 285 nm to 360 nm, which is attributed to strong quinolinium absorbance. 
This strong absorbance filters the vast majority of the light between these wavelengths meaning 
that the excitation spectrum of umbelliferone changes in the presence of the substrate. 
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Importantly, at pH 8.0 the optimum lex = 370 nm, where the substrate does not absorb, allowing 
for quantitative measurement of the fluorescence intensity. 
Figure 6.3: A combined graph of the excitation spectra of umbelliferone in 50 mM pH 8.0 
NaPi buffer with and without the presence of the starting transfer hydrogenation substrate and 
the absorbance spectra of the transfer hydrogenation substrate at 1 mM measured using the 
same instrument conditions. As evidenced by the flat line between 300 nm and 330 nm the 
absorbance measured is the maximum the machine under those conditions can measure.  
Calibration curves for umbelliferone at pH 7.0 and at pH 8.0 in 50 mM sodium phosphate 
buffer have been measured, Figure 6.4. 100 mM formate has been added to the pH 8.0 
calibration curve to more accurately represent the conditions under which transfer 
hydrogenation will occur.  
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6.3.3. Testing for Transfer Hydrogenation Activity  
The Cyt b562 – ruthenium hybrids 1-8, the bipyridine complexes [3], [4], [11], [12], [15], [16] 
and dimer III were tested for transfer hydrogenation activity by monitoring the fluorescence 
intensity over a 16 hr period with an lex = 370 nm and an lem = 460 nm. The rate of transfer 
hydrogenation was measured by taking the steady state rate and normalising to the ruthenium 
concentration of the sample, Figure 6.5. Hybrids 1-4 showed no transfer hydrogenation 
activity so are removed from Figure 6.5.  
Figure 6.5: A graph to show the rate of transfer hydrogenation for the Cyt b562 – Ru hybrids 
5-8, the Ru-cymene complexes, [3], [11] and [15], Ru-hexamethylbenzene complexes, [4], [12] 
and [16], the dimeric complex III. Concentrations of the protein-metal hybrids ranged from 20 
µM to 70 µM, with a concentration of 100 µM used for all ruthenium complexes. Error bars 
are one standard error of the mean. For the ruthenium complexes these errors are calculated 
from 3 independent measurements. Errors for hybrids 5 and 6 are calculated from 5 
independent repeats and errors for hybrids 7 and 8 are calculated from 4 independent repeats.  
A key finding from these data is that a Cyt b562 – Ru hybrid has been generated from a ligand 
exchange reaction between a Ru(arene)(bipyridine) complex and Cyt b562 WT that has an 
activity that is 35 times faster than the starting ruthenium complex. Additionally, hybrids 5-8 
all show increased catalytic activity than the known transfer hydrogenation catalyst dimer III, 
[Ru(Cym)Cl2]2. In particular hybrids 5 and 7 are more than 5 times faster than dimer III. These 













reaction with an appropriate protein scaffold. This is the desirable reactivity, discussed in detail 
in Section 6.1.2. The key to this activity is taking a stable complex and activating it into a 
metastable catalytically active species with weak ligands held by the protein fold. 
These data clearly display the increased activity of the Ru(arene) unit with direct coordination 
to a protein scaffold, compared to free dimeric complex which is likely to undergo hydrolysis 
within aqueous solution. The increased activity of these protein-ruthenium hybrids could be 
due to the propensity for side reactions and catalyst decomposition being lowered once the 
Ru(arene) unit is in the hydrophobic protein pocket of Cyt b562. Furthermore, the hydrophobic 
pocket in the protein could not only provide a localisation site for the Ru(arene) unit, but also 
be a suitable binding site for the organic, hydrophobic substrate. Bringing together the catalytic 
substrate and metal centre into close proximity within the protein scaffold will enhance 
catalysis. Important to consider is that Cyt b562 WT is not evolved to bind either the Ru(arene) 
unit nor the large hydrophobic substrate, highlighting the potential for a directed evolution 
campaign in order to optimise catalysis. For transfer hydrogenation to occur via the well-
studied catalytic mechanism, the Ru centre must initially undergo a ligand exchange reaction 
with formate to form a Ru-hydride species. In all of the active hybrids, we hypothesise that the 
metal centre has weak coordination bonds to Asn6 and Ala. Therefore, these ligands have a 
propensity to undergo ligand exchange with formate in order to form the hydride species, thus 
initiating the catalytic cycle.  
Hybrid pairs 5/7 and 6/8 have the same catalytic activity (within error), while the activity is 
significantly different between the pairs of hybrids 5/6 and 7/8. A number of pieces of evidence 
support the hypothesis that hybrids 5/7 are structurally the same adduct (Cyt WT + 
[Ru(HMB)]), as are hybrids 6/8. Hybrids 5/7 and hybrids 6/8 have the same retention times 
and charge state distributions. Additionally, measuring the same activity for these hybrids 
further supports this hypothesis. The differing activity between hybrids 5/6 and hybrids 7/8 
further supports the hypothesis that these species are structurally different, with a potentially 
different fold or conformation around the metal centre. This is potentially exciting as its gives 
more than one starting point for an evolutionary campaign from one protein-metal complex 
combination. Additionally, different starting metal complexes can be used to give the same 
hybrid species upon only slight variations of reaction conditions.  
The thermal stability experiments using CD were previously particularly enlightening to 
demonstrate that hybrids 5 and 6 were different species. Additional CD temperature melt 
experiments are consistent with hybrids 5/7 and hybrids 6/8 being the same species, Figure 
 148 
6.6. Hybrids 5 and 7 had similar melting temperatures of 63.4 and 64.0 °C respectively, and 
hybrids 6 and 8 also had similar melting temperatures of 59.4 and 57.8 °C.  
Figure 6.6: Normalised measure of proportion of unfolded protein as a function of temperature 
for Cyt b562 WT and hybrids 5-8. The melting temperatures, Tm, i.e. the temperature where 50% 
of the protein is unfolded, are given for the five different protein species. 
6.3.4. Direct Observation of Active Catalyst Formation 
The catalytic protein-metal hybrids presented so far have all undergone a purification process 
after incubation with the metal complexes in order to isolate individual species and remove 
excess ruthenium complex. As these hybrids display much increased activity than the free 
ruthenium complexes, the rate increase upon hybrid formation should be detectable by 
monitoring the fluorescence as the hybrid forms in the presence of the transfer hydrogenation 
substrate. Referring back to the speciation reactions, 2 Eq. of complex [16] were incubated for 
2 hrs with Cyt b562 WT before purification. Here, in subsequent reactions, 0.5, 1 and 2 Eq. of 
complex [16] were incubated with 100 µM of Cyt b562 WT in the presence of 1 mM substrate 
and the fluorescence was monitored over time, Figure 6.7. 
 149 
 
Figure 6.7: A graph showing the evolution of fluorescence activity upon hybrid formation in 
comparison to free complex [16] (black trace). The transfer hydrogenation substrate is 
combined with Cyt b562 WT and complex [16] at the start of the experiment. Varying 
equivalents of complex [6] are added 0.5 Eq. (light blue trace), 1 Eq. (dark blue trace) and 2 
Eq. (purple trace). The insert is zoomed in to the first part of the experiment to demonstrate the 
lag period which occurs whilst the hybrid is forming.  
As shown by Figure 6.7, there is an initial lag in the rate of transfer hydrogenation. In this lag 
period, the rate of reaction matches the rate of the free ruthenium complex. As the Cyt b562 WT 
– [Ru(HMB)] hybrids begin to form, there is an increase in the rate of transfer hydrogenation. 
Assuming full conversion with 1 Eq. and 50 % conversion with 0.5 Eq. to the species Cyt b562 
WT – [Ru(HMB)] (with a mass of 12042 Da), the normalised rates of transfer hydrogenation 
within the linear section of the graph corroborate with the rates observed for the purified 
hybrids 7-8 shown in Figure 6.5. When 2 Eq. of complex [16] is used, the observed rate is 
faster than the purified hybrids, which is hypothesised to be due to the presence of an even 
more active double addition product. This double addition product, Cyt b562 WT + 2 
[Ru(HMB)] (12402 Da) confirmed by LC-MS, has activity arising from two different locations 
of [Ru(HMB)], with the second location likely to be a weakly-bound metal fragment.  
6.3.5. Discussion of Transfer Hydrogenation Activity  
Catalysis which starts with an inert complex which is catalytically activated upon protein-metal 
coordination is a particularly attractive approach in the development of ArMs. This concept is 
most clearly exemplified by the vitamin B12 cobalt cofactor, which upon direct coordination 
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to the protein methionine synthase, methyl transfer activity is unmasked with great control and 
substrate specificity.172 Most literature examples of ArMs involving unnatural metal complexes 
to date, start with catalytically proficient complexes that upon incorporation into a protein 
scaffold show increased catalytic efficiency (kcat/KM) or enhanced stereoselectivity. 
This increased catalytic efficiency is often as a result of the proximity of the metal and substrate 
within a hydrophobic protein pocket. In many literature examples, directed evolution has been 
used to evolve this hydrophobic pocket which increases substrate binding affinity which, under 
simplifying assumptions, is characterised by a decrease in KM. In these systems, the chemical 
turnover rate (in many systems characterised by the initial kcat) does not increase significantly 
from the rate observed from free metal complex. This is in contrast to the data presented above, 
where there is a large rate enhancement between the starting metal complex and the protein-
metal hybrid generated upon coordination.  
In hybrids 5/7 and 6/8 there are protein-metal coordination bonds from the [Ru(arene)] 
fragment to Cyt b562 WT, that have a direct influence on the transfer hydrogenation turnover 
rate, kcat at the metal centre. The differential activity between samples is strong evidence that 
the protein environment is influencing catalytic activity in different ways. Directed evolution 
has the potential to test a large number of variants of the protein matrix which will each have 
differing electronic contributions to the metal centre, that could be beneficial for catalysis.  
6.3.6. Measuring the Turnover of the Reaction 
The rate enhancement in transfer hydrogenation of hybrids 5/7 over the free complexes [12] 
and [16] highlights an excellent evolutionary starting point. Knowing the concentration of the 
hybrids in solution, as well as an accurate umbelliferone calibration curve allows for 
determination of the turnover number of the reaction. After 7 days at 37 °C, a TON of 1.32 was 
measured for hybrid 7, however throughout the reaction, the rate was diminishing back towards 
the background rate of complex [16]. It was confirmed by LC-MS that approximately over 
70% of the [Ru(HMB)] had dissociated from the hybrid, thus explaining the drop off in rate of 
transfer hydrogenation. Although a relatively modest TON was measured at this concentration, 
it is important to observe that the enzyme is acting catalytically and to reiterate that this protein 
is not evolved for binding of the [Ru(HMB)] or the catalytic substrate.  
6.3.7. An Olefin Metathesis Assay 
In Section 1.4.2, the mechanism of olefin metathesis (OM) is discussed, and it is highlighted 
how catalysis with small molecule ruthenium catalysts has been optimised through ligand 
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development, in particular the introduction of N-heterocyclic carbene ligands. Performing 
metathesis in polar protic solvents like water is particularly challenging as the catalysts are 
often vulnerable to poisoning with coordinating solvent ligands.173 No metathesis reactivity 
has been observed in natural systems, however Ward et al. have demonstrated that metathesis 
can be introduced in-vivo using a biotinylated 2rd generation Grubbs-Hoveyda catalyst which 
assembles with a streptavidin scaffold in the periplasm of E.coli cells.87 One could envisage 
the usefulness in synthetic biology of having an in-vivo artificial metathase complementing a 
metabolic or synthetic pathway. Ward et al. have developed a number of pro-fluorescent 
substrates that yield a fluorescent product upon ring closing metathesis (RCM),174 Scheme 6.3 
shows the pro-fluorescent OM substrate used in this study.  
Scheme 6.3: The pro-fluorescent OM substrate which upon RCM releases the fluorescent 
derivative umbelliferone.   
Synthesis of an olefin metathesis (OM) substrate was performed using a modified synthesis as 
reported in Section 3.3.4, and catalytic activity was initially tested using the known Grubbs 2nd 
generation catalyst.  
Historically, in order to minimise presence of the nucleophilic hydroxide ion and degeneration 
of Grubbs 2nd generation catalyst, aqueous metathesis reactions are performed in buffer at low 
pH. To test the viability of the reaction, fluorescence was monitored over 18 hours with the 
OM substrate and Grubbs 2nd generation catalyst in 50 mM sodium acetate buffer, pH 4.0. An 
lex = 325 nm and lem = 460 nm was used and, unlike the TH substrate, the OM substrate does 
not strongly absorb at 325 nm allowing for quantitative monitoring at that wavelength. The 
strong activity of Grubbs 2nd generation catalyst at pH 4.0 highlighted the potential to monitor 
this reaction in aqueous conditions, however to test the protein-metal hybrids, a pH of reaction 
closer to biological pH was preferable.  
6.3.8. Metathesis Activity of Cytochrome b562 – Ruthenium Adducts 
The metathesis activity of Grubbs 2nd generation catalyst, complexes [12] and [16] and hybrids 
7 and 8 was tested in two different buffer conditions: sodium acetate buffer pH 4.0 and sodium 






phosphate buffer pH 7.0. The activity of Grubbs catalyst was majorly reduced moving to more 
neutral pH, however a small signal was observed above the blank. Preliminary data shows that 
hybrids 7 and 8, also showed low levels of metathesis activity comparable to Grubbs catalyst 
at pH 7.0, but showed no activity at pH 4.0, Figure 6.8. 
Figure 6.8: A graph to show the rate of olefin metathesis for the Cyt b562 – Ru hybrids 7 and 
8, the Ru-cymene complex, [16] and Grubbs 2nd generation catalyst. The rate has been 
measured and normalised by the ruthenium concentration. Error bars are one standard error of 
the mean. Errors are calculated from 3 independent measurements. 
That any form of metathesis activity is observed from these Cyt b562 – Ru hybrid is promising. 
Following the classical Chauvin mechanism for metathesis, there is a [2+2] cycloaddition of 
an alkene double bond to a Ru-alkylidene species to form a metallacyclobutane, which is a 
Ru(IV) species. Ruthenium complexes are often stabilised in the +II oxidation state by bonding 
modes to the arene. The metathesis activity observed from the [Ru(HMB)]-protein adduct 
emphasises the potential catalysis that can occur when you can localise a ruthenium cofactor 
and substrate within a protein hydrophobic pocket. Additionally, the protein provides a scaffold 
that has the ability to rearrange and stabilise the ruthenium centre at a higher oxidation state, 
enabling metathesis to occur. 
6.4. Conclusions 
A series of cytochrome b562 – ruthenium(II) arene adducts were purified via anion exchange 
chromatography. These species varied in which ligands coordinate to the metal, either those 












was developed to quantify the concentration of the adducts generated, so that any potential 
catalytic experiments could be normalised to protein-ruthenium hybrid concentration.  
Transfer hydrogenation activity and metathesis activity of all Cyt b562 – Ru(II) arene adducts 
was explored using fluorescence-based assays. Transfer hydrogenation activity was observed 
in hybrids where [Ru(HMB)] fragments have coordinated to Cyt b562 WT. In these active 
hybrids transfer hydrogenation activity has been unmasked from the relatively inert Ru(II) 
arene complexes [12] and [16] upon protein coordination. Through a combination of ion-
exchange chromatography, LC-MS and CD, it was confirmed that the same adducts, hybrids 5 
and 7 and hybrids 6 and 8 could be generated from incubations of Cyt b562 WT with different 
Ru(HMB) complexes. In particular, hybrids 5/7 were particularly active transfer hydrogenation 
catalysts in comparison to the known dimeric catalyst III and the Ru(II) arene bipyridine 
complexes. Hybrids 5/7 were over 5 times more active than the dimer and up to 35 times more 
active than the Ru(II) arene complexes.  
The enhancement in the rate of transfer hydrogenation demonstrated in this chapter has shown 
the ability to activate relatively inert metal complexes towards catalysis through cooperative 
ligand loss and coordination to a protein scaffold in a controlled manner. However, the hybrids 
generated still have limited activity as highlighted by the relatively modest TON. This is not 
necessarily too surprising as the protein is not evolved to bind either a [Ru(HMB)] unit or the 
catalytic substrate. The hybrids generated are, however, a fantastic starting point to begin an 
evolutionary campaign to evolve hybrids into very efficient catalysts. The two key reasons for 
this are the evolvability of the protein scaffold and the direct coordination between the metal 
and the scaffold.  
The optimum protein scaffold must be able to accommodate metal coordination and substrate 
association and have potential evolvability (robustness and plasticity) to enhance catalysis at 
the metal centre. The four helical bundle protein, apocytochrome b562 has been identified as an 
excellent starting point due to its hydrophobic cavity, dynamic nature and ability to withstand 
mutations.  
In more detail, mutations could be made to the hydrophobic pocket which accommodates the 
metal complex and substrate that could place the metal cofactor into an entatic, sub-optimal 
state, poised for catalysis, and improve the binding and pre-organisation of the hydrophobic, 
fluorogenic substrate. Further, of particular interest could be the effect on activity of mutations 
to dynamic regions of the protein, for example the loop between a2 and a3 and, separately, 
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a4. Predicting changes and designing mutations to bring about enhanced activity is however 
challenging, if not impossible, highlighting the importance of being able to screen a large 
library of mutants of apocytochrome b562. 
Direct protein-metal coordination enables directed evolutionary campaigns to attenuate and 
significantly vary the electronic environment experienced by the metal. In the active example 
identified above, there are three protein-metal coordination environments (Ala1, Asp6 and 
His63) including two comparatively weak interactions, enabling substrate and co-catalyst 
coordination. Varying the electronic contribution of these three ligands to the ruthenium centre 
through genetic mutation, could enhance the turnover number (kcat) associated with that distinct 
metal coordination environment.  
A concept that is central to the development of ArMs with direct protein-unnatural metal 
coordination is catalytic promiscuity. One way to define catalytic promiscuity is whether the 
same initial protein-metal hybrids can be used as evolutionary starting points to achieve 
different catalytic transformations. Observing preliminary results of both metathesis and 





7. Developing a Ruthenium Fragment 
Library for Catalytic Screening 
7.1.  Introduction 
Building upon the understanding of the aqueous and biological speciation of Ru(II) arene 
complexes with bipyridine ligands, this chapter outlines the synthesis and biological reactivity 
of novel Ru(II) arene complexes with alternative bidentate ligands to bipyridine.  
Many transition metal catalysed transformations involve the metal accessing a variety of 
oxidation states, acting as either single electron donors/acceptors or as two electron 
donors/acceptors as seen in oxidative addition and reductive elimination chemistry. For 
example, in ruthenium catalysed olefin metathesis the metal centre shuttles between Ru(II) and 
Ru(IV). Ligands that can both donate electron density and withdraw electron density from the 
metal centre (referred to as push-pull ligands) are ubiquitous in organometallic catalysis, by 
virtue of their ability to stabilise both high and low metal oxidation states.  
Ligands which can act as strong electron donating ligands are capable of stabilising high 
oxidation states. A common example is phosphanes (PR3), which can modulate activity 
depending on the substituent R groups. A further example is N-heterocyclic carbene (NHC) 
ligands which will be discussed in detail in the following section. The majority of phosphanes 
and NHCs are not stable as free species in aqueous solution, due to the high Lewis basicity of 
the lone pair on the phosphorous or the carbon, however they could have great potential for 
catalysis when coordinated to a metal within a biological setting. In order to realise this 
potential, and explore their effect on catalysis in biological systems, the Lewis basic lone pair 
must be involved in bonding to a metal centre before the metal species is exposed to an aqueous 
biological environment.  
Many metalloenzymes are capable of performing multi-electron reactions under physiological 
conditions. In natural metalloenzymes, Fe, Cu and Mo are the most frequently employed redox 
active metal centres. These metal centres have specific biological ligands (the primary 
coordination sphere) and are optimally positioned within an active site to tune both reductive 
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and oxidative chemistry.175 This is clearly evidenced by differing redox potentials of the 
FeIIIFeIII/II [2Fe2S] clusters found in ferrodoxins (-460 to -300 mV versus the standard 
hydrogen electrode (SHE)) and Rieske proteins (-100 to 490 mV versus SHE). In ferrodoxins 
the [2Fe2S] cluster is anchored through four Cys residues, whereas in Rieske proteins the 
cluster has two Cys ligands and two His ligands.4 These direct changes in the primary 
coordination sphere, as well as changes in the protein fold and secondary coordination sphere, 
tune the redox properties of metal cofactors to ensure enzymatic function.  
In many literature studies, the redox properties of Ru(II) arene complexes have been 
investigated and, under physiological conditions, the +II oxidation state is stabilised by 
bonding interactions of the arene ligand, making oxidation to higher oxidation states 
challenging.176 This made it somewhat surprising that olefin metathesis was measured (shown 
in Chapter 6) for a Ru(II) arene fragment coordinated to cytochrome b562, as oxidation to a 
Ru(IV) species is required. As discussed in Chapter 6, it was suggested that the localisation of 
the ruthenium metal and the catalytic substrate within the protein scaffold enabled catalysis to 
occur, with the protein capable of stabilising the ruthenium centre in the +IV oxidation state. 
An exciting question we asked was, if the arene ligand was replaced (in the protein-metal 
hybrid) with a ligand more capable of stabilising a metal in a higher oxidation state, would an 
increase in catalytic activity be observed? 
Therefore, in order to expand the catalytic potential of the fragments within the library under 
study, this chapter will explore the reactivity and biological speciation (particularly with Cyt 
b562) of a number of novel ruthenium complexes with abiological, synthetic ligands capable of 
stabilising higher oxidation states.  
7.1.1. N-Heterocyclic Carbene Complexes in Biology 
A carbene is a molecule containing a neutral carbon atom with a valence of two and two 
unshared electrons. Metal carbene complexes are often classified into either Fischer-type 
(singlet) carbenes where the carbene carbon atom is electrophilic and usually possesses 
adjacent p-donor groups stabilising the empty p-orbital or Schrock-type (triplet) carbene 
complexes which are nucleophilic and carry alkyl groups or hydrogen atoms on the carbene 
carbon. A third class of carbene complexes are N-heterocyclic carbenes (NHCs), which are 
defined as having a carbene carbon and at least one nitrogen atom within the ring structure. 
NHCs exhibit a singlet ground-state electronic configuration where the HOMO is the sp2-
hybridised orbital with the carbon lone pair, and the LUMO is the unoccupied p-orbital on the 
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carbon. The neighbouring nitrogen atoms (which are s-electron withdrawing and p-electron 
donating) stabilise this singlet configuration through inductively lowering the energy of the 
occupied s-orbital and mesomerically by donating electron density into the empty p-orbital, 
Figure 7.1.177 
Figure 7.1: Simplified structures of three different carbene classes, with the electronic 
stabilisation shown on the structure of the N-heterocyclic carbene. 
The strong s-donation of NHCs is the most important component of the bonding to transition 
metals, however, the contribution of p -back-bonding into the carbene p-orbital and p -donation 
from the carbene p-orbital can amount for up to 20 % of the overall bond energy in some metal-
NHC complexes.177 However, in comparison to Fischer and Schrock carbenes which are 
depicted with double bonds to the metal, NHCs coordinated to metal centres are drawn with a 
single bond which best reflects the experimentally observed potential for rotation around the 
M-C bond. In 1991, Arduengo and co-workers reported NHCs with extraordinary stability 
(they referred to them as ‘bottle-able’), ease of synthesis and applicability.178 NHC ligands 
have attractive features for use in small molecule catalysis; they can stabilise high oxidation 
states through increased electron donation and the electronics can be altered by changing the 
nature of the azole ring. Referencing Grubbs 2nd generation catalyst, this metal complex has 
two types of carbene ligands present; first, the NHC ligand plays an important role as a strong 
s-donating ligand helping stabilise the metal when in the +IV oxidation state and encouraging 
phosphine dissociation to allow for alkene association, second the Ru(C=C(H)(Ph)) carbene 
ligand initiates the metathesis catalytic cycle.  
The use of NHC ligands in biocatalysis is a virtually unexplored area, and modification of 
natural metalloenzymes using an NHC ligand has very minimal literature precedent. Within 
the field of ArMs, NHC ligands have been introduced in metal complexes which also have 























of Ward et al. and Tanaka et al. who have assembled ArMs based on the supramolecular 
assembly of Grubbs 2nd generation catalyst within their chosen protein scaffold.87,91 
There is, however, a body of research which has explored the antimicrobial and anticancer 
activity of metal-carbene complexes. Gold NHC complexes in particular have shown 
meaningful application in the medicinal anticancer field, with the inhibition of thioredoxin 
(TrxR) being a possible mechanism for their activity.179,180 Recent research by Hartinger et al. 
has explored the speciation and biological activity of a range of ruthenium-carbene complexes, 
including [Ru(Cym)(dmb)Cl2] (dmb = 1,3- dimethylbenzimidazol-2-ylidene), Figure 7.2, 
which inhibits TxrR at µM concentrations. 
Figure 7.2: Structure of [Ru(Cym)(dmb)Cl2] 
In a recent structural study the reactivity and speciation of [Ru(Cym)(dmb)Cl2] with the model 
protein hen-egg white lysozyme (HEWL) was explored.181 Upon saturating a crystal of HEWL 
with a solution of the complex [Ru(Cym)(dmb)Cl2] and analysing the resultant structure, 
different sites of metal coordination were identified. One site of coordination indicated that, 
upon protein-metal coordination, the p-cymene ligand dissociates from the ruthenium centre 
and a [Ru(dmb)Cl2(OHx)] fragment coordinates to His15 and Arg14, Figure 7.3. Detailed EPR 
studies have explored the impact of arene ligand exchange on the oxidation state of the Ru 
centres and identified that this ruthenium centre has been oxidised to Ru(III) which is 
paramagnetic and EPR active. This highlights the importance of the arene ligand in stabilising 
the ruthenium centre in the +II oxidation state as, once ligand exchange occurs, the metal centre 
is susceptible to oxidation. This methodology, of controlled ligand exchange upon direct 








Figure 7.3: Coordination sites identified after reaction of [Ru(Cym)(dmb)Cl2] with HEWL. 
Site 1 is highlighted and shows axial coordination of His15 and the dmb ligand and equatorial 
coordination of Arg14, two Cl ligands and an OHx ligand. Site 2 has been identified as 
monodentate coordination of a Ru(dmb)(OHx)2Cl2 fragment to Lys33. Site 3 was identified 
after crystal soaking for one month and involves the weak coordination of a [Ru(OHx)4Cl2] 
fragment to the carbonyl backbone on Ala107. This figure was supplied by Dr Matthew 
Sullivan. 
7.1.2. Pyridylidene amide (PYA) Complexes a New Class of Push and Pull ligands. 
For the purpose of redox catalysis, ligands that can both accept and donate electron density 
based on the oxidation state of the metal are particularly useful. Pyridylidene amide (PYA) 
ligands are a particularly attractive class as they are characterised by two different resonance 
structures: (i) a zwitterionic structure with a p-basic N-donor site (Figure 7.4 (left)) and (ii) a 
neutral structure with a p-acidic N-donor site (Figure 7.4 (right)). Electron donation is 
dependent on many factors including solvent polarity, the spectator ligands and metal oxidation 
state. When coordinated to a redox active metal centre this ligand system has the potential to 
promote both oxidative addition and reductive elimination in its zwitterionic p-basic and 
p-acidic forms, respectively. 
Figure 7.4: Resonance structure of the PYA ligand. (Left) The zwitterionic p-basic N-donor 
site which stabilises high-valent metal species. (Right) The neutral p-acidic N-donor site 










These ligands have been utilised most effectively by Albrecht et al. who have developed 
ruthenium complexes incorporating PYA ligands for the oxidative cleavage of olefins using 
NaIO4 as a sacrificial oxidant, in water/organic solvent mixtures. In this study, they postulate 
a catalytic cycle involving the formation of a bis-PYA stabilised high valent ruthenium (IV) 
dioxo species [Ru(bis-PYA)(=O)2] which activates and oxidises the olefin.182  
7.2. Experimental Goals  
The aim of this chapter was to synthesise and characterise a series of Ru(II) (p-cymene) 
complexes with different bidentate ligands, based around the NHC, PYA or pyridine (PYR) 
framework. Upon synthesis, the coordination and ligand exchange properties of these 
complexes were explored with cytochrome b562 .  
7.3.  Results and Discussion 
7.3.1. Synthesis and Characterisation 
Three different Ru(II) (p-cymene) complexes were identified as synthetic targets. Complex 
[18] is novel and has a mixed PYA-PYR framework,115 complex [19] has a bis-PYA 
framework and was developed as a novel complex, however has been recently reported by 
Albrecht et al,182. and complex [20] has a mixed NHC-PYR framework and has been reported 
by Hartinger et al, Figure 7.5.183 These synthetic targets were chosen as they all contained 
bidentate ligands, and could be synthesised readily from the common starting material dimer 
III. Furthermore, they provided some functional group variety to explore the ligand exchange 
properties of PYA and NHC ligands. The synthesis of complexes [18], [19] and [20] are all 
developed from various literature procedures and reported in Section 3.3.5. 
 161 
Figure 7.5: Structures of complexes [18], [19] and [20]. 
Structure of Complex [19] 
Complex [19] was purified with a triflate counter ion and diffraction quality crystals were 
obtained via vapour diffusion methods (Et2O:MeCN). During the process of writing this thesis 
the structure of complex [19] with the PF6 counter ion was reported by Albrecht et al.182 The 
structure of complex [19] derived from the synthetic procedure outlined in Section 3.3.5 was 
also determined as part of this work and is shown in Figure 7.6. 
Figure 7.6: Crystal structure of complex [19] showing displacement ellipsoids at 50 % 
probability. The counterions and hydrogen atoms have been omitted for clarity. (Left) 























Table 7.1: Selected bond lengths (Å) for complex [19]. The Ca, Cb, Cg, Cexo, N* and N** labelling 
scheme for the pyridyl ring has been introduced in Figure 7.6. 












By analysing the bond lengths of complex [19] the charge localisation around the pyridyl ring 
can be explored. The average Cb-Cg bond length (1.394(13) Å) is longer than the average 
Ca-Cb bond length (1.366(13) Å), however this is not statistically significant. This difference 
in bond length is corroborated by the published structure from Albrecht et al., who report 
statistically different bond lengths between the Cb-Cg bond (1.405(3) Å) and the Ca-Cb bond 
(1.371(3) Å). These data support there being double bond localisation between the a and 
b carbons, as indicated in the neutral resonance structure, Figure 7.4 (right).182 However, the 
bond lengths from the Cg  to the exocyclic nitrogen’s (N1-Cg = 1.402(12) and 
N2-Cg = 1.385(11)) are not particularly short as would be expected for an exocyclic imine, 
hence highlighting that solid state information is not enough to support the distribution of 
electron density fitting the neutral resonance model.  
7.3.2. Effect of Solvent Polarity on Complex [19] 
1H NMR spectroscopy was used to probe the electronic flexibility of the PYA ligand by 
modifying the polarity of the solvent environment, Table 7.2. An adequate approximation of 
solvent polarity is given by the dielectric constant (e) or relative permittivity, which simply 
measures the solvents ability to insulate charges from one other. A higher e means a higher 
solvent polarity and greater ability to stabilise charges. 
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Table 7.2: Selected 1H NMR shifts (ppm) of complex [19] in different solvents. Ha and 
Hb were identified from NOE spectroscopy, as the Ha gave a clear cross peak with the Cexo 
hydrogens found at 4.1 ppm.  
Solvent e  Ha Hb Dd [ppm] 
d2-DCM 8.93 8.733 8.029 0.704 
d6-acetone 21.01 8.736 8.487 0.249 
d4-MeOH 32.04 8.562 8.468 0.094 
d3-MeCN 35.94 8.544 8.181 0.363 
d6-DMSO 46.45 8.417 8.515 -0.098 
Figure 7.7: Section of the 1H NMR spectra of complex [19] in d6-DMSO, d4-MeCN and d2-
DCM showing how changing solvent polarity impacts the chemical shift of the pyridyl protons 
Ha and Hb. Again, Ha is assigned through a NOE peak to the hydrogen atoms on Cexo. The 
small peak in the DMSO spectra at 8.1 ppm is a minor contaminant. 
In non-polar solvents, Hb is upfield of Ha and there is a larger Dd suggesting a higher 
contribution of the neutral diene-type resonance structure, (Figure 7.7 (bottom structure)). At 
higher solvent polarities, the zwitterionic complex is stabilised to a greater extent, therefore the 
Ha and Hb have similar chemical shifts, even to an extent where Hb shifts downfield of 
Ha, confirmed through NOE spectroscopy (Figure 7.7 (top structure)). Attempts have 
previously been made to linearly correlate the dielectric constant with the Dd in different 
solvents.116 From our experience, the plot can be fitted differently depending on which solvent 
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systems are selected, as indicated by Figure 7.8. For example, if MeCN is not considered, then 
the corresponding plot is consistent with an e-1/2 relationship, (where e is the dielectric 
constant) often found for phenomena dominated by electrostatic effects in solution. However, 
if MeCN is considered the trend could be argued to be linear as reported by Albrecht et al.116 
Figure 7.8: A plot of dielectric constants of a range of different deuterated solvents against the 
difference in chemical shift between pyridyl protons Ha and Hb  in complex [19].  
7.3.3. Incubations of Complexes [18], [19] and [20] with Cytochrome b562 
A range of experiments were performed varying the number of equivalents of ruthenium 
complexes [18], [19] and [20] and concentration of the two Cyt b562 variants, the cysteine 
mutant, Cyt b562 L10C, and the wild-type, Cyt b562 WT. Samples were taken after 1, 3 and 6 
hours and the extent of modification was monitored via LC-MS, Figure 7.9. Building upon an 
understanding of the reactivity of the bipyridine complexes with the cysteine mutant Cyt b562 
L10C, fewer ruthenium equivalents (two) were used in order to focus on the reactivity of the 
more favourable Ru(II) binding site, Cys10.  
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Figure 7.9: Mass spectra from incubations of complexes [18], [19], [20] with Cyt b562 L10C – 
referred to as Cyt 1 (Left) (50 µM protein, 2 Eq. Ru, 310 K, 6 Hr) and Cyt b562 WT (Right) 
(50 µM protein, 20 Eq. Ru, 310 K, 6 Hr). 
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7.3.4. Discussion of Reactivity of Complexes [18], [19] and [20] with Cytochrome b562 
Complex [18] has a bidentate N,N-coordinating PYR-PYA framework. Incubation of 2 Eq. of 
complex [18] with Cyt b562 shows reactivity with Cys10 occurring to a moderate extent 
(approximately 50 % modification after 6 hrs) with the most abundant peak at 12211 Da, 
consistent with modification of Cyt b562 L10C with a [Ru(Cym)(PYR-PYA)] fragment. There 
is also a peak at 11998 Da, consistent with modification of a [Ru(Cym)] fragment to a much 
lesser extent. A similar spectrum, and pattern of modifications, is observed when incubating 
20 Eq. of complex [18] with Cyt b562 WT. In previous studies, the reactivity of Ru(II)(h6-
arene)(bipyridine) complexes with Cyt b562 WT is very slow, unless complex [16] was used 
and bipyridine dissociation occurs upon coordination. The major species in this incubation at 
12226 Da is consistent with modification of Cyt b562 WT with a [Ru(Cym)(PYR-PYA)] 
fragment. Although modification is still slow, the adduct retains coordination of the PYR-PYA 
fragment which could be a potential avenue of interest to test for catalysis.  
In comparison to complex [18], modification of the cytochrome variants occurs to an even 
lesser extent with complex [19], which has a bidentate N,N-coordination bis-PYA framework. 
With 2 Eq. of complex [19] modification at the Cys10 site occurs moderately with the most 
abundant peak at 11998 Da consistent with modification of a [Ru(Cym)] fragment and 
dissociation of the bis-PYA ligand. Incubation of Cyt b562 WT with 20 Eq. of complex [19] 
leads to two peaks of similar peak intensity at 12014 Da and 12284 Da, which is consistent 
with modification of [Ru(Cym)] and [Ru(Cym)(PYA-PYA)] respectively. The major peak, 
however, is the un-modified protein. 
From the incubations of complex [18] and [19] with the cytochrome b562 variants there is no 
sign of p-cymene dissociation, therefore, these bidentate N,N-coordinating ligands do not 
appear to be acting as strong s-donating ligands, which have been shown to promote arene 
dissociation. Upon coordination of complex [18] to both Cyt b562 L10C and Cyt b562 WT the 
major metal modified species for both these incubations retains coordination of the PYR-PYA 
ligand. There is some minor species that have undergone PYR-PYA dissociation upon 
coordination to both cytochrome variants. For complex [19] dissociation of the bidentate bis-
PYA ligand occurs more readily, with almost complete dissociation upon coordination to Cyt 
b562 L10C and approximately 50 % dissociation upon coordination to Cyt b562 WT. This, 
however, does not compare with the rapid dissociation of the N,N-coordinating 5,5’-TFMBipy 
ligand in complex [16] observed in Chapter 5, highlighting the controlled speciation we have 
with this species.  
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In comparison to complexes [18] and [19] the bidentate N,C-coordinating complex [20] will 
react with Cyt b562 WT almost to completion, with no un-modified protein left. The key 
observation is that upon reaction of complex [20] with Cyt b562 WT the major peak observed 
at 12038 Da is consistent with coordination of a [Ru(PYR-NHC)] fragment where p-cymene 
dissociation has occurred. This reactivity draws clear resemblance to the example outlined 
above, where a [Ru(NHC)] fragment is coordinated to HEWL (Figure 7.3). The presence of 
the NHC ligand at the Ru centre upon coordination to the protein appears to labilise the p-
bound p-cymene ligand. In other, related work, structural analyses of bond lengths trans to an 
NHC ligand have revealed an elongation, suggesting a weakening of the bond.181,184 
Dissociation of the p-cymene ligand which stabilises the Ru centre in the +II oxidation state, 
could open up the potential for redox catalysis allowing access to the +III oxidation state and 
altering the reactivity of the metal complex in situ.  
Unfortunately attempts to purify these protein – ruthenium carbene adducts via ion exchange 
chromatography have proved unsuccessful to date, however this remains an active area of 
research.  
7.4. Conclusions 
Throughout chapters 4 and 5 the bipyridine ligand has been modified with different fluorinated 
substituents to act as a direct reporter of the coordination environment at the metal and also to 
modulate the ligand exchange behaviour with protein scaffolds in an attempt to develop 
artificial metalloenzymes. Transfer hydrogenation and olefin metathesis activity was measured 
in Chapter 6 for species which had undergone bipyridine dissociation upon coordination to Cyt 
b562 WT, leaving a [Ru(arene)] fragment coordinated to the protein. 
This chapter aimed to explore changing the bipyridine ligand to alternative bidentate ligands 
which can encourage arene dissociation upon coordination to Cyt b562. The bonding of the h6-
arene ligand to the ruthenium centre stabilises the +II oxidation state of the metal, potentially 
limiting the redox catalysis that can occur within a protein scaffold. It was therefore 
hypothesised that more electron donating ligands, including N-heterocyclic carbene (NHC) and 
pyridylidene amide (PYA) ligands, could promote arene dissociation upon protein 
coordination, and henceforth stabilise higher oxidation states in redox catalytic cycles.  
Three different ruthenium complexes with alternative bidentate ligands (NHC-PYR, bis-PYA, 
PYA-PYR) were successfully synthesised and characterised through a combination of NMR 
spectroscopy, mass spectrometry and X-ray crystallography. The [Ru(Cym)(bis-PYA)Cl] 
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complex demonstrated some intriguing electron donating/withdrawing properties which could 
be probed through variation of the solvent polarity.   
These three species were then incubated with both the cysteine mutant Cyt b562 L10C and Cyt 
b562 WT. Gratifyingly the [Ru(Cym)(NHC-PYR)Cl] complex undergoes arene dissociation 
upon coordination to both Cyt b562 variants, particularly the wild-type, resulting in a protein-
metal hybrid with a [Ru(NHC-PYR)] fragment coordinated to the protein scaffold. These 
hybrids have four potential ligands provided by the protein scaffold which resembles an 
exciting evolutionary starting point. Combining this reactivity, with that observed with the 
bipyridine complexes, highlights the control in ligand exchange that can be achieved through 
modulating the electron donating properties of the metal ligands. This thesis has highlighted 
how a number of different protein-metal hybrids can be accessed incorporating a range of 
distinct metal fragments, and the subtle biochemistry demonstrated in this chapter further adds 




8. Concluding Remarks and Future Work 
8.1. Restatement of Project Aims 
This overall aim of this project was to understand the fundamental reactivity and speciation of 
Ru(II) arene complexes with proteins. Within this, the aim was to develop novel spectroscopic 
approaches and use traditional analytical techniques to understand the ligand exchange 
behaviour of different ruthenium complexes coordinating to proteins. The information gathered 
on the ligand exchange behaviour of Ru(II) arene complexes can now hopefully be applied to 
further explore the catalytic potential of ruthenium artificial metalloenzymes with direct 
protein-metal coordination.  
8.2.  Conclusions 
8.2.1. Understanding the Speciation and Reactivity of Ru(II) Arene Complexes 
Throughout this thesis a number of different analytical methods have been used to shed light 
on the reactivity of Ru(II) arene complexes with proteins. Proteins have a number of potential 
Lewis basic residues which will form coordination bonds to ruthenium, it is therefore 
challenging to predict which residue, how fast and to what extent metal modification will occur.  
A suite of Ru(II)(arene)(bipyridine) complexes [1]-[17] were synthesised and characterised. 
Their ligand exchange behaviour has been explored in aqueous buffer, with small molecule 
amino acid complexes and with proteins through the powerful combination of NMR 
spectroscopy and mass spectrometry. Fluorinated ligands were incorporated into complexes 
[5]-[17], and due to the magnetic sensitivity of the fluorine atoms to changes in coordination 
at the metal centre, the 19F NMR spectra show for the first time the varied, dynamic behaviour 
of organoruthenium compounds when exposed to simple biomolecules in complex mixtures. 
Incorporating an NMR-active heteroatom into ruthenium organometallic complexes provides 
a quantitative, diagnostic ‘fingerprint’ to track solution-phase behaviour and allow for 
unambiguous assignment of any given amino acid adduct. 
Using 19F NMR spectroscopy, coordination of these Ru(II) arene complexes to the Lewis basic 
side chains of the small molecules His, Cys, Glu and Met was confirmed, with a clear 
thermodynamic preference for all complexes for the cysteine thiol. Extending this finding, 
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chosen Ru(II)(arene)(bipyridine) complexes were incubated with seven different cysteine-
containing proteins and the extent of modification was monitored using LC-MS. Proteins with 
naturally occurring free cysteines and genetically introduced cysteines were purified with each 
protein displaying differential reactivity with the ruthenium complexes. Having differential 
speciation activity with different proteins is not overly surprising, however being able to 
monitor and manipulate this activity is challenging. 
The cysteine mutants of Ubq K63C and Cyt b562 L10C displayed the fastest, most efficient 
metal modification. The binding preference was confirmed to be the cysteine thiol through 19F 
NMR spectroscopy and incubations with the cysteine modifying small molecule N-
ethylmaleimide. The 19F NMR spectra of purified Cyt b562-Ru adducts are extremely sensitive 
to the coordination site and also indicate how the protein environment imparts varying 
electronic and steric pressures on different parts of the metal complex through non-covalent 
interactions, emphasised by distinct relaxation properties of fluorine substituents across the 
bipyridine ring. These distinct relaxation properties could potentially be explained by more 
buried and solvent exposed fluorine positionings, thus highlighting the ability of the scaffold 
to create asymmetric conditions for an unnatural cofactor.  
8.2.2. Controlled Ligand Exchange 
Throughout this thesis, the concept of controlled ligand exchange upon protein-metal 
coordination is crucial. For a [Ru(II)(arene)(bipyridine)Cl]+ complex to coordinate to a 
cysteine residue, the proposed dominant mechanism, supported by 19F NMR, is initial 
exchange of the chloride ligand to a water/hydroxide ligand, followed by exchange of the 
water/hydroxide for the Lewis basic protein ligand, which is driven by the formation of a strong 
coordination bond. Through varying the electronic contribution of the arene and bipyridine 
ligands, it was observed that some species will undergo a further ligand exchange process, 
whereby the bipyridine ligand will dissociate and the protein will provide the necessary ligands 
to saturate the metal coordination sphere.  
This reactivity is exemplified upon incubation of complex [16] (which has three ligands, a 
chloride, an h6-hexamethylbenzene and a 5,5’-di(trifluoromethyl)bipyridine) with Cyt b562 WT 
where the major species observed is a Cyt b562 WT – [Ru(h6-hexamethylbenzene)] adduct, 
whereby the bipyridine and chloride ligands have undergone a ligand exchange process to 
ligands provided by residues His63, Ala1 and Asn6. In this reaction, we hypothesise that initial 
coordination to the protein occurs at the His63; following this, the steric and conformational 
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pressure on the complex results in bipyridine dissociation with Asn and Ala providing the 
required ligands to satisfy the metal complex. In comparison, upon incubation of complex [16] 
to the cysteine mutant Cyt b562 L10C, the major species retain coordination of the fluorinated 
bipyridine ligand. Upon coordination to the cysteine thiol, dissociation of the fluorinated 
bipyridine ligand is observed but to a much lesser extent than when initial coordination occurs 
at His63. This could be due to the different electronic contributions of the ligand and/or the 
different steric pressures of the metal complex within the protein.  
By changing the bipyridine ligand to the strongly electron donating, bidentate pyridine-carbene 
ligand, coordination to the protein can promote arene dissociation from the metal centre. As 
demonstrated from the above examples, the strength of metal-ligand coordination bonds in the 
complex and the steric and electronic pressures that the protein imparts on the metal complex 
upon coordination are crucial in controlling ligand dissociation.   
Understanding this fundamental ligand exchange behaviour of the metal complex in the 
development of ArMs with direct protein-metal coordination is imperative. The concept of an 
inert complex being activated towards catalysis upon protein coordination (similar to vitamin 
B12 and methionine synthase) is attractive as it ensures that reactivity can only occur within 
the specific protein environment evolved for rapid turnover and pristine enantioselectivity. This 
metal complex must be stable for long enough in aqueous conditions, but when the desired 
protein coordination site is found, ligand exchange must occur and catalytic activity can then 
be unmasked.   
8.2.3. Developing an Artificial Metalloenzyme with Direct Coordination 
To develop an ArM which can deliver un-paralleled catalytic activity for a desired reaction, 
there are many crucial factors to consider including: (i) The starting metal pre-cursor complex, 
(ii) the starting protein scaffold, (iii) forming protein-metal coordination bonds in a controlled 
ligand exchange reaction, (iv) non-covalent interactions between the protein and the metal 
complex and (v) the catalytic substrate interactions to both the metal complex and the protein 
scaffold.  
The molten globule, apocytochrome b562 has potential as a starting point for ArM formation 
and subsequent catalysis. It has a dynamic, four a-helical fold capable of accommodating 
different ruthenium fragments within a central hydrophobic core by providing multiple ligands 
to the metal centre from different parts of the protein. Additionally, it is evolvable, i.e. it is 
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robust enough to withstand mutation and malleable enough for mutations to impact catalysis, 
therefore it is a good candidate for subsequent directed evolution campaigns.  
Throughout this research, it has been identified that cytochrome b562 – Ru(II) arene hybrids are 
a promising starting point to explore the catalytic transfer hydrogenation of imines. One 
particular Cyt b562 WT – [Ru(h6-hexamethylbenzene)] hybrid showed approximately 5 times 
faster activity than a known dimeric ruthenium catalyst and up to 35 times faster than the 
starting ruthenium cofactor. The enhanced activity over the free metal complex highlights the 
potential to activate a metal complex for catalytic activity through a controlled ligand exchange 
reaction with a protein. Preliminary results have also shown the potential of cytochrome b562 – 
Ru(II) arene hybrids to perform olefin metathesis, reactivity thought to be beyond the capability 
of these hybrids. Tentatively, this demonstrates that localising a metal cofactor and substrate 
within a hydrophobic pocket of a protein can access activity not realised by small molecule 
catalysis.  
What we believe to be crucial for directed evolution of ArMs to make significant improvements 
in catalysis is direct protein-metal coordination. Directed evolution can significantly improve 
how the substrate binds and interacts with the metal centre (lowering KM), but with direct 
protein-metal coordination directed evolution has the potential to drastically change the ligands 
coordinated to the metal and vary the proteins electronic contribution to catalysis, thus improve 
the chemical turnover rate (kcat).  
8.2.4. Concluding Remarks 
The work presented in this thesis has further developed the understanding of how and where 
ruthenium complexes form coordination bonds to protein scaffolds. The legacy of this work 
and the Ru(II) arene fragment stems from the requirement to understand the cellular speciation 
of Ru(II) arene complexes in order to develop and design new ruthenium complexes that could 
be relevant within a clinical setting for the treatment of cancer. Although the methodologies 
described here for monitoring biological speciation are highly transferable to this application, 
recent advances have been made in developing artificial metalloenzymes with direct protein-
ruthenium coordination bonds. Direct coordination between metal ions and a protein scaffold 
is essential in order to deliver artificial metalloenzymes where the metal and protein are truly 
interdependent. This represents a method to access entatic states which deliver enhanced 
reactivity, efficiency and selectivity that cannot easily be replicated in conventional, synthetic 
metal catalysis. This novel class of hybrid enzymatic catalysts have the potential to greatly 
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impact chemical production on this planet; hopefully the work presented in this thesis will 
underpin future advancements made in artificial metalloenzymes with direct protein-metal 
coordination. 
8.3. Future Work 
Future work from this research is being directed towards developing artificial metalloenzymes 
with direct-protein coordination. As this research moves more into the realms of protein 
engineering and synthetic catalytic chemistry to optimise ArM activity, an appreciation of the 
metal-ligand coordination environment and ligand exchange behaviour of metal complexes 
must remain, particularly an understanding of how metal complexes enhance catalytic activity. 
Time and thought must be given into deciphering the catalytic mechanism of an artificial 
metalloenzyme and an understanding of this mechanism must also be tested through rational 
design of protein scaffolds alongside laboratory evolution.   
8.3.1. Characterising Cytochrome b562 – Ruthenium Coordination 
Characterising protein-ruthenium hybrids will continue to be crucial in the development of 
ArMs as identifying the optimal protein-metal coordination environment for catalysis is 
essential. Mass spectrometry methods have been ubiquitously used throughout this thesis to 
confirm protein-ruthenium modification, and in particular tandem MS/MS has proved 
particularly enlightening. Other structural biology techniques could prove informative in 
characterising Cytochrome b562 – ruthenium adducts, including X-ray crystallography, 
cryogenic electron microscopy (cryoEM), electron paramagnetic resonance (EPR) and 
isotopically labelled NMR spectroscopy.  
8.3.2. Developing a Ruthenium Fragment Library Coordinated to Cytochrome b562 
Throughout this thesis, a number of different fragments have been coordinated to variants of 
cytochrome b562 including: [Ru(arene)(bipyridine)], [Ru(arene)(bis-PYA)], [Ru(arene)(PYR-
PYA)], [Ru(arene)(PYR-Carbene)], [Ru(arene)] and [Ru(PYR-Carbene)]. Expanding this 
library of fragments, for example [Ru(phosphane)] fragments, could widen the scope of 
potential reactions catalysed by Cyt b562 – ruthenium metalloenzymes. Within this research, a 
number of synthetic advancements have been made in the synthesis, purification and 
characterisation of Ru(II) arene complexes. Continuing these synthetic advancements could 
identify novel ruthenium complexes which could have unpredictable and potentially useful 
ligand exchange properties with protein scaffolds, particularly Cyt b562.  
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8.3.3. Directed Evolution of a Cytochrome b562 – Ruthenium Artificial Metalloenzyme 
Following initial transfer hydrogenation activity observed for cytochrome b562 WT – 
[Ru(HMB)] hybrids with direct protein-metal coordination, directed evolutionary campaigns 
have the potential to evolve this protein scaffold to enhance the catalytic activity of this protein-
metal hybrid. This thesis has highlighted three key considerations for a directed evolutionary 
campaign for ArMs which are: (i) Expressing protein variants with a genotype-phenotype 
linkage, (ii) a clean and efficient metal modification step and (iii) a quick, sensitive and robust 
activity assay. This thesis has demonstrated controlled ligand exchange methods that lead to 
clean and efficient metal modification. Further, fluorescence-based assays have been 
developed that are sensitive and robust.  
For ArMs where an unnatural metal cofactor has been anchored to a protein scaffold, all 
examples of directed evolution campaigns have been performed in-vivo which links the 
genotype and phenotype through compartmentalization within a cell. Cells expressing different 
protein variants are separated, typically through colony picking into 96 well plates, and 
following metal modification, catalytic activity is screened in a plate assay using a fluorogenic 
or chromogenic substrate. Upon identification of active variants, the cells are lysed and the 
gene is recovered for continual rounds of evolution.  
The major limitations of in-vivo methods in the directed evolution of ArMs are: (i) catalytic 
activity must be compatible with cellular conditions, (ii) the metal modification step must be 
able to withstand complex biological environments, which is particularly challenging as the 
cell has many potential catalyst poisons, e.g. glutathione and (iii) low transformation efficiency 
limits the library size which restricts the sequence space that can be explored in each round of 
directed evolution.  
Considering these limitations, future work will focus on directed evolution of cytochrome b562 
– ruthenium ArMs through in-vitro methods involving compartmentalisation in water in oil 
emulsions (microfluidics) and covalent linkages between the genotype and phenotype. Upon 
generation of a gene library, protein expression will be performed in droplets using modern in-
vitro translation (IVTT) kits. Within the droplet, both the expressed protein variant and gene 
will be covalently linked to a polyacrylamide hydrogel bead maintaining a covalent genotype-
phenotype linkage. At this stage, the droplets can be broken up and protein-metal modification 
can occur before the beads (with gene and protein variant still covalently attached) are re-
encapsulated within a droplet with a fluorogenic substrate. Droplets are sorted based on 
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fluorescence intensity (FADS), with the genes of active variants recovered and subjected to 
iterative rounds of directed evolution.  
These in-vitro translation on beads and droplet compartmentalization methods are particularly 
attractive techniques for the directed evolution of ArMs. Possibly most important is being able 
to perform the metal modification step outside of a cellular environment. Additionally, much 
larger protein libraries can be generated in comparison to in-vivo and well-plate systems 
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Table A.1: X-ray crystallographic data for complexes [1] to [4].  
Complex [1] [2] [3] [4] 
CCDC No.   N/A  N/A   N/A N/A   
Empirical formula [C16H14ClN2Ru]+(PF6–) [C17H16ClN2Ru]+(PF6–) [C20H22ClN2Ru]+(PF6–) [C22H26ClN2Ru]+(PF6–) 
Formula weight 515.78 529.81 571.88 599.94 
Temperature 180(2) K 180(2) K 180(2) K 180(2) K 
Wavelength 0.7107 Å 1.54178 Å 1.54178 Å 1.54178 Å 
Crystal system orthorhombic monoclinic orthorhombic orthorhombic 
Space group Cmc21 P 21/c P 212121  Pna21 
Unit cell dimensions   11.8079(2) a = 90 ° 14.4572(4) Å a = 90  ° 11.6945(2) Å a = 90 °  18.1054(5) Å a = 90 ° 
  10.8639(2) b = 90 ° 8.3310(3) Å b = 109.350(2) 
° 
12.2925(2) Å b = 90 ° 7.6932(2) Å b = 90 ° 
 14.2305(3) g = 90 ° 16.4324(5) Å g = 90 ° 15.2581(3) Å g = 90 ° 16.6857(5) Å g = 90 ° 
Volume 1825.49(6) Å3 1867.37(10) Å3  2193.42(7) Å3 2324.13(11) Å3 
Z 4 4 4 4 
Density (calculated) 1.877 mg/m3 1.885 mg/m3  1.732 mg/m3 1.715 mg/m3 
Absorption coefficient 1.155 mm-1 9.531 mm-1  8.164 mm-1 7.736 mm-1 
F(000) 1016 1048 1144 1208 
Crystal size 0.21 x 0.18 x 0.14 mm3 0.08. x 0.05. x 0.02 mm3 0.20 x 0.05 x 0.05 mm3 0.12 x 0.10 x 0.04 mm3 
Theta range 1.00 to 32.03 ° 3.24 to 66.76  ° 4.62 to 66.63° 4.89 to 66.70 ° 








Reflections collected 10174 21414 15177 21012 
Independent reflections 3120 [R(int) = 0.030] 3295 [R(int) =  0.077]  3853 [R(int) = 0.0406] 4073 [R(int) =  0.065] 
Completeness to q(max)  99.8 % 99.9 % 99.9 % 
Data / restraints / param. 3120 / 1 / 133 3295 / 0 / 254 3853 / 0 / 283 4073 / 1 / 305 
Goodness-of-fit on F2 1.036 1.068 1.096 1.042 
R indices [I>2sigma(I)] R1 = 0.028 wR2 = 0.066 R1 = 0.032 wR2 = 0.061 R1 = 0.022 wR2 = 0.051 R1 = 0.027 wR2 = 0.056  
R indices (all data) R1 = 0.031 wR2 = 0.067 R1 = 0.046 wR2 = 0.064 R1 = -0.025 wR2 = 0.052 R1 = 0.032 wR2 = 0.057 
Largest diff. peak and hole  0.52 and -0.42 e.Å-3 0.26 to -0.41e.Å-3 0.033 to -0.36 e.Å-3 
Flack parameter -0.04(4)  -0.022(6) 0.020(13) 
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Table A.2: X-ray crystallographic data for complexes [5] to [8]. 
 
Complex [5] [6] [7] [8] 
CCDC No. 1867665 1867666 1867667 1867668 
Empirical formula [C16H12ClF2N2Ru]+(PF6–) [C17H14ClF2N2Ru]+(PF6–) [C20H20ClF2N2Ru]+(PF6–) [C22H24ClF2N2Ru]+(PF6–) 
Formula weight 551.77 565.79 607.87 635.92 
Temperature 180(2) K 180(2) K 180(2) K 180(2) K 
Wavelength 0.7107 Å 1.5418 Å 1.5418 Å 1.5418 Å 
Crystal system Triclinic Orthorhombic Orthorhombic Orthorhombic 
Space group P–1 Cmc21 Pca21 Pna21 
Unit cell dimensions a = 8.0630(5) Å a = 
104.378(3) °  
a = 11.8675(3) Å a = 90° a = 12.3683(3) Å a = 90 ° a = 18.4489(5) 
Å 
a = 90 ° 
 b = 8.3719(5) Å b = 95.336(3) 
° 
b = 11.3437(3) Å b = 90 ° b = 13.3931(3) Å b = 90 ° b = 7.8290(2) Å b = 90 ° 
 c = 13.8505(11) 
Å 
g = 96.409(3) 
° 
c = 14.2301(4) Å g = 90 ° c = 13.3561(3) Å g = 90 ° c = 16.0806(4) 
Å  
g = 90 ° 
Volume 892.90(11) Å3 1915.68(9) Å3 2212.44(9) Å3 2322.62(10) Å3 
Z 2 4 4 4 
Density (calculated) 2.052 mg/m3 1.962 mg/m3 1.825 mg/m3 1.819 mg/m3 
Absorption coefficient 1.203 mm-1 9.498 mm-1 8.273 mm-1 7.912 mm-1 
F(000) 540 1112 1208 1272 
Crystal size 0.10 x 0.04 x 0.01 mm3 0.12 x 0.10 x 0.02 mm3 0.25 x 0.06 x 0.02 mm3 0.40 x 0.08 x 0.03 mm3 
Theta range 3.53 to 25.14° 5.39 to 70.42° 3.30 to 66.78° 4.79 to 66.93° 








Reflections collected 7589 14279 27010 14417 
Independent reflections 3118 [R(int) = 0.105] 1909 [R(int) = 0.042] 3787 [R(int) = 0.043] 3794 [R(int) = 0.042] 
Completeness to q(max) 97.6 % 99.9 % 99.9 % 99.5 % 
Data / restraints / param. 3118 / 0 / 262 1909 / 43 / 164 3787 / 1 / 301 3794 / 1 / 322 
Goodness-of-fit on F2 1.10 1.03 1.05 1.04 
R indices [I>2sigma(I)] R1 = 0.072 wR2 = 0.110 R1 = 0.033 wR2 = 0.087 R1 = 0.019 wR2 = 0.044 R1 = 0.025 wR2 = 0.054 
R indices (all data) R1= 0.124 wR2 = 0.128 R1 = 0.035 wR2 = 0.088 R1 = 0.022 wR2 = 0.045 R1 = 0.030 wR2 =0.056 
Largest diff. peak and hole 0.73 and -0.76 e.Å-3 0.71 and -0.48 e.Å-3 0.25 and -0.31 e.Å-3 0.45 and -0.30 e.Å-3 
Flack parameter  0.003(17) 0.017(6) 0.017(6) 
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Table A.3: X-ray crystallographic data for complexes [9] to [12] 
Complex [9] [10] [11] [12] 
CCDC No. 1867661 1867662 1867663 1867664 
Empirical formula [C16H12ClF2N2Ru]+(PF6–) [C17H14ClF2N2Ru]+(PF6–) [C20H20ClF2N2Ru]+(PF6–) [C22H24ClF2N2Ru]+(PF6–) 
Formula weight 551.77 565.79 607.87 635.92 
Temperature 180(2) K 180(2) K 180(2) K 180(2) K 
Wavelength 0.7107 Å 1.5418 Å 0.7107 Å 1.5418 Å 
Crystal system Orthorhombic Triclinic Orthorhombic Triclinic 
Space group Pbcm P–1 Pca21 P–1 
Unit cell dimensions a = 8.18600(10) 
Å  
a = 90° a = 7.1872(3) Å a = 99.964(2)° a = 12.0020(2) Å a = 90° a = 8.4825(3) Å a = 
103.1690(11)° 
 b = 12.7339(2) Å b = 90° b = 11.6858(4) Å b = 97.263(2)° b = 13.7944(2) Å b = 90° b = 11.8360(4) Å b = 94.0286(11)° 
 c = 17.9660(3) Å g = 90° c = 11.9743(4) Å g = 101.058(2)° c = 13.2815(2) Å g = 90° c = 12.4837(4) Å g = 
103.4380(10)° 
Volume 1872.77(5) Å3 958.79(6) Å3 2198.89(6) Å3 1176.89(7) Å3 
Z 4 2 4 2 
Density (calculated) 1.957 mg/m3 1.960 mg/m3 1.836 mg/m3 1.795 mg/m3 
Absorption coefficient 1.147 mm-1 9.488 mm-1 0.986 mm-1 7.808 mm-1 
F(000) 1080 556 1208 636 
Crystal size 0.30 x 0.23 x 0.18 mm3 0.04 x 0.04 x 0.03 mm3 0.32 x 0.30 x 0.18 mm3 0.18 x 0.12 x 0.06 mm3 
Theta range 3.73 to 32.02° 3.80 to 66.73° 3.70 to 33.70° 3.67 to 67.18° 








Reflections collected 16324 12013 24942 12913 
Independent reflections 3323 [R(int) = 0.035] 3393 [R(int) = 0.049] 8467 [R(int) = 0.031] 4156 [R(int) = 0.025] 
Completeness to q(max) 99.3 % 99.6 % 99.8 % 98.8 % 
Data / restraints / param. 3323 / 0 / 135 3393 / 0 / 275 8467 / 1 / 301 4156 / 34 / 360 
Goodness-of-fit on F2 1.09 1.05 1.00 1.08 
R indices [I>2sigma(I)] R1 = 0.032 R1 = 0.040 R1 = 0.040 wR2 = 0.091 R1 = 0.027 wR2 = 0.069 R1 = 0.024 wR2 = 0.059 
R indices (all data) R1 = 0.039 R1 = 0.054 R1 = 0.054 wR2 = 0.096 R1 = 0.032 wR2 = 0.071 R1 = 0.025 wR2 = 0.060 
Largest diff. peak and hole 0.87 and -0.78 e.Å-3 1.38 and -0.59 e.Å-3 0.74 and -0.83 e.Å-3 0.45 and -0.30 e.Å-3 
Flack parameter   -0.030(14)  
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Table A.4: X-ray crystallographic data for complexes [13] to [16]. 
Complex [13] [14] [15] [16] 
CCDC No. 1867670      
Empirical formula [C18H12ClF6N2Ru]+(PF6–) [C19H14ClF6N2Ru] +(PF6–) [C22H20ClF6N2Ru] +(PF6–) [C24 H24ClFN2PRu] +(PF6–) 
0.425(H2O) 
Formula weight 651.79 665.81 707.89 743.66 
Temperature 180(2) K 180(2) K 180(2) K 180(2) K 
Wavelength 0.7107 Å 1.5418 Å 0.7107 Å 1.5418 Å 
Crystal system Orthorhombic monoclinic Orthorhombic orthorhombic 
Space group Pca21 P 21/n Pbca Pca21 
Unit cell dimensions a = 16.0681(5) Å a = 90° 9.5903(3) Å a = 90 ° a = 15.8815(4) a = 90° 22.9874(9) Å a = 90 ° 
 b = 8.0666(3) Å b = 90° 13.5886(5) Å b = 95.963(2) ° b = 17.5702(4) b = 90° 8.9895(5) Å b = 90 ° 
 c = 15.9972(5) Å g = 90° 17.1719(6) Å g = 90 ° c = 18.4954(7) g = 90° 27.0327(11) Å g = 90 ° 
Volume 2073.48(12) Å3  2225.71(13) Å3 5161.0(3) 5586.2(4) Å3 
Z 4 4 8 8 
Density (calculated) 2.088 mg/m3 1.987 mg/m3 1.822 mg/m3 1.768 mg/m3 
Absorption coefficient 1.080 mm-1 8.565 mm-1 0.876 mm-1 6.909 mm-1 
F(000) 1272 1304 2800 2962 
Crystal size 0.10 x 0.07 x 0.05 mm3 0.10 x 0.10 x 0.10 mm3 0.22 x 0.18 x 0.08 mm3 0.15 x 0.12 x 0.05 mm3 
Theta range 4.39 to 27.50° 4.16 to 66.94° 3.58 to 25.02° 4.18 to 54.28° 








Reflections collected 8822 26162 22559 40731 
Independent reflections 3778 [R(int) = 0.057] 3967 [R(int) = 0.055] 4531 [R(int) = 0.104] 6815 [R(int) = 0.19] 
Completeness to q(max) 97.6 % 99.8 % 99.5% 99.9 % 
Data / restraints / param. 3778 / 1 / 316 3967 / 25 / 331 4531 / 0 / 355 6815 / 289 / 761 
Goodness-of-fit on F2 1.07 1.02 1.008 1.03 
R indices [I>2sigma(I)] R1 = 0.041 wR2 = 0.074 R1 = 0.029 wR2 = 0.063  R1 = 0.052 wR2 = 0.0741 R1 =  0.066 wR2 = 0.13 
R indices (all data) R1= 0.061 wR2 = 0.082 R1 = 0.036 wR2 = 0.066 R1 = 0.110 wR2 = 0.0833 R1 = 0.098  wR2 = 0.14 
Largest diff. peak and hole 0.59 and -0.64 e.Å-3 1.01 and -0.83 e.Å-3 0.73 and -0.44 e.Å-3 0.44 to -0.50 e.Å-3 
Flack parameter -0.04(4)    
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Table A.5: X-ray crystallographic data for complexes [17] and [19]. 
Complex [17] [19] 
CCDC No. 1867669 N/A 
Empirical formula [C16H12ClF2N2Ru]+(PF6–) [C24H28ClN4O2Ru]+ (CF3SO3)- 
Formula weight 551.77 690.09 
Temperature 180(2) K 180(2) K 
Wavelength 0.7107 Å 1.54178 Å 
Crystal system Monoclinic triclinic 
Space group P21/n P -1 
Unit cell dimensions a = 11.8901(4) Å  a = 90° 8.8457(4) Å a =  
100.884(4)° 
 b = 11.9766(4) Å b = 
101.146(2)° 
11.3399(6) Å b = 
101.826(4)° 
 c = 12.8399(5) Å  g = 90° 14.6021(8) Å g =  
98.315(4)° 
Volume 1793.95(11) Å3 1382.01(13) Å3 
Z 4 2 
Density (calculated) 2.043 mg/m3 1.658 mg/m3 
Absorption coefficient 1.198 mm-1 6.756 mm-1 
F(000) 1080 700 
Crystal size 0.10 x 0.05 x 0.03 mm3 0.05 x 0.02 x 0.02 mm3 
Theta range 3.66 to 27.50° 3.17 to 66.66° 




Reflections collected 11426 7365 
Independent reflections 4031 [R(int) = 0.086] 4493 [R(int) = 0.063] 
Completeness to q(max) 97.7% 91.7 % 
Data / restraints / param. 4031 / 0 / 262 4493 / 121 / 407 
Goodness-of-fit on F2 1.03 1.04 
R indices [I>2sigma(I)] R1 = 0.051 wR2 = 0.085 R1 = 0.073 wR2 = 0.192 
R indices (all data) R1 = 0.105 wR2 = 0.103 R1 =  0.116 wR2 = 0.162 
Largest diff. peak and hole 0.65 and -0.99 e.Å-3 1.24 to -0.69e.Å-3 




Appendix B – Mass Spectrometry 
Supporting Information  
Table B.1: LR-ESI-MS spectra recorded of the solution mixture when complexes [9]-[12] are 
incubated in 10 mM phosphate buffered D2O. Samples are taken directly from the solution 
mixture and diluted before direct injection into the Micromass Quattro mass spectrometer.  
Species Mobs Mcalc Molecular Formula / Assignment 
[9]-Cl 406.82 406.97 C16H12ClF2N2Ru 
[9]-Phoshate 468.77 468.97 C16H14F2N2O4PRu 
[10]-Cl 420.83 420.99 C17H14ClF2N2Ru 
[10]-Phoshate 482.84 482.99 C17H16ClF2N2O4PRu 
[11]-Cl 462.85 463.03 C20H20ClF2N2Ru 
[11]-Phoshate 524.87 525.03 C20H22ClF2N2O4PRu 
[12]-Cl 491.08 491.06 C22H24ClF2N2Ru 





Table B.2: ESI-MS data from the incubations of complexes [1] – [4] with the protected amino 
acids, N-Ac-Cys-OMe, N-Z-Glu-OMe, N-Bz-His-OMe, N-Ac-Met-OMe and reduced 
glutathione (2 mM Ru, 3 eq. amino acid, 24 hr, 310 K). Samples are diluted in D2O diluted 
before direct injection into the Micromass Quattro mass spectrometer, therefore the titratable 
groups present remain deuterated. 
 
Species Mobs Mcalc Molecular Formula / Assignment 
[9]-Cys 549.09 549.05 C22H21DF2N3O3RuS 
[9]-Glu 667.15 667.11 C30H27DF2N3O6Ru 
[9]-His 323.68 323.33 C30H25D2F2N5O3Ru 
[9]-Met 289.10 288.82 C24H26DF2N3O3RuS 
[9]-GSH 683.13 683.11 C26H23D5F2N5O6RuS 
[10]-Cys 563.01 563.06 C23H23DF2N3O3RuS 
[10]-Glu 681.07 681.12 C31H29DF2N3O6Ru 
[10]-His 330.79 330.34 C31H27D2F2N5O3Ru 
[10]-Met 296.14 295.83 C25H28DF2N3O3RuS 
[10]-GSH 697.08 697.12 C27H25D5F2N5O6RuS 
[11]-Cys 605.00 605.11 C26H29DF2N3O3RuS 
[11]-Glu 722.96 723.17 C34H35DF2N3O6Ru 
[11]-His 350.39 351.60 C34H33D2F2N5O3Ru 
[11]-Met 317.30 317.08 C28H34DF2N3O3RuS 
[11]-GSH 740.31 740.17 C27H30D6F2N5O6RuS 
[12]-Cys 633.27 633.14 C28H33DF2N3O3RuS 
[12]-Glu 751.16 751.20 C36H39DF2N3O6Ru 
[12]-His 365.71 365.61 C36H37D2F2N5O3Ru 
[12]-Met 331.28 331.09 C30H38DF2N3O3RuS 
[12]-GSH 768.24 768.20 C32H35D6F2N5O6RuS 
 
Table B.3: ESI-MS data from the incubations of complexes [12] with the protected amino 
acids N-Ac-Cys-OMe upon the addition of 0.5 Eq. of H2O2. Samples are diluted in D2O diluted 
before direct injection into the Micromass Quattro mass spectrometer, therefore the titratable 
groups present remain deuterated. 
 
Species Mobs Mcalc Molecular Formula / Assignment 
[12]-Cl 491.08 491.06 C22H24ClF2N2Ru 
[12]-Cys 633.27 633.14 C28H33DF2N3O3RuS 
[12]-Cys + [O] 649.27 649.13 C28H33DF2N3O4RuS 
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Figure B.1: A typical analysis of a metal protein conjugation reaction followed by LC–MS. 
The total ion chromatogram (Top), combined ion series (Middle) and deconvoluted spectra 
(Bottom) are shown for the product of the reaction. Identical analyses were carried out for all 
the conjugation reactions performed in this work. Conversion rates were determined by 
integration of the peak area in liquid chromatogram, with the area integrated shown by the 
arrow in the above figure.  
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Figure B.2: (Top) Deconvoluted LC-MS spectra of Cyt b562 L10C (Mobs = 11766 Da, Mcalc = 
11764 Da). (Middle) Deconvoluted and ion series spectra of an incubation of Cyt b562 L10C 
and N-ethyl maleimide (20 uM Prot, 2 Eq. NEM, 15 mins). The cysteine residue is modified 
by the maleimide – Cyt b562 L10C-(Mal) (Mobs = 11890 Da, Mcalc = 11889 Da). (Bottom) 
Deconvoluted and ion series spectra of an incubation of Cyt b562 L10C + [Ru(HMB)(Bipy)] 
(Mobs = 12182 Da, Mcalc = 12184 Da) and N-ethyl maleimide (20 uM Prot, 2 Eq. NEM, 15 
mins). Upon addition of the maleimide, there is no change in mass to the ruthenium modified 
protein, indicating that the cysteine residue is blocked.  
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Figure C.1: The 19F{1H} NMR peaks of [Ru(h6-benzene)(5,5’-difluorobipyridine)(N-ac-
cysteine-OMe)]+ when complex [1] is incubated with N-acetyl cysteine methyl ester (2 mM 
Ru, 3 eq amino acid) at a temperature range 278 K – 328 K. 
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Figure C.2: The 19F{1H} NMR peaks observed when complex [9] is incubated with both chiral 
amino acids and achiral small molecules (2 mM Ru, 3 eq. AA, 8 hours, 310 K). The achiral 
species cysteamine, N-mercaptopropianoate and glycine give rise to singlet adduct peaks, 
whereas the chiral amino acids N-Ac-Cys-OMe (protected cysteine) and Z-Glu-OMe 
(protected glutamic acid) give rise to two peaks.  
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Figure C.3: A comparison between the incubations of complex [9] (Top) and [13] (Bottom) 
with N-Ac-Cys-OMe. This indicates the reduced chemical shift sensitivity changing the 
substituent on the bipyridyl ring from a fluorine to a trifluoromethyl group.  
